AMCP Dossier

EXPAREL® (bupivacaine liposome injectable suspension)

2012-06-26
Contents

1 Executive Summary ........................................................................................................... 3
  1.1 Clinical Benefits ........................................................................................................ 3
  1.2 Conclusions .............................................................................................................. 5
2 Product Information and Disease Description6
  2.1 Product Description .................................................................................................. 6
    2.1.1 Generic Name, Brand Name, and Therapeutic Class ......................................... 6
    2.1.2 Dosage Forms, Strengths, and Package Sizes ..................................................... 6
    2.1.3 NDC for all Formulations .................................................................................. 6
    2.1.4 WAC Cost per Unit .......................................................................................... 6
    2.1.5 AHFS or Other Drug Classification .................................................................. 6
    2.1.6 FDA-Approved Indications .............................................................................. 6
    2.1.7 Pharmacology .................................................................................................... 7
    2.1.8 Pharmacokinetics/Pharmacodynamics .................................................................. 10
    2.1.9 Contraindications Warnings/Precautions/Adverse Effects ................................ 13
    2.1.10 Interactions ..................................................................................................... 18
    2.1.11 Specific Populations/Disease ......................................................................... 20
    2.1.12 Dosing and Administration ............................................................................ 21
    2.1.13 Access ............................................................................................................. 22
    2.1.14 Co-Prescribed/Concomitant Therapies ............................................................. 22
    2.1.15 Comparison Products ..................................................................................... 23
  2.2 Place of the Product in Therapy .................................................................................. 23
    2.2.1 Disease Description .......................................................................................... 23
    2.2.2 Approaches to Treatment .................................................................................. 25
    2.2.3 Relevant Treatment Guidelines and Consensus Statements From National and/or
         International Bodies ............................................................................................. 27
3 Supporting Clinical Evidence .......................................................................................... 32
  3.1 Summarizing Key Clinical Studies ............................................................................ 32
    3.1.1 Published and Unpublished Data and Clinical Studies Supporting Labelled Indications.... 32
    3.1.2 Clinical Studies Supporting Off-label Indications (Administration Other Than by Wound
         Infiltration) .............................................................................................................. 58
    3.1.3 Clinical Evidence Summary Table ...................................................................... 65
    3.1.4 Summarizing of Evidence from Secondary Sources ........................................... 74
    3.1.5 Integrated Analysis of Efficacy and Safety .............................................................. 74
    3.1.6 Integrated Cardiac Safety Analysis ..................................................................... 77
4 Economic Value and Modelling Report ......................................................................... 81
  4.1 Modelling Overview ................................................................................................... 92
5 References ...................................................................................................................... 93
1 Executive Summary

1.1 Clinical Benefits

EXPAREL® is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated for single-dose local administration into the surgical site to produce postsurgical analgesia. After injection of EXPAREL into soft tissue, bupivacaine is released from the multivesicular liposomes providing effective local analgesia for up to 72 hours.

The efficacy and safety of EXPAREL as a treatment for postsurgical pain following single-dose local administration was established in 2 multicenter, randomized, double-blind, placebo-controlled, pivotal Phase 3 clinical trials in subjects undergoing hemorrhoidectomy1 or bunionectomy.2 In the Phase 3 hemorrhoidectomy trial, EXPAREL achieved a statistically significant 30% reduction in pain, as measured by the area under the curve (AUC) of the numeric rating scale at rest (NRS-R) pain scores, at 72 hours (primary endpoint) and all additional time points measured up to 72 hours. In addition, EXPAREL reduced the use of opioid rescue medication, including 45% less opioid usage compared with placebo at 72 hours (secondary endpoint).1 In the Phase 3 bunionectomy trial, EXPAREL demonstrated a statistically significant reduction in pain at 24 hours (primary endpoint), and this reduction was also statistically significant at 36 hours (secondary endpoint). The trial also met other secondary endpoints related to pain measurement and the use of opioid rescue medication.2 In addition; eight Phase 2 and 3 clinical trials comparing EXPAREL to unencapsulated bupivacaine HCl have been conducted. Medication was administered into the surgical site in subjects undergoing hemorrhoidectomy,3-5 inguinal hernia repair,6,7 breast augmentation,8,9 bunionectomy,10 and total knee arthroplasty (TKA).11-13 In total, 823 subjects have been studied with EXPAREL administration into the surgical site via infiltration in a variety of surgical settings providing a robust safety database.

The most common treatment-emergent adverse events (TEAEs) reported with EXPAREL were nausea, constipation, and vomiting.14,15 The type and overall incidence of TEAEs are similar with EXPAREL and bupivacaine HCl (62% vs 75%, respectively).14,15 Long-term follow-up safety assessments have been obtained in several studies, including orthopedic studies, which demonstrated no impact on malunion or non-healing at up to 6 weeks after study drug administration, and breast augmentation surgery studies, which demonstrated no clinical sequelae regarding the patency of the implant at up to 21 months after study drug administration. No long-term adverse effects were observed in these studies.

The goals of postsurgical pain management are to improve patient comfort and satisfaction, facilitate rapid recovery and early ambulation, and reduce morbidity. Additionally, ideal postsurgical pain management should help shorten length of stay (LOS). As shown in Figure 1, EXPAREL provides effective pain control for 72 hours following a single administration while reducing the need for opioid therapy.1

---

EXPAREL® Dossier
Figure 1. Cumulative 72-hour pain score in patients receiving EXPAREL or placebo after hemorrhoidectomy$^1$ *P < 0.0001 vs placebo

<table>
<thead>
<tr>
<th>Postsurgical Hemorrhoidectomy Pain Management</th>
<th>EXPAREL 266 mg (n=94)</th>
<th>Placebo (n=93)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compared to placebo, EXPAREL reduced</td>
<td>141.8</td>
<td>202.5</td>
</tr>
<tr>
<td>• Need for opioids (P=0.0007)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Total consumption of opioids (P=0.0006)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EXPAREL delayed the time to first opioid (P&lt;0.001)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EXPAREL group reported better patient satisfaction with their postsurgical analgesia (P=0.0007)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

These findings closely align to the goals of postsurgical pain management. National surveys have found that, among patients undergoing surgery, approximately 80% report pain that is moderate, severe, or extreme in intensity during the 2 weeks immediately following the procedure.\textsuperscript{16,17} The most intense pain occurs on postsurgical days 1 and 2, with visual analog scale (VAS) scores indicating pain of moderate or severe intensity, particularly during the first 24 hours.\textsuperscript{18-21} The more extensive the surgery, the more prolonged and intense the pain is.\textsuperscript{16}

Providing adequate pain relief following surgery is paramount to patient satisfaction and recovery but has also been shown to reduce morbidity and long-term sequelae (such as chronic pain). Current therapies often fail to adequately address postsurgical pain.\textsuperscript{16} In addition; the medications used to treat postsurgical pain have numerous limitations due to their systemic side effects such as opioid related adverse side effects (nausea and vomiting, ileus, respiratory depression, and somnolence). Patients undergoing surgery are acutely aware of the limitations of our current pain management modalities. In a survey conducted by Apfelbaum and colleagues, “approximately 94% of patients thought that some pain medications prescribed after surgery caused adverse effects, and, if given a choice of pain relievers, 72% of patients would choose a non-narcotic drug. The main reasons for this choice were that non-narcotic drugs are less addictive (49%) and have fewer adverse effects (18%).\textsuperscript{16}

As a liposomal non-opioid postsurgical analgesic, EXPAREL is expected to simplify postsurgical pain management, reduce the need for elastomeric pump systems, decrease the need for patient-controlled
analgesia (PCA) devices (with their inherent potential for infection and errors), minimize breakthrough pain episodes, reduce opioid-related adverse effects (ORAEs) by reducing peak systemic levels, and minimize the need for supplemental opioid medications. Therefore, better postsurgical pain management may then potentially allow earlier ambulation, earlier discharge from the hospital, and a faster return to regular activity. The clinical information available for EXPAREL provides robust evidence to support a potential economic advantage if EXPAREL is considered as part of a multimodal postsurgical pain management strategy.

1.2 Conclusions

Postsurgical pain should be treated adequately in order to improve patient comfort, facilitate early recovery, and avoid postsurgical complications including the development of chronic pain. Although opioids are effective, it is known and accepted that a patient’s opioid burden can contribute to their length of stay and hospital cost. When administered into the surgical site in a variety of surgical settings, EXPAREL is an effective non-opioid analgesic agent that reduces the intensity of postsurgical pain for up to 72 hours and limits the use of postsurgical opioids, as demonstrated in Phase 3 placebo-controlled pivotal trials. In the Phase 3 pivotal trials, the adverse event (AE) profile was similar to placebo. The efficacy and safety of EXPAREL was also demonstrated compared with bupivacaine HCl in multiple Phase 2 clinical trials. By expanding the duration of local analgesic therapy from under 12 hours to several days, EXPAREL may allow for decreased use of other pain control agents, including opioids, thereby filling an unmet medical need in the postsurgical pain management landscape.
2 Product Information and Disease Description

2.1 Product Description

2.1.1 Generic Name, Brand Name, and Therapeutic Class
- Generic Name: bupivacaine liposome injectable suspension
-Brand Name: EXPAREL
-Therapeutic Class: anesthetics, anesthetics local, amides (ATC code: N01BB01)

2.1.2 Dosage Forms, Strengths, and Package Sizes
Supplied as single-use vials for local administration:
- 10 mL vial, 1.3% (13.3 mg/mL) packaged in cartons of 10 – not available at this time
- 20 mL vial, 1.3% (13.3 mg/mL) packaged in cartons of 10

2.1.3 NDC for all Formulations
- Vials of 10 mL, 1.3%: NDC 65250-133-10 - not available at this time
- Vials of 20 mL, 1.3%: NDC 65250-266-20

2.1.4 WAC Cost per Unit
- Vials of 10 mL, 1.3% - not available at this time
- Vials of 20 mL, 1.3% -WAC: $285.00 per vial

2.1.5 AHFS or Other Drug Classification
- 72.00 Local Anesthetics

2.1.6 FDA-Approved Indications
EXPAREL (bupivacaine liposome injectable suspension) is a liposomal formulation of bupivacaine, an amide-type local anesthetic, indicated for administration into the surgical site to produce postsurgical analgesia. EXPAREL was approved by the U.S. Food and Drug Administration on October 28, 2011.

Although bupivacaine is used for local anesthesia including nerve block, epidural, and intrathecal nerve block, EXPAREL is currently not indicated for this purpose. Studies are planned to assess the safety and efficacy of EXPAREL in a variety of indications, including peripheral nerve block administration and use in pediatric patient populations.
2.1.7 Pharmacology

The pharmacology of local anesthetics such as bupivacaine is well documented. Briefly, local anesthetics block nerve impulses by binding to sodium channels on the neuronal cell wall, preventing sodium influx, and therefore, preventing cell depolarization. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of effected nerve fibers. Nerve conduction is more readily hindered by anesthetics in sensory nerve fibers because these fibers have longer action potentials, allowing more anesthetic to bind. This means that small, unmyelinated C-fibers (which mediate pain) and small myelinated Aδ-fibers (which mediate pain and temperature sensation) are blocked more readily than larger myelinated Aγ-, Aβ-, and Aα-fibers (which mediate touch, pressure, muscle and postural sensations).25 The potency of any given local anesthetic is governed by its lipid solubility. Agents that are highly lipid soluble are more able to penetrate connective tissue and cell membrane walls than those that are less soluble. The duration of action of local anesthetics is determined by the degree to which they bind proteins. Those with a high affinity for protein binding remain bound to nerve cells for longer, thus increasing their duration of action. Binding to serum proteins also reduces the potential for toxicity in primary organs by decreasing the drug availability in the blood.26

Structurally, local anesthetics are characterized by a lipophilic aromatic ring and a hydrophilic molecule joined by a hydrocarbon chain. The molecule that links the aromatic ring to the hydrocarbon chain is what classifies local anesthetics as either ester (-CO-) or amide (-NHC-) anesthetics. Bupivacaine is an amide-type local anesthetic. It is a homologue of mepivacaine and is chemically related to lidocaine. Chemically, bupivacaine is 1-butyl-N-(2,6- dimethylphenyl)-2-piperidinecarboxamide and has a molecular weight of 288.4. The structural formula for bupivacaine is shown in Figure 2.

Figure 2. Structural formula of bupivacaine

![Structural formula of bupivacaine](image)

EXPAREL is a sterile, nonpyrogenic, preservative-free aqueous suspension of multivesicular liposomes (DepoFoam® drug delivery system) containing bupivacaine. Bupivacaine is present at a concentration of 13.3 mg/mL. Almost all of the bupivacaine in EXPAREL is encapsulated in the multivesicular liposomes, but a small amount (3%) is present as free bupivacaine. After injection of EXPAREL into soft tissue, the free bupivacaine is released immediately and the rest is released from the multivesicular liposomes over a period of time.
Bupivacaine HCl was first approved as an anesthetic/analgesic agent by the FDA in 1972 and DepoFoam (Figure 3) was first approved in 1999 as a component of the chemotherapeutic agent DepoCyt(e)® (cytarabine liposome injection).

Figure 3. DepoFoam multivesicular liposome

DepoFoam is a proven product delivery technology used in two other commercially available products (cytarabine liposome injection, DepoCyt(e) and morphine sulfate extended-release liposome injection, DepoDur®).27 The drug delivery system consists of microscopic, polyhedral, lipid-based particles composed of a honeycomb-like structure of numerous, nonconcentric, internal aqueous chambers containing the encapsulated drug.27 Each chamber is separated from adjacent chambers by lipid membranes. In vivo, the DepoFoam particles release the drug over an extended period of time by erosion and/or reorganization of the particles’ lipid membranes. Release rates are determined by the choice and relative amounts of the lipids in the formulation. The lipids (i.e., phospholipids, cholesterol, and triglycerides) are naturally occurring or close analogues of endogenous lipids so they are well tolerated and cleared by normal metabolic pathways. Overall, the lipid content of DepoFoam is less than 3%. The DepoFoam particles are suspended in sodium chloride 0.9% weight/volume in water for injection and are 10 to 30 μm in diameter, which allows for simple injection through fine-gauge needles.27-29

Composition of EXPAREL
The composition of EXPAREL is described in Table 1.
Table 1. Components of EXPAREL

<table>
<thead>
<tr>
<th>Component</th>
<th>Nominal content per mL</th>
<th>Nominal content per vial (10 mL)</th>
<th>Nominal content per vial (20 mL)</th>
<th>Molar ratio (lipid:drug substance)</th>
<th>Weight ratio (lipid:drug substance)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bupivacaine</td>
<td>13.3 mg</td>
<td>133 mg</td>
<td>266 mg</td>
<td>(1.00)</td>
<td>(1.00)</td>
</tr>
<tr>
<td>Dierucoylphosphatidylcholine (DEPC)</td>
<td>8.2 mg</td>
<td>82 mg</td>
<td>164 mg</td>
<td>0.198</td>
<td>0.547</td>
</tr>
<tr>
<td>Dipalmitoylphosphatidylglycerol (DPPG)</td>
<td>0.9 mg</td>
<td>9 mg</td>
<td>18 mg</td>
<td>0.026</td>
<td>0.060</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>4.7 mg</td>
<td>47 mg</td>
<td>94 mg</td>
<td>0.263</td>
<td>0.313</td>
</tr>
<tr>
<td>Tricaprylin</td>
<td>2.0 mg</td>
<td>20 mg</td>
<td>40 mg</td>
<td>0.092</td>
<td>0.133</td>
</tr>
<tr>
<td>Sodium Chloride</td>
<td>5.4 mg</td>
<td>54 mg</td>
<td>108 mg</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Phosphoric Acid (85%)</td>
<td>qs</td>
<td>qs</td>
<td>qs</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Water for Injection</td>
<td>qs to 1.0 mL</td>
<td>qs to 10 mL</td>
<td>qs to 20 mL</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Nitrogen, NF</td>
<td>qs</td>
<td>qs</td>
<td>qs</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

Lipid Formulation

The median diameter of the liposome particles ranges from 24 to 31 μm. The liposomes are suspended in a 0.9% sodium chloride solution. Each vial contains bupivacaine at a nominal concentration of 13.3 mg/mL. Inactive ingredients and their nominal concentrations are: cholesterol, 4.7 mg/mL; 1, 2-dipalmitoyl-sn-glycero-3-phospho-rac-(1-glycerol) (DPPG), 0.9 mg/mL; tricaprylin, 2.0 mg/mL; and 1, 2-dierucoylphosphatidylcholine (DEPC), 8.2 mg/mL. The pH of EXPAREL is in the range of 5.8 to 7.4.

Liposomal encapsulation or incorporation in a lipid complex can substantially affect a drug’s functional properties relative to those of the unencapsulated or non-lipid-associated drug. In addition, different liposomal or lipid-complexed products with a common active ingredient may vary from one another in the chemical composition and physical form of the lipid component. Such differences may affect functional properties of these drug products. Do not substitute.
2.1.8 Pharmacokinetics/Pharmacodynamics

2.1.8.1 Pharmacodynamics

Local administration of EXPAREL 40 mg was associated with a 2-minute time to onset of local anesthesia in a pain model undertaken in 128 healthy volunteers. Pain was elicited by making a small incision with an automated, disposable, bleeding-time device followed by immediate topical application of acetic acid to the wound. Subjects were then given EXPAREL, unencapsulated bupivacaine HCl, or saline and asked to rate their pain intensity on a 100-mm VAS. Pain scores for both formulations of bupivacaine were significantly lower than for saline (P<0.0001) at each time point assessed (2, 5, 15, and 30 min), and both achieved more than a 30% reduction in pain within 5 minutes of administration.

Initial Phase 1 trials undertaken in healthy volunteers showed that EXPAREL was effective for producing analgesic activity regardless of whether it was administered as a subcutaneous (SC) injection or an epidural. Administered as a nerve block at a dose level of 155 mg, a single injection of EXPAREL sustained nerve blockade for longer than a single dose of unencapsulated bupivacaine HCl 75 mg in volunteers undergoing cold, warmth, and vibratory threshold nociceptive tests. A dose-finding study of epidural EXPAREL in 40 volunteers determined that sensory block was achieved at doses as low as 89 mg and that the effect increased in intensity and duration as doses were increased. At a dose of 266 mg, EXPAREL demonstrated prolonged analgesic activity for a duration of up to 72 hours, whereas the sensory block observed with bupivacaine HCl 50 mg returned to baseline levels within 6 to 12 hours. Importantly, EXPAREL did not cause any major motor block at doses up to 266 mg and where motor block did occur, its maximum duration was 4 hours compared to 12 hours in the unencapsulated drug group. However, additional studies of sufficient sample size are necessary to fully address the occurrence and significance of motor blockade following epidural administration of EXPAREL. Of additional interest is that plasma levels of EXPAREL were significantly lower than those associated with systemic bupivacaine toxicity.

2.1.8.2 Pharmacokinetics

Absorption

The clinical pharmacokinetics (PK) of EXPAREL are consistent with a 2-compartment model: short-term first order release followed by zero-order kinetic release over a variable length of time depending on the surgical procedure (see Figure 4 below). In Phase 1/2 trials, the shape of the concentration-time curve remained the same regardless of whether EXPAREL was administered via SC infiltration or via an epidural. This profile reflects the nature of the liposomal formulation and the absorption characteristics of bupivacaine once it is released from the drug-delivery system. EXPAREL is a suspension of bupivacaine-containing DepoFoam particles in 0.9% sodium chloride solution along with a small amount of free (unencapsulated) bupivacaine. When EXPAREL is administered, the free bupivacaine in the solution is immediately available for absorption into the systemic circulation (first peak), while the bupivacaine in the DepoFoam particles is released more gradually over an extended period of time (second peak; Figure 4). Following its release from the DepoFoam particles, the rate of systemic absorption of bupivacaine is dependent upon the total dose of the drug...
administered, the route of administration, and the vascularity of the administration site.36

Figure 4. Absorption profile of EXPAREL vs bupivacaine HCl following local infiltration in men undergoing inguinal hernia repair6

Because the kinetics of unencapsulated bupivacaine HCl differ in relation to the dose level, administration route, and vascularity of the administration site,36 the PK parameters of EXPAREL after local administration were evaluated in several surgical procedures, including bunionectomy and hemorrhoidectomy (Table 2).37-39
Table 2. Summary of pharmacokinetic parameters for bupivacaine after administration of single doses of EXPAREL and bupivacaine HCl

<table>
<thead>
<tr>
<th>Parameter* [1]</th>
<th>Dose and Surgery/Incision Size</th>
<th>EXPAREL</th>
<th>Bupivacaine HCl</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>106 mg &lt;3 cm</td>
<td>266 mg ≥3 cm</td>
<td>532 mg Major Orthopedic/Reconstructive</td>
</tr>
<tr>
<td></td>
<td>Bunionectomy Study 317 (N=26)</td>
<td>Hemorrhoidectomy Study 316 (N=25)</td>
<td>Inguinal Hernia Study 402-C-201 (N=12)</td>
</tr>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt; (ng/mL)</td>
<td>166 (92.7)</td>
<td>867 (353)</td>
<td>365 (128)</td>
</tr>
<tr>
<td>T&lt;sub&gt;max&lt;/sub&gt; (h)</td>
<td>2</td>
<td>0.5</td>
<td>12</td>
</tr>
<tr>
<td>AUC&lt;sub&gt;(0‐t)&lt;/sub&gt; (h·ng/mL)</td>
<td>5864 (2038)</td>
<td>16,867 (7868)</td>
<td>16,028 (5455)</td>
</tr>
<tr>
<td>AUC&lt;sub&gt;(inf)&lt;/sub&gt; (h·ng/mL)</td>
<td>7105 (2283)</td>
<td>18,289 (7569)</td>
<td>16,758 (6288)</td>
</tr>
<tr>
<td>t&lt;sub&gt;1/2&lt;/sub&gt; (h)</td>
<td>34.1 (17.0)</td>
<td>23.8 (39.4)</td>
<td>14.6 (4.64)</td>
</tr>
</tbody>
</table>

*Arithmetic mean (standard deviation), except T<sub>max</sub> (median).

As shown in Table 2, there is a dose-related increase in the mean maximum plasma concentration (C<sub>max</sub>) of bupivacaine after EXPAREL doses of 106 mg, 266 mg, and 532 mg were administered into the surgical site in bunionectomy, hemorrhoidectomy or inguinal hernia repair, and major orthopedic/reconstructive surgical procedures (such as TKA wounds), respectively. Mean values for the area under the plasma concentration-time curve (AUC<sub>0‐t</sub>) were comparable for both 266-mg doses administered to large wounds, and the exposure was 2.3-fold greater than after administration of 106-mg doses to small wounds, consistent with the 2.5-fold difference in dose. There was a 3.6-fold increase in AUC<sub>0‐t</sub> between the 266-mg doses administered to large wounds and the 532-mg dose administered to major orthopedic/reconstructive wounds. This greater-than-dose-proportional increase in exposure after administration by infiltration is consistent with the cross-study analysis of the effect of dose on exposure.

Distribution

After bupivacaine has been released from EXPAREL and is absorbed systemically, bupivacaine distribution is expected to be the same as for any bupivacaine HCl solution formulation. Local anesthetics, including bupivacaine, are distributed to some extent to all body tissues, with high concentrations found in highly perfused organs such as the liver, lungs, heart, and brain.
Local anesthetics, including bupivacaine, appear to cross the placenta by passive diffusion. The rate and degree of diffusion is governed by:

- The degree of plasma protein binding,
- The degree of ionization, and
- The degree of lipid solubility

Fetal/maternal ratios of local anesthetics appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer. Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4). The extent of placental transfer is also determined by the degree of ionization and lipid solubility of the drug. Lipid soluble, non-ionized drugs such as bupivacaine readily enter the fetal blood from the maternal circulation.

**Metabolism**

Amide-type local anesthetics, such as bupivacaine, are metabolized primarily in the liver via conjugation with glucuronic acid. Pipecolylxylidine (PPX) is the major metabolite of bupivacaine; approximately 5% of bupivacaine is converted to PPX. Elimination of drug depends largely upon the availability of plasma protein binding sites in the circulation to carry it to the liver where it is metabolized. Various PK parameters of the local anesthetics can be significantly altered by the presence of hepatic disease. Patients with hepatic disease, especially those with severe hepatic disease, may be more susceptible to the potential toxicities of the amide-type local anesthetics.

**Excretion**

After bupivacaine has been released from EXPAREL and is absorbed systemically, bupivacaine excretion is expected to be the same as for other bupivacaine formulations.

The kidney is the main excretory organ for most local anesthetics and their metabolites. Only 6% of bupivacaine is excreted unchanged in the urine.

Urinary excretion is affected by urinary perfusion and factors affecting urinary pH. Acidifying the urine hastens the renal elimination of local anesthetics. Various PK parameters of the local anesthetics can be significantly altered by the presence of renal disease, factors affecting urinary pH, and renal blood flow.

2.1.9 **Contraindications Warnings/Precautions/Adverse Effects**

2.1.9.1 **Warnings and Precautions for Bupivacaine-Containing Products**

See Package Insert.
Chondrolysis

EXPAREL is not approved for intraarticular use. There have been a number of reports, dating back to in vitro work of Chvapil and colleagues in 1979, concerning the impact of bupivacaine and other local anesthetics on cartilage viability. Several cases of chondrolysis have been reported over the past decade in patients who were exposed to various intraarticular doses of bupivacaine, although the medical attribution of these is uncertain. Notably, these reports had been following bupivacaine infusion directly into the joint.

There have been no cases reported of cartilage damage resulting from local, single-dose administration of bupivacaine into a non-joint surgical wound and no cases of chondrolysis observed with EXPAREL to date. Nonetheless, since EXPAREL contains bupivacaine, Pacira has done exploratory work in this area with EXPAREL. This includes preclinical studies, outcome studies in the orthopedic setting, and tissue distribution studies. The distribution of bupivacaine following wound infiltration of EXPAREL around the knee joint was examined in a Phase 2 TKA trial to assess how the joint concentrations of bupivacaine compared to a direct intraarticular infusion of doses of bupivacaine associated with chondrolysis. A total of 138 patients were administered either EXPAREL (133 mg, 266 mg, 399 mg or 532 mg) or unencapsulated bupivacaine HCl (150 mg) by wound infiltration close to the intraarticular space. Fluid was then collected from drainage tubes that had been placed into the intraarticular space for 12 hours post injection. The amount of bupivacaine recovered was similar, whether the injection was bupivacaine HCl or EXPAREL; the total was less than 6 mg. For comparison, the amount of bupivacaine exposed to the intraarticular space in the case of bupivacaine-based “pain pump” infusions (such as On-Q, I-Flow) is 150 mg over 12 hours.

Toxicology Studies

Preclinical work has included two pivotal toxicity studies in which a total of 40 dogs and 40 rabbits underwent meniscectomy and osteochondral debridement (a standard intraarticular surgical model). The animals had been dosed with either EXPAREL (1.5 or 4.5 of 15 mg/mL or 7.5 mg/kg of 25 mg/mL), or bupivacaine HCl (7.5 mg/mL), or saline, and then sacrificed at Day 3 or Day 15. A longitudinal section through the femur and tibio-femoral joint, slanted to go through the osteochondral lesion site (approximately in the midline of the femur), was then examined. No effect on wound healing was present, and there was no effect on histopathology of the surgical sites other than the expected hemorrhage/acute inflammation on Day 3 and fibrosis/neovascularization on Day 15. In sum, there was no evidence of bupivacaine-induced chondrocyte toxicity in the articular cartilage and meniscus in either the EXPAREL or bupivacaine animals. It must be emphasized, however, that bupivacaine-induced chondrocyte toxicity is an infrequent event and therefore many toxicology studies with bupivacaine have not resulted in observation of chondrolysis.
EXPAREL® Studied in Orthopedic Surgical Models

The effect of EXPAREL on new bone formation was examined in a placebo-controlled Phase 3 bunionectomy trial in 186 patients receiving either EXPAREL 106 mg or placebo (saline) by determining the incidence of mal-union or non-union. The potential for impact on bone healing following EXPAREL infiltration into the bunionectomy site was collected by a follow-up physical exam and/or a foot radiograph at approximately 2 to 3 months postsurgery. No abnormal findings in the EXPAREL group were noted.

An additional study of the area of numbness after SC injection provided indirect evidence that EXPAREL, when administered via wound infiltration, will largely remain in the infiltrated area. In a Phase 1 study, nine healthy volunteers were injected subcutaneously with EXPAREL or bupivacaine and the surface area of anesthesia at 24 hours was measured. This study demonstrated that the area of bupivacaine spread in the EXPAREL formulation, as determined by reduced sensitivity to pin prick sensation, was no greater than that of bupivacaine and suggests that local delivery of EXPAREL near a joint will not diffuse more readily into the intraarticular surface than bupivacaine.

Summary of Findings

In reviewing the totality of data, including the orthopedic literature, animal, volunteer, and patient studies, there does not appear to be an increased risk to chondrocytes or cartilage when EXPAREL is used via local administration to the surgical (non-joint) wound, particularly in light of its single-use administration compared to locally administered bupivacaine. EXPAREL or bupivacaine HCl, when administered by wound infiltration, exposes chondrocytes to comparable doses of bupivacaine—and this is substantively less than when bupivacaine is given into a joint space by continuous infusion. However, the clinical trial database for EXPAREL is not of sufficient size to detect very low incidence events.

EXPAREL is contraindicated in obstetrical paracervical block anesthesia. While EXPAREL has not been tested with this technique, the use of bupivacaine HCl with this technique has resulted in fetal bradycardia and death.

2.1.9.2 Adverse Effects

A total of 823 human subjects undergoing various surgical procedures received EXPAREL by local administration into the surgical site in 10 randomized, double-blind clinical studies. There were adequate numbers in the ≥65 years of age category (171 subjects); in the ≥75 years of age category (47 subjects), and the ASA Class 3-4 category (135 subjects). These sample sizes are sufficient to allow a meaningful assessment of EXPAREL safety in these subgroups.

Across all studies, doses ranged from 9 mg to 665 mg and were administered by various routes: local administration into the surgical wound, subcutaneous, perineural, and epidural. In the Phase 2 and Phase 3 studies, the highest dose of EXPAREL administered was 532 mg. EXPAREL has been generally well tolerated. The most common adverse reactions associated with EXPAREL during controlled clinical trials of local administration into a surgical wound were nausea, constipation, and vomiting. Across all study pools,
most of the TEAEs were assessed as mild or moderate in severity and unrelated to study drug. In clinical studies with an active control, no clinically relevant differences between EXPAREL and bupivacaine HCl were observed regarding the frequency, severity, or relationship to study medication of TEAEs. In the pooled analysis of Phase 2 and 3 studies, the percentage of patients who exhibited at least one TEAE for EXPAREL, bupivacaine HCl, and placebo were 62%, 75%, and 43%, respectively.

See package insert for listing of TEAEs.

Cardiac Safety

Pacira has examined the cardiac safety of EXPAREL from several different vantage points, including animal studies, which led to two International Conferences on Harmonisation (ICH) E14-compliant electrocardiogram (ECG) studies and a total of 21 clinical studies, including:

- One trial in which Holter monitoring was performed
- Seven trials in which ECGs were obtained at one or multiple timepoints
- Sixteen patients who, after local administration into the surgical wound, had a plasma bupivacaine C\text{max} greater than 1000 ng/mL.

In this program, no cardiac signal of any kind has been detected. The safety of EXPAREL is emphasized given its single-use administration, often in a monitored postsurgical setting.

In animal studies, a repeat-dose study in dogs was conducted with no qualitative or quantitative abnormalities on ECG measurements caused by EXPAREL noted at doses up to three times greater than the maximum human single dose used in clinical studies of 532 mg (10 mg/kg), on a body weight comparison.

Impact of EXPAREL on QT Interval

Pacira conducted two studies to obtain definitive cardiac safety data as recommended by the ICH E14 guidance. A single-center, Phase 1, randomized, double-blind, placebo- and positive- controlled, five-way, crossover study in 49 healthy volunteers evaluated the effects of two dose levels of EXPAREL on the QT interval (including standard corrections for heart rate, termed either the QTc, QTcF, QTcB) when administered subcutaneously. This was extended to a second study to evaluate two additional higher doses (532 mg and 665 mg) in 16 of the same subjects to be certain that an adequate supratherapeutic dose was studied.

The results of the QTc analysis show that the largest corrected time-matched mean difference from placebo was $-7.67$ milliseconds (ms) for EXPAREL 665 mg and $-3.60$ ms for EXPAREL 532 mg. These values (and their surrounding 90% confidence intervals) indicate that a single dose of EXPAREL 665 mg or 532 mg does not prolong QTc interval. Additionally, no subjects on EXPAREL 665 mg or EXPAREL 532 mg had increases from baseline in QTc corrected analyses which were >60 ms, or absolute values >500 ms. Together, the findings of these studies demonstrate that a single dose of EXPAREL at doses up to 665 mg does not prolong the QTc interval. The mean C\text{max} for the 532 mg dose and 665 mg dose in these healthy volunteers was 310.15 ng/mL and 427.75 ng/mL, respectively.
Impact of EXPAREL® on ECG Parameters

Another Phase 1 study was performed in 30 patients given doses up to 266 mg of EXPAREL epidurally. Holter monitoring was performed with ECG snapshots obtained at 4 hours postdose, time to maximum plasma concentration (T_max), and 24 hours postdose. There was no significant effect seen for treatment alone, assessment time alone, or treatment assessment time interaction indicating that none of these variables had a significant effect on the change in QTcF from baseline value. Regression analysis showed that there was no significant correlation between any of the ECG parameters (QTcB, QTcF, PR interval, and QRS complex) and C_max. 44

A Phase 2 study examined ECG findings from 138 patients with doses up to 532 mg via wound infiltration in TKA. 44 Patients received 133 mg, 266 mg, 399 mg, or 532 mg of EXPAREL (n=28, 25, 26, and 25, respectively) or 150 mg bupivacaine (n=34). The mean change from baseline in mean heart rate (HR) across the entire time of observation after the single dose of EXPAREL was similar across all dose levels, in a range of 12-16 beats per minute (bpm) compared to the 13 bpm change for the 150 mg dose of bupivacaine. The mean change from baseline in mean PR duration across the entire time of observation after the single dose of EXPAREL was similar across all dose levels in a range of -5 to -11 ms compared to the -6 ms change for the 150 mg dose of bupivacaine. The mean change from baseline in mean QTcF duration across the entire time of observation after the single dose of EXPAREL was similar across all dose levels in a range of −7 to −10 ms compared to the −6 ms change for the 150 mg dose of bupivacaine. These changes were similar, and are summarized in Table 3.

Table 3. HR, and PR and QTcF duration changes with EXPAREL

<table>
<thead>
<tr>
<th></th>
<th>Change in HR</th>
<th>Change in PR Duration</th>
<th>Change in QTcF Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXPAREL</td>
<td>12-16 bpm</td>
<td>-5 to -11 ms</td>
<td>-7 to -10 ms</td>
</tr>
<tr>
<td>Bupivacaine</td>
<td>13 bpm</td>
<td>-6 ms</td>
<td>-6 ms</td>
</tr>
</tbody>
</table>

Program-wide Cardiac Safety Database 43

Throughout the entirety of the clinical program, 1307 patients/volunteers have been exposed to EXPAREL, including 823 in the wound infiltration setting. There have been no cardiac deaths. Analysis of the 823 patients for pre-specified cardiac and cardiac-related events revealed a similar AE rate in EXPAREL patients (1.7%) and in the 446 bupivacaine patients in the program (1.8%). The most common cardiac TEAEs were tachycardia (3.9% incidence) and bradycardia (1.6%). 15 Other cardiac TEAEs occurring at an incidence of <2% included syncope, hypertension, hypotension, palpitations, and supraventricular or ventricular extrasystoles. 37

Across the program, a total of 16 patients after administration of EXPAREL via wound infiltration reached a bupivacaine C_max >1 mg/L (maximum plasma bupivacaine concentration 1.57 mg/L). The AE profile in these subjects was reviewed, and no consistent cardiac or CNS profile emerged. Three additional patients in the
Phase 2 TKA study were identified who had PK values consistent with inadvertent intravascular injection (maximum plasma bupivacaine concentration 34.3 mg/L). None of these patients had a clinically relevant change from baseline in any ECG interval, including HR, PR, RS, QT, and QTcB. Furthermore, no relevant changes in QTcF were noted.46-51

### 2.1.10 Interactions

#### 2.1.10.1 Drug/Drug

Some physicochemical incompatibilities exist between EXPAREL and several other drugs. Direct contact of EXPAREL with these drugs results in a rapid increase in free (unencapsulated) bupivacaine, altering EXPAREL characteristics. Therefore, admixing EXPAREL with other drugs prior to administration is not recommended.

EXPAREL is not to be admixed with any other product in the same syringe. Even with this caution, however, the potential may exist that EXPAREL could be used in combination with other drug products. Co-administered drug products known to interact with EXPAREL, however, may potentially adversely affect the properties of EXPAREL and may lead patients to be exposed to potentially toxic levels of bupivacaine.

Physicochemical interactions of EXPAREL with several types of drug products that could be co-administered were evaluated in several studies. It was found that some drug products could cause rapid release of bupivacaine from the multivesicular liposome, and as such, are not compatible with EXPAREL and should be avoided. The interaction potential of the more commonly locally administered drugs or antiseptics with EXPAREL are outlined below. In addition, the compatibility of EXPAREL with commonly employed surgical materials is also discussed:

**Lidocaine and Other Non–Bupivacaine-Based Local Anesthetics**

All non-bupivacaine based local anesthetics (such as lidocaine, ropivacaine, mepivacaine) have a strong interaction with EXPAREL. If they are mixed with EXPAREL, there will be an immediate displacement of the bupivacaine from the DepoFoam matrix. This displacement is the result of lidocaine and similar non-bupivacaine-based local agents having a higher affinity for DepoFoam than bupivacaine. As a result, the dose of free bupivacaine will be increased and will not be predictable, and patients may be exposed to potentially toxic levels of bupivacaine.

Local administration of EXPAREL and lidocaine must be separated by at least 20 minutes to mitigate this displacement.

EXPAREL can be administered in the same area at least 20 minutes after it was infiltrated with the other non-bupivacaine based local anesthetics. Regarding lidocaine, Table 4 demonstrates the potential increase in the Cmax when clinically relevant doses of lidocaine and EXPAREL are given at specific times after one another.
Table 4. Impact of time between lidocaine and EXPAREL® administration on C<sub>max</sub>

<table>
<thead>
<tr>
<th>Time between lidocaine and EXPAREL</th>
<th>Plasma bupivacaine C&lt;sub&gt;max&lt;/sub&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 Minutes</td>
<td>1000% Increase</td>
</tr>
<tr>
<td>10 Minutes</td>
<td>67% Increase</td>
</tr>
<tr>
<td>20 Minutes</td>
<td>No Increase</td>
</tr>
</tbody>
</table>

Therefore, if lidocaine is administered at the beginning of a case, and the case lasts for at least 20 minutes, EXPAREL can be infiltrated at the close of the procedure for postsurgical analgesia.

**Bupivacaine**

Bupivacaine HCl products, such as Marcaine® and Sensorcaine®, demonstrate only a minor interaction with EXPAREL. The higher the ratio of local anesthetic to EXPAREL during co-administration, the more bupivacaine is rapidly released from EXPAREL. At a 2:1 or higher ratio of EXPAREL to bupivacaine HCl, less than 10% of encapsulated bupivacaine is released from EXPAREL. These drugs could be co-administered in the same infiltration area when using that ratio or greater. Specifically, this means that if the plan is to use 266 mg (molar equivalent to 300 mg of bupivacaine HCl) of EXPAREL, up to 150 mg of bupivacaine HCl could be co-administered in the same infiltration area without substantially impacting the bupivacaine release from EXPAREL.

**Topical Antiseptics**

Topical antiseptics, such as povidone iodine (Betadine®) or chlorhexidine (Hibiclens®), demonstrated a strong interaction with EXPAREL when the solutions are admixed. This is due to the surface active nature of antiseptics interacting with lipids. However, if topical antiseptics are applied to the skin surface and allowed to dry prior to local administration of EXPAREL, no interactions were demonstrated, and thus, this is not expected in normal clinical practice.

**Epinephrine**

Epinephrine (with and without stabilizers) demonstrated a minor interaction. This drug could be co-administered in the same infiltration area as EXPAREL.

**Corticosteroids**

Corticosteroids (such as Kenalog® and DepoMedrol®) showed little to no interaction, particularly at clinically relevant doses. These drugs could be co-administered in the same infiltration area as EXPAREL.

**Gentamicin, Bacitracin, and Cefazolin Antibiotics**

Antibiotics (such as gentamicin, bacitracin, and cefazolin) had no interaction with EXPAREL and could be co-administered in the same infiltration area.
Ketorolac

Non-steroidal anti-inflammatory drug (NSAID) pain medications (such as ketorolac) showed essentially no interaction and could be co-administered in the same infiltration area as EXPAREL.

Opioids

Opioids (such as morphine sulfate) have essentially no interactions. Opioid medications and EXPAREL could be co-administered in the same infiltration area.

The degree of bupivacaine release from EXPAREL was cumulative of the individual drugs studied, and no synergistic effects were found. In other words, if EXPAREL were co-administered in the same infiltration area as two other products, each of which is listed above, then the two products together would also have no interaction.

Surgical Materials

Additionally, the compatibility of EXPAREL with several materials frequently used in surgery including polypropylene, expanded polypropylene (PTFE) mesh, silicon shells from breast implants (both textured and smooth), stainless steel, and titanium alloys was studied. Results from clinically relevant exposure studies conducted between EXPAREL and these most common implantable materials (outlined above) demonstrated that none of these materials are affected by the presence of EXPAREL any more than they would be from saline (representing normal body fluids), and none of the materials have a significant adverse effect on key EXPAREL physical/chemical/release properties.

2.1.10.2 Drug/Food

None

2.1.11 Specific Populations/Disease

Pregnancy Category C See package insert Pediatric use

Safety and effectiveness in pediatric patients below the age of 18 have not been established.

Geriatric use

See package insert

In general, similar responses in the AUC of NRS-R scores across the age groups were seen for EXPAREL and placebo in the All Wound Infiltration Studies as in the combined data for the two pivotal studies, and the comparisons of EXPAREL to bupivacaine HCl across age groups did not appear to show any relationship of efficacy to age of the subjects. Furthermore, No overall differences in safety were observed between these patients and younger patients.
Hepatic Impairment

Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, these drugs should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.

The effects of decreased hepatic function on the PK of EXPAREL (following local infiltration) were studied by comparing volunteers with moderate hepatic impairment with age-, gender-, and weight-matched normal controls. Subjects were given a single dose of EXPAREL 266 mg and PK parameters were assessed for the next 21 days. Concentration-time curves for bupivacaine were consistent with the drug’s hepatic clearance route. Mean plasma concentrations were higher in subjects with moderate hepatic impairment than in the healthy control volunteers with approximately 1.5- and 1.6-fold increases in mean C\textsubscript{max} and AUC values, respectively (Table 5). The ratio of free to total protein binding was also increased, being 50% higher in those with moderate hepatic impairment vs normal hepatic function. However, these differences may not be clinically meaningful due to the dynamic equilibrium between the bound and free fractions of bupivacaine.

Table 5. Influence of hepatic function on bupivacaine PK after EXPAREL administration

<table>
<thead>
<tr>
<th>Mean (standard deviation)</th>
<th>Moderate hepatic impairment (n=9)</th>
<th>Normal hepatic function (n=9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C\textsubscript{max} (ng/mL)</td>
<td>149.1 (42.6)</td>
<td>102.8 (37.7)</td>
</tr>
<tr>
<td>T\textsubscript{max} (h)</td>
<td>42.7 (28.2)</td>
<td>54.7 (28.8)</td>
</tr>
<tr>
<td>AUC\textsubscript{0-\textsubscript{last}} (h • ng/mL)</td>
<td>17,177.8 (2349.3)</td>
<td>10,682.7 (4392.6)</td>
</tr>
<tr>
<td>AUC\textsubscript{0-\textsubscript{\infty}} (h • ng/mL)</td>
<td>17,975.5 (2447.0)</td>
<td>11,050.7 (4498.8)</td>
</tr>
<tr>
<td>Half-life (h)</td>
<td>46.5 (26.3)</td>
<td>37.6 (9.8)</td>
</tr>
<tr>
<td>Cl/F (L/h)</td>
<td>17.0 (2.2)</td>
<td>31.2 (11.5)</td>
</tr>
<tr>
<td>Vd/F (L)</td>
<td>1131.6 (624.4)</td>
<td>1742.1 (861.9)</td>
</tr>
</tbody>
</table>

Renal Impairment

See package insert

2.1.12 Dosing and Administration

EXPAREL is a liposomal injection of bupivacaine which is administered as a single dose locally into surgical wounds to produce postsurgical analgesia. EXPAREL should be injected slowly, deep into soft tissue and the dosage level should be guided by the surgical site and the volume required to cover the area (Table 6). EXPAREL can be injected through needles as narrow as 25 gauge with no impact on particle integrity or drug encapsulation.

EXPAREL was studied in bunionectomy and hemorrhoidectomy surgeries in the two pivotal trials
submitted as the basis of efficacy for drug approval.

Table 6. EXPAREL® dosing used in pivotal trials

<table>
<thead>
<tr>
<th>Surgery</th>
<th>Dose of EXPAREL</th>
<th>Volume of EXPAREL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bunionectomy</td>
<td>106 mg</td>
<td>8 mL</td>
</tr>
<tr>
<td>Hemorrhoidectomy</td>
<td>266 mg</td>
<td>20 mL</td>
</tr>
</tbody>
</table>

2.1.13 Access

There is no anticipated risk for drug shortages. There are no prescribing limitations.

2.1.14 Co-Prescribed/Concomitant Therapies

There are no co-prescribed medications. EXPAREL may be used alone or as part of a multimodal approach to postsurgical pain control. EXPAREL may be diluted with 0.9% saline (up to 0.89 mg/mL; i.e., 1:14 dilution by volume). Lactated Ringer's solution has been used in place of saline to provide sufficient volume to cover the surgical area for infiltration. EXPAREL has been tested along with various antibiotics commonly used in surgical procedures.

Antibiotic Cocktail

Three antibiotics; bacitracin, cefazolin, and gentamycin are commonly used during breast implant operations. A triple antibiotic cocktail was prepared according to Table 7 below. EXPAREL was manufactured at 40L scale and stored for approximately 5 months at 2°C to 8°C before initiation of the study; during manufacture it was concentrated to potency by decanting of the supernatant after initial bulk settling. EXPAREL was mixed with 20 mL of the antibiotic cocktail and incubated at 37°C (1INC-26) for 1-, 2-, 4- and 24-hours. Controls, consisting of 15 mL of lot 07PD-002 mixed with 20 mL of 0.9% saline, were also incubated 37°C at the same intervals.

Table 7. Triple antibiotic cocktail

<table>
<thead>
<tr>
<th>Antibiotics</th>
<th>Manufacturer</th>
<th>l. of diluent used</th>
<th>Vol. used to prepare cocktail (mL)</th>
<th>Total volume after dilution with 0.9% saline (mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacitracin</td>
<td>Pharmacia &amp; Upjohn</td>
<td>9.8 mL of 0.9% saline</td>
<td>5.0</td>
<td>250</td>
</tr>
<tr>
<td>Cefazolin</td>
<td>Watson</td>
<td>2.5 mL of MilliQ water</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>Gentamycin</td>
<td>Hospira</td>
<td>Used as is</td>
<td>1.0</td>
<td></td>
</tr>
</tbody>
</table>

For the antibiotic cocktail compatibility mixture, the percentage of free bupivacaine, pH, and PSD (d10, d50 and d90) showed very little change between the control and the sample over the 24-hour period. At the end of the 24-hour incubation, the % free bupivacaine increased from 4.7% to 5.4%, pH decreased from 6.5 to 6.3 and the median (d50) particle size increased from 27.9 µm to 29.4 µm.
2.1.15 Comparison Products

Different formulations of bupivacaine are not bioequivalent at the same milligram strengths, their bioavailability (rate and extent of availability) are not similar enough to the extent that their effects can be expected to be essentially the same. Therefore, it is not possible to convert dosing from other formulations to EXPAREL.

2.2 Place of the Product in Therapy

2.2.1 Disease Description

Surgical procedures can produce tissue damage and pain from 3 separate quarters: somatic tissue (bone, joint, muscle, skin or connective tissue), visceral (caused by damage to/manipulation of the viscera or chest cavity), and the nervous system. Somatic or visceral pain is evoked when noxious thermal, mechanical, and/or chemical (e.g., release of potent inflammatory mediators) stimuli are detected by peripheral nerve fiber nociceptors. Nociceptors in visceral structures are highly sensitive to stretch, ischemia, and inflammatory mediators, while somatic tissue contains nociceptors of both deep (tendons, bones, blood vessels, muscles, etc.) and superficial (skin) origin. Neuropathic pain occurs when neurons are directly impaired or damaged as a result of the procedure. The degree to which a patient experiences one or more of these types of pain is determined by the type and duration of the surgery they undergo. Beyond the initial assault (surgery), pain also arises from ongoing stimuli during the recovery phase when inflammatory mediators released around the incision site sensitize nociceptors in the normally silent primary afferent neurons (Aδ- and C-fibers). No single anesthetic/analgesic is able to target all 3 types of pain (e.g., local anesthetics target only somatic pain), prompting physicians to explore a multimodal approach that utilizes different combinations of agents in the pursuit of effective postsurgical pain relief. The majority of patients who undergo surgery of any kind experience pain that persists for at least several days, or longer if they have undergone more extensive surgery. Appropriate postsurgical pain management is therefore important to improve healing, fast-track patient mobilization, shorten hospital stays (in relation to extensive surgery), and reduce costs.

2.2.1.1 Disease Burden

2.2.1.1.1 Epidemiology

Approximately 100 million surgical procedures are performed every year in the United States. The most recent figures from the US Department of Health and Human Services state that 53.3 million surgical and nonsurgical procedures were performed during 34.7 million ambulatory surgery visits and 46.7 million inpatient procedures were undertaken in 2007. Other national surveys have found that, among patients undergoing surgery, approximately 80% report pain that is moderate, severe, or extreme in intensity during the 2 weeks immediately following the procedure. The most intense pain occurs on days 1 and 2 post-procedure with VAS indicating pain of moderate (score of 4-6) or severe (7-10) intensity particularly during the first 24 hours. Unrelieved acute pain not only causes unnecessary patient suffering, it can also lead to other health
problems, thus delaying recovery from surgery and hospital discharge, and resulting in higher healthcare costs.65,66 Controlling acute postsurgical pain is also important because the intensity of acute pain is a predictor of ongoing chronic pain postsurgery.59,67

The incidence and severity of postsurgical pain can vary significantly from patient to patient, but is primarily determined by the type and duration of the surgery and the type of pain relief given intra- and postoperatively.58-60,67,68 Approximately 25% to 40% of patients will experience moderate to severe pain within 24 hours of “minor” types of surgery (i.e., procedures that can be accomplished in the ambulatory setting),18,19,21 while approximately 80% to 90% of inpatients experience moderate to extreme pain for up to 2 weeks following surgery.16,17 After discharge, pain may continue to interfere with daily activities (e.g., sleep, work) for several days,18,69 and the occurrence of severe pain at home may reflect inadequate pain control during the first few hours after surgery.18

2.2.1.1.2 Societal, Humanistic, and/or Economic Burden

The ASA states that undertreated postsurgical pain may increase the risk of thromboembolic and pulmonary complications, the length of hospital and/or intensive care stay and hospital readmission rates, impair health-related quality-of-life, and increase the risk of developing chronic pain.24 An analysis by the US Department of Health and Human Services’ Agency for Healthcare Research and Quality (AHRQ) of more than 7000 published studies found that pain relief is inadequate in >50% of patients given conventional therapy following surgery,65 and that such patients continue to feel pain of moderate to severe intensity.65,70 The AHRQ recommends that physicians establish pain control plans prior to surgery and ensure that patients are informed about what to expect because administering pain medication on an “as needed” basis can lead to long delays triggered by patient reluctance to ask for help.65 Long delays may then be associated with adverse sequelae because once pain is established, it is more difficult to suppress. Aggressive prevention of pain is therefore better than treatment.65 Furthermore, the economic consequences of under-managed postsurgical pain are many and varied, and more aggressive management could reduce inpatient costs61 as well as costs due to pain-related readmissions among day surgery patients.62

The main costs associated with inpatient postsurgical pain management are for the drugs and devices used, nursing care, and the daily charges for time spent in hospital.71 The hospital LOS is the primary driver of cost and any surgical- or analgesic-related complications in the acute postsurgical period can lengthen LOS and increase costs.71 Aggressive use of evidence-based acute pain management practices in hospitals can lead to reductions in LOS, hospital service costs and daily total costs to produce savings of more than $1,500 per inpatient stay.61

Opioids are a mainstay of postsurgical pain control,72 but are associated with a variety of unwanted and potentially severe side effects such as respiratory depression, drowsiness and sedation, postsurgical nausea and vomiting, pruritus, urinary retention, and ileus. ORADEs tend to increase in frequency with higher dosages,73 and significantly increase LOS and the cost of care in postsurgical patients.73-76 Increased costs are often related to the greater nursing time and monitoring associated with the risk and/or
occurrence of delirium\textsuperscript{77} or respiratory depression,\textsuperscript{78} or the prolonged LOS caused by infection,\textsuperscript{79} noninfectious complications (e.g., falls),\textsuperscript{80} and delayed ambulation\textsuperscript{80} associated with urinary catheterization. Opioids have been shown to be problematic in key patient populations, including:

- Elderly
- Comorbid airway disease (asthma, chronic obstructive pulmonary disease, obstructive sleep apnea)
- Chronic opioid users

The recovery process following ambulatory surgery is also highly dependent on the effectiveness of pain management, with high pain scores predicting increased recovery time and delayed discharge.\textsuperscript{66} In addition, there is a clear need for better and more prolonged pain relief after discharge for ambulatory patients. As many as 30\% to 40\% of day surgery patients experience moderate to severe pain following hospital discharge and as many as 25\% experience breakthrough pain that requires subsequent contact with a healthcare provider.\textsuperscript{18,62}

Pain is a major factor contributing to unanticipated admissions or readmissions following prior day surgery,\textsuperscript{62,81-83} and the inability to effectively control post-discharge pain in ambulatory patients leads to excess healthcare resource utilization and increases the overall economic burden. One study estimated that the mean charge for a patient with an unanticipated admission/readmission due to pain was $1,869 per visit. Return visits to the emergency department due to pain were significantly more costly than returns not due to pain ($986 vs $729, respectively). In total, day surgery patients unexpectedly returning to the hospital because of pain within 30 days of their procedure cost the institution an extra $218,756 that year.\textsuperscript{62}

The indirect costs of poor pain management (e.g., lost productivity, caregiver time) have not been estimated for patients with acute postsurgical pain. However, it can be assumed that any prolongation of recovery time consequent to uncontrolled pain is likely to increase productivity losses, and if inadequate management of acute pain leads to the development of chronic pain, indirect costs may be further increased.\textsuperscript{71} The indirect cost associated with time spent managing the AEs of pain medication should also be considered, but this has yet to be formally studied.\textsuperscript{71}

\subsection*{2.2.2 Approaches to Treatment}

Postoperative pain management is challenging and complex, because the pathophysiology of postsurgical pain is multifaceted. The current approach to treatment is therefore to employ a multimodal or “balanced” treatment approach using a variety of analgesic modalities, preventing postsurgical pain by combining opioid and non-opioid agents that act at different sites within the central and peripheral nervous systems to provide a broad spectrum of pain relief. While the main aim is to effectively reduce pain using all the pharmacological tools currently available, there is an increasing secondary drive toward minimizing opioid use and thus opioid-related side effects (approximately 98\% of patients currently receive opioids for postsurgical pain relief in the United States).\textsuperscript{68,81} This in turn hastens the recovery
process, allows “fast-tracking” of patient ambulation and return to normal activities, and so reduces hospital stays and their associated costs. Additionally, proactive multimodal pain management may have benefits in decreasing the “wind-up” (central sensitization) and conversion to chronic, long-term pain.

There are 4 main classes of pharmacotherapy used for postsurgical analgesia. The regional anesthetic agents (amides such as bupivacaine and lidocaine, and esters such as procaine) act by binding to neuronal sodium channels and blocking nerve impulses. The opioids (e.g., morphine, fentanyl) agonize or antagonize endogenous opiate receptors, while the NSAIDs and acetaminophen mediate pain relief through anti-inflammatory pathways, such as the cyclooxygenase enzyme. Glucocorticoids are also anti-inflammatory agents, but their mechanism of action remains unclear.

The choice of a particular agent or combination of agents, as well as the route of administration, is driven by a number of factors including: type of surgery, patient population (e.g., children, elderly), and the potential magnitude of the postsurgical pain intensity, as well as a thoughtful assessment of the risk and benefits of each modality for each individual patient.\textsuperscript{24,56,72}

Typically, surgeons initiate postsurgical pain relief intra-operatively or at the end of surgery with the administration of local anesthetics/analgesics such as bupivacaine HCl at the surgical site. Local agents are very effective, but relatively short acting (bupivacaine HCl is one of the longest-acting agents with a duration of approximately 7 hours).\textsuperscript{36}

Multimodal approaches that use local anesthetics/analgesics improve postsurgical pain scores and facilitate earlier hospital discharge as well as provide a means of reducing opioid use.\textsuperscript{66} Some experts recommend that infiltration of local anesthetics into a surgical incision should be a component of all multimodal techniques used for “superficial” procedures (e.g., inguinal herniorrhaphy, breast, anorectal surgery, and knee/shoulder arthroscopy).\textsuperscript{84} Even for more invasive surgical procedures, infiltration of local anesthetics has been shown to diminish intra- and postsurgical opioid requirements and ORAEs.\textsuperscript{84}

Following the establishment of the initial local anesthetic/analgesic pain relief platform, most physicians initiate some form of opioid treatment in the immediate postsurgical period, often via epidural or intravenous PCA systems. As described earlier, monitoring for and managing ORAEs in patients who receive opioids is a significant contributor to the cost of care in postsurgical patients.\textsuperscript{73-76}

Elastomeric pumps are pressurized reservoir balls which administer a continuous flow of analgesic to the wound site via a catheter and allow these agents to be used for several days following cardiovascular, urologic, gynecologic, obstetric, orthopedic, and general surgical procedures.\textsuperscript{85,86} However, after a decade of use, it is becoming clear that elastomeric pumps are associated with numerous drawbacks, including medication errors (filling with the wrong medication, use of nonstandard concentrations, inaccurate filling that affects infusion rates), deflation problems leading to insufficient analgesia, use of the pump for an inappropriately long time, and the need for intensive staff education on their use (and the pitfalls of inadequate training).\textsuperscript{85-88} Similarly, PCA systems present technical challenges during set-up and require maintenance and monitoring, which impose a significant burden on staff. As with elastomeric pumps, medication errors are common during PCA (e.g., programming mistakes,
nomenclature errors, conversion mistakes, battery errors), and the use of a catheter increases the risk of infection and other catheter issues (e.g., migration, leakage, disconnection, incorrect placement), which can result in paresthesia or insufficient pain control.\textsuperscript{89,91} Oversights that result in overdosing can be particularly problematic with subsequent oversedation, respiratory depression, and/or death.\textsuperscript{90}

Although the main goal of multimodal therapy is to maximize the analgesic effect, both national and international guidelines emphasize that this must be balanced against any undesirable side effects so the use of opioids should be minimized as much as possible. One way to reduce the need for opioids is to administer NSAIDs or acetaminophen intraoperatively in conjunction with local anesthetics/analgesics or postsurgically to boost the effect of stronger analgesics. NSAIDs and acetaminophen target different pain pathways than local anesthetics or opioids but are relatively weak analgesics on their own.

Glucocorticoids may also be used as adjunctive agents for the short-term prevention of postsurgical pain. These potent anti-inflammatory drugs are usually administered following arthroscopic, lumbar disc, or other orthopedic surgery and oral surgery. According to the limited evidence available, glucocorticoids can significantly reduce the postsurgical need for other oral or injectable analgesics and can contribute to earlier patient mobilization, reduced convalescence time, and shorter hospital stays.\textsuperscript{72}

Multimodal strategies for pain relief have improved postsurgical analgesia, but considerable challenges remain. The introduction of elastomeric pumps and PCA devices has endeavored to provide more seamless and continuous pain management from surgery to discharge, but these devices are hindered by various shortcomings. Furthermore, the number and complexity of operations being performed on an outpatient basis is increasing, making conventional opioid-based, IV, PCA, and central neuroaxial analgesia impractical and outmoded.\textsuperscript{92} Bupivacaine HCl, the longest acting of the local anesthetics, only has a duration of action of approximately 7 hours.\textsuperscript{36}

A medical need still exists to extend the pain relief supplied by bupivacaine HCl, thereby delaying, decreasing, and/or eliminating the need for opioids and injectable NSAIDs. In clinical studies, EXPAREL has been shown to extend pain relief up to 72 hours.\textsuperscript{11} The 3-day pain relief provided by EXPAREL should simplify postsurgical pain management, minimize breakthrough pain episodes, and reduce opioid-specific side effects by reducing the need for supplemental opioid medications.\textsuperscript{27}

2.2.3 Relevant Treatment Guidelines and Consensus Statements From National and/or International Bodies

The PROSPECT guidelines are the most recent postsurgical pain management guidelines to be developed. PROSPECT stands for “\textsuperscript{\textsc{P}}RO\textsuperscript{\textsc{C}}edure-\textsuperscript{\textsc{S}}PEC\textsuperscript{\textsc{i}}fic Postoperative Pain ManagementT” and was developed by the European Society of Regional Anaesthesia and Pain Therapy (ESRAPT).\textsuperscript{93} PROSPECT differs somewhat from traditional guidelines in that it is a web-based clinical decision support program developed and managed by anesthesiologists and surgeons.\textsuperscript{94} Because both the type and duration of surgery have a direct impact on the incidence and severity of pain, the online tool (http://www.postoppain.org/frameset.htm) provides evidence-based recommendations specific to each of the following procedure types: abdominal
hysterectomy, colonic resection, hemorrhoid surgery, herniorrhaphy, laparoscopic cholecystectomy, non-cosmetic breast surgery, thoracotomy, total hip arthroplasty, and TKA.\textsuperscript{94} A summary of the intra- and postoperative recommendations for the pharmacological management of pain in selected types of surgery are provided in Table 8 below. One of the most notable updates included in these guidelines is the recommended use of a long-acting local anesthetic for hernia repair (long-acting anesthetics were not available at the time of earlier guideline development).

With respect to more traditional practice guidance, the ASA\textsuperscript{24} and the Veterans Health Administration (part of the United States Department of Defense; VHA/DoD)\textsuperscript{72} have both published guidelines for the management of postsurgical pain. The VHA/DoD is the more comprehensive of the 2 US guidelines, providing pre- and postsurgical pain management algorithms and information about pain assessment, site- and surgery-specific pain control, the pharmacological treatment choices available, and patient education.\textsuperscript{72} The ASA takes a more generalized, evidence-based approach, giving brief guidance on what institutional policies and procedures should be in place, the preoperative evaluation and preparation of the patient, perioperative and multimodal techniques for pain management, and approaches to special patient subpopulations.\textsuperscript{24} Both guidelines recommend a multimodal approach to pain management that uses at least 2 agents that act via different mechanisms to achieve a superior analgesic effect without increasing AEs. Such multimodal approaches should be individualized according to the patient, operation, and any other relevant circumstances.
Table 8. PROSPECT: intra- and postoperative local anesthetic pharmacological postsurgical pain management recommendations for selected surgeries\textsuperscript{94}

<table>
<thead>
<tr>
<th>Type of surgery</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemorrhoid surgery</td>
<td>When used as an adjunct to anaesthesia, perianal LA infiltration is recommended for intra- and postoperative analgesia (Grade A), based on procedure-specific evidence for analgesic efficacy (LoE 1)</td>
</tr>
</tbody>
</table>
| Herniorrhaphy                    | • Local anaesthetic injection techniques (inguinal nerve block/field block/infiltration), administered pre-operatively or intra-operatively, or both, are recommended (Grade A) because they reduce early postoperative pain and supplementary analgesic use compared with placebo. The effect of pre-operative administration is comparable to post-incisional administration  
  • There are insufficient data to recommend (Grade D) one injection technique (inguinal nerve block/field block/infiltration), or combination, in preference to another  
  • Local anaesthetic instillation administered at closure cannot be recommended at this time, despite some evidence for its analgesic efficacy, because of limited data (grade D)  
  • Long-acting local anaesthetics are recommended in preference to short-acting local anaesthetics (Grade D)  
  • Addition of dextran or corticosteroid to local anaesthetic solution is not recommended (Grade D) because of limited procedure-specific evidence |
| Abdominal hysterectomy           | • Pre-operative local anaesthetic infiltration at the proposed site of incision is not recommended for abdominal hysterectomy because of its lower benefit compared with post-incisional infiltration for reducing postoperative pain in hysterectomy (Grade A). Post-incisional wound infiltration is recommended (see \textit{Intra-operative Wound Infiltration})  
  • Intra-operative wound infiltration is recommended based on specific evidence that it reduces pain following hysterectomy at 8 h (Grade A). Although this outcome did not reach clinical significance, this method of analgesia is convenient and has a favourable safety profile |
| Laparoscopic cholecystectomy      | • Long-acting LA wound infiltration is recommended (Grade A) for reducing wound pain (procedure-specific evidence, LoE 1), but not for reducing shoulder pain (procedure-specific evidence, LoE 1)  
  • There is evidence that pre-operative administration is of no greater analgesic benefit than intra- or postoperative administration (procedure-specific evidence, LoE 1) |

LA=local anesthetic.

The choice of a particular agent or combination of agents, as well as the route of administration, is driven by a number of factors including: type of surgery, patient population (e.g., children, elderly), and the potential magnitude of the postsurgical pain intensity, as well as thoughtful assessment of the risks and benefits of each modality for each individual patient. The ASA recommends 3 main types of pain...
technique in the immediate perioperative period: epidural or intrathecal opioid analgesia, PCA with systemic opioids, and regional analgesia (e.g., intercostal blocks, plexus blocks, local anesthesia/analgesia).²⁴ The society notes that, according to current literature, 2 routes of administration may be more effective for providing perioperative analgesia than a single route. For example:

1. Epidural or intrathecal opioid analgesia combined with intravenous, intramuscular, oral, transdermal or SC analgesics provide better analgesia than epidural opioids alone

2. Intravenous opioids combined with oral NSAIDs, COXIBs, or acetaminophen provide better analgesia than intravenous opioids alone.²⁴

Similarly, the VHA/DoD guidelines for the management of postsurgical pain also advocate a multimodal approach to pain management, stressing the importance of developing a collaborative plan in conjunction with patients.⁷² They advocate different treatment approaches, depending on the type of surgery the patient is undergoing (summarized in Table 9). The VHA/DoD recommendations were last updated in 2002.
Table 9. VHA/DoD recommendations for postsurgical pain management based on surgical site

<table>
<thead>
<tr>
<th>Type of surgery by body region</th>
<th>Pharmacologic Therapy (Route)</th>
<th>Non-Pharmacologic</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Head and Neck</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ophthalmic</td>
<td>OP,NS</td>
<td>OP,NS</td>
<td>LA</td>
</tr>
<tr>
<td>Craniotomy</td>
<td>OP,NS</td>
<td>OP,NS</td>
<td>LA</td>
</tr>
<tr>
<td>Radial neck</td>
<td>OP,NS</td>
<td>OP,NS</td>
<td>OP,LA</td>
</tr>
<tr>
<td>Oral-maxillofacial</td>
<td>OP,NS,CS</td>
<td>OP,NS,CS</td>
<td>OP,LA</td>
</tr>
<tr>
<td><strong>2. Thorax noncardiac</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thoracotomy</td>
<td>OP,NS</td>
<td>OP,NS</td>
<td>OP,LA</td>
</tr>
<tr>
<td>Mastectomy</td>
<td>OP,NS</td>
<td>OP,NS</td>
<td>OP,LA</td>
</tr>
<tr>
<td>Thoracotomy</td>
<td>OP,NS</td>
<td>OP,NS</td>
<td>OP,LA</td>
</tr>
<tr>
<td><strong>3. Thorax-Cardiac</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CABG</td>
<td>OP,NS</td>
<td>OP,NS</td>
<td>OP,NS</td>
</tr>
<tr>
<td>MID-CAB</td>
<td>OP,NS</td>
<td>OP,NS</td>
<td>OP,NS</td>
</tr>
<tr>
<td><strong>4. Upper abdomen</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laparotomy</td>
<td>OP,NS</td>
<td>OP,NS</td>
<td>OP,NS</td>
</tr>
<tr>
<td>Laparoscopic cholecystectomy</td>
<td>OP,NS</td>
<td>OP,NS</td>
<td>OP,NS</td>
</tr>
<tr>
<td>Nephrectomy</td>
<td>OP,NS</td>
<td>OP,NS</td>
<td>OP,NS</td>
</tr>
<tr>
<td><strong>5. Lower abdomen/pelvis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hysterectomy</td>
<td>OP,NS</td>
<td>OP,NS</td>
<td>OP,NS</td>
</tr>
<tr>
<td>Radical prostatectomy</td>
<td>OP,NS</td>
<td>OP,NS</td>
<td>OP,NS</td>
</tr>
<tr>
<td>Hernia</td>
<td>OP,NS</td>
<td>OP,NS</td>
<td>OP,NS</td>
</tr>
<tr>
<td><strong>6. Extremities</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vascular</td>
<td>OP,NS</td>
<td>OP,NS</td>
<td>OP,NS</td>
</tr>
<tr>
<td>Total hip replacement</td>
<td>OP,NS</td>
<td>OP,NS</td>
<td>OP,NS</td>
</tr>
<tr>
<td>Total knee replacement</td>
<td>OP,NS</td>
<td>OP,NS</td>
<td>OP,NS</td>
</tr>
<tr>
<td>Knee arthroscopy/Arthroscopic</td>
<td>OP,NS</td>
<td>OP,NS</td>
<td>OP,NS</td>
</tr>
<tr>
<td>Amputation</td>
<td>OP,NS</td>
<td>OP,NS</td>
<td>OP,NS</td>
</tr>
<tr>
<td>Shoulder</td>
<td>OP,NS</td>
<td>OP,NS</td>
<td>OP,NS</td>
</tr>
<tr>
<td><strong>7. Back/Spinal</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laminectomy</td>
<td>OP,NS</td>
<td>OP,NS</td>
<td>OP,NS</td>
</tr>
<tr>
<td>Spinal fusion</td>
<td>OP</td>
<td>OP</td>
<td>OP</td>
</tr>
</tbody>
</table>

**Indications for Use:**
- **Bold/Italicized:** Preferred based on consensus evidence (QE=III; Plain Text: Possible Use; *= bleeding is not contraindication for COX-2.
- **Bold/Shaded:** Common usage based on consensus evidence (QE=I; Plain Text: Possible Use; *= bleeding is not contraindication for COX-2.

**Comments:**
- OP= opioids; NS=Naproxen; CS=corticosteroids; LA=local anesthetics; C=cold; E=exercise; I=immobilization; T=TENS; X=use of cognitive therapy is patient-dependent rather than procedure-dependent.
3  Supporting Clinical Evidence

EXPARÈL has been investigated in 6 randomized double-blind Phase 2 studies, \(^3-7,10,95,96\) one randomized open-label Phase 2 study that was terminated early for administrative reasons, \(^97\) and 5 randomized double-blind parallel group Phase 3 studies. \(^1,2,8,9,13,98\) The pivotal Phase 3 studies supporting the labelled indication for EXPARÈL are studies 316 and 317. \(^1,2\) These, and additional relevant studies, are summarized below.

3.1  Summarizing Key Clinical Studies

3.1.1  Published and Unpublished Data and Clinical Studies Supporting Labelled Indications

EXPARÈL administered via wound infiltration has been examined in five Phase 2 and five Phase 3 studies. \(^1,10,13,96,98\) All of these were randomized, double-blind studies using either active comparators (bupivacaine HCl) or placebo. The pivotal Phase 3 studies were placebo-controlled studies in subjects undergoing hemorrhoidectomy (316) and bunionectomy (317). \(^1,2\)

These studies shared many common characteristics in terms of the patient inclusion/exclusion criteria (Table 10), endpoints, and the way in which the data were analyzed. In order to avoid repetition in the individual clinical trial summaries, the common features are summarized below. Features specific to individual studies are described within each study summary.

These studies used a number of validated instruments for efficacy assessments including:

- The NRS for pain intensity scores. This 11-point scale (from 0 to 10) has been widely used and validated in a number of pain settings. Specifically in a postsurgical setting, the NRS had the best psychometric profile (low error rate, high validity [face, convergent, divergent and criterion]) compared with 4 other pain intensity scales in 504 subjects undergoing general surgery and receiving PCA. \(^99\) As well as individual NRS scores, the EXPARÈL studies also included an assessment of the cumulative pain intensity, represented by the AUC of NRS scores over designated time periods. This measure was reviewed with the FDA as a means of assessing pain control throughout the postsurgical period, rather than at a single designated time point. A lower number indicates less cumulative pain.
- The EuroQol (EQ-5D) is a widely used and validated instrument for assessing quality of life (QOL) in a range of health conditions. \(^100,101\)
- The Brief Pain Inventory (BPI) measures both the severity of pain and pain’s interference with function. It has been validated in a number of languages and in different types of pain (cancer, chronic rheumatic pain, and postsurgical pain). \(^102,103\)
- Subjects’ overall satisfaction with postsurgical pain relief was assessed in all the pivotal Phase 3 studies.
In addition, in a number of studies, an integrated rank analysis of pain intensity and opioid consumption was undertaken. This analysis, first published by Silverman et al in 1993,\(^{104}\) combines the NRS scores and opioid usage to account for pain despite the presence of rescue medication.

Statistical tests were performed against a 2-sided alternative hypothesis with a significance level of 5% (\(\alpha=0.05\)), and all confidence intervals (CIs) calculated were 2-sided 95% CIs. All tests were declared to be statistically significant if the calculated \(P\) value was \(\leq 0.05\).

All studies were funded by Pacira Pharmaceuticals, Inc., San Diego, CA. The two pivotal studies have been published in peer-reviewed literature\(^{1,2}\); some data have been presented as oral presentations or posters at international meetings.\(^{4,7,12,35,105-107}\)

After completion of these studies, an integrated analysis was undertaken of NRS AUC\(_{0-72}\) and NRS AUC\(_{0-24}\) data from the 10 studies in which EXPAREL was administered by wound infiltration.\(^{14}\) These data are presented in Section 3.1.5.
Table 10. Key common inclusion/exclusion criteria (Pivotal Phase 3 studies are shaded in dark gray)

<table>
<thead>
<tr>
<th>Inclusion criteria</th>
<th>Hemorrhoidectomy</th>
<th>Bunion-ectomy</th>
<th>Inguinal hernia repair</th>
<th>Total knee arthroplasty</th>
<th>Bilateral mammoplasty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>≥18</td>
<td>≥18</td>
<td>≥18</td>
<td>≥18</td>
<td>18-75</td>
</tr>
<tr>
<td>ASA class</td>
<td>1-3</td>
<td>1-4</td>
<td>1-3</td>
<td>1 or 2</td>
<td>1-3</td>
</tr>
<tr>
<td>Female subjects</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>postmenopausal, surgically sterile, or using an effective</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exclusion criteria</th>
<th>Hemorrhoidectomy</th>
<th>Bunion-ectomy</th>
<th>Inguinal hernia repair</th>
<th>Total knee arthroplasty</th>
<th>Bilateral mammoplasty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregnant, nursing, or planning to become pregnant</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Concurrent painful physical condition or concurrent surgery that may require analgesic treatment in postsurgical</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>History of suspected or known addiction to or abuse of illicit drugs, prescriptions medicines, or alcohol</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>History of hypersensitivity to amide-type local</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Administration of an investigational drug or procedure during 30 days (or 5 elimination half-lives) prior to study drug</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Uncontrolled anxiety, schizophrenia, or psychiatric disorder that may interfere with</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Significant medical conditions or laboratory results that may increase risk of</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>course or increase their vulnerability</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>A clinically significant event or condition uncovered during</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

ASA=American Society of Anesthesiology.
*NA=not applicable; only males enrolled in this study.
3.1.1.1 Phase 3 Hemorrhoidectomy Study

Study 316: A Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the safety and efficacy of local administration of EXPAREL for prolonged postoperative analgesia in subjects undergoing hemorrhoidectomy (NCT00890721 on www.clinicaltrials.gov)\(^1,38,105,107\)


This randomized, parallel-group, placebo-controlled double-blind study was performed at 4 hospitals in the Republic of Georgia, 4 in Poland and 5 in Serbia between May 11, 2009 and August 18, 2009.\(^1\) The primary objective was to evaluate the magnitude and duration of the effect of a single intraoperative administration of 266 mg EXPAREL compared with placebo in the reduction of postsurgical pain in subjects undergoing hemorrhoidectomy under general anesthesia.\(^1\) Other efficacy measures included use of opioid medication, time to first opioid dose, BPI assessment at 24 hours, 72 hours, and day 30 after surgery, and the patient’s rating of satisfaction with their postsurgical analgesia.

Main eligibility criteria are outlined in Table 10. This pivotal Phase 3 study applied rigorous inclusion/exclusion criteria (i.e., subjects were included only if they were undergoing hemorrhoidectomy using the Milligan-Morgan technique under general anesthesia, and were excluded if they were using NSAIDs [including selective COX-2 inhibitors], opioids, selective serotonin reuptake inhibitors, tricyclic antidepressants, gabapentin, or pregabalin within 3 days of surgery; using acetaminophen within 24 hours of surgery; and had a history of hepatitis [other than hepatitis A]).\(^1\)

Patients were randomized 1:1 to EXPAREL or placebo.\(^1\) Once a patient was ready for surgery, the research designee randomized patients via a centralized Interactive Web Response System and prepared the medications. Finger cots were applied to syringes to ensure that the content of each syringe was completely concealed.\(^38\)

A total of 189 subjects were treated with study drug or placebo.\(^1\) Mean age was 48 years (range 18 to 86), most subjects (n=130) were male, and all (n=189) were white. There were no significant differences between groups in demographic or surgical characteristics.\(^1\) Of the 189 subjects randomized, one in each group was excluded from the FAS because they did not have sufficient data to compute the primary endpoint (at least 2 NRS at rest [NRS-R] pain scores after surgery). Two additional subjects in the EXPAREL group and one in the placebo group were excluded from the per-protocol (PP) population because of protocol violations in the EXPAREL group (taking prohibited medications; morphine in 1 patient and acetaminophen in the other), or because their diary was lost (placebo group).

EXPAREL was compared with placebo using ANOVA with treatment and site as main effects. Comparisons of EXPAREL to placebo for the secondary efficacy endpoints were to use analysis of variance, Cochran-Mantel-
Haenszel tests, and log-rank tests for continuous and categorical endpoints where appropriate. When post-baseline NRS-R values were missing, results were imputed using a combination of the worst observation prior to use of rescue medication within a medication window and last-observation-carried-forward (wWOFC + LOCF). For calculation of rescue medication usage, the projected amounts through 24 hours were calculated. Treatment was with 30 mL of study drug containing either EXPAREL 266 mg or placebo (0.9% sodium chloride for injection) injected at the end of surgery in a fanlike fashion outside of the anal sphincter; 10 mL was injected on the left side, 10 mL on the right side, 5 mL anteriorly, and 5 mL posteriorly.

There was a statistically significant reduction in pain over 72 hours in the group receiving EXPAREL vs placebo as measured by the AUC of the NRS-R pain intensity scores through 72 hours (NRS-R AUC$_{0-72}$; primary endpoint, Figure 5).¹ Mean NRS-R AUC$_{0-72}$ was 202.5 in the placebo group vs 141.8 in the EXPAREL group ($P<0.0001$) in the FAS population and in each individual country.¹ Significantly lower cumulative pain scores (NRS AUC) were noted at all time points to 60 hours (secondary endpoints; Figure 5).

A significantly higher proportion of EXPAREL than placebo recipients required no supplemental opioid medication through 12, 24, 36, 48, 60 and 72 hours ($P\leq0.0007$), and the median time to first supplemental opioid dose was 14 hours and 20 minutes with EXPAREL compared with 1 hour and 10 minutes with placebo ($P<0.0001$). Total opioid consumption was significantly reduced in the EXPAREL-treated vs placebo-treated group through 72 hours ($P=0.0006$).²

Figure 5. Cumulative pain scores (NRS-R AUC) through 72 hours¹
Subjects’ satisfaction with their postsurgical analgesia significantly favored EXPAREL at 24 and 72 hours ($P=0.0007$ in both cases). Overall, 95% of EXPAREL vs 73% of placebo recipients were extremely satisfied or satisfied. Similarly, BPI scores were significantly lower with EXPAREL (4.4) vs placebo (6.6; $P<0.0001$).\(^1\)

The study was undertaken in an exclusively white population and therefore the data cannot be extrapolated to other racial/ethnic groups. Nor can it be extrapolated to subjects undergoing other forms of surgery, including for 1-column hemorrhoids.

### 3.1.1.2 Phase 3 Bunionectomy Study

**Study 317. A Phase 3, multicenter, randomized, double-blind, parallel-group, placebo- controlled study to evaluate the safety and efficacy of a single administration of EXPAREL for prolonged postoperative analgesia in subjects undergoing first metatarsal osteotomy (bunionectomy) [NCT00890682 on www.clinicaltrials.gov]\(^2,39,106\)**


This parallel-group, placebo-controlled, randomized, double-blind study was undertaken at 4 sites in the United States between April 27, and September 17, 2009. The primary objective was to evaluate the magnitude and duration of the effect of a single intraoperative administration of EXPAREL 106 mg, compared with placebo (0.9% sodium chloride for injection) in the reduction of postsurgical pain, with secondary objectives of assessing AUC of NRS scores through 36, 48, 60, and 72 hours; proportion of patients pain-free at 24 hours and other time points (NRS ≤1); proportion of patients who received no rescue pain medication; total oxycodone/acetaminophen consumption (mg) through 24, 36, 48, 60, and 72 hours; and time to first use of oxycodone/acetaminophen. The study sample size was estimated to be 186 subjects (93 per group), based on a previous study with capsaicin in bunionectomy,\(^110\) and assuming that EXPAREL would have an effect similar to capsaicin. At a 2-sided significance level of 0.05, 93 subjects per treatment group in the study would have 90% power to detect a difference of 22.\(^2\)

Adult subjects were included if they were scheduled to undergo primary unilateral first metatarsal osteotomy without hammertoe, able to receive Mayo block for intraoperative local analgesia and propofol and/or midazolam for intraoperative sedation, had clinical laboratory values less than or equal to twice the upper limit of normal or, if abnormal, deemed not clinically significant per the investigator.\(^2\) Additional inclusion criteria are outlined in Table 10. In addition to the exclusion criteria outlined in Table 10, subjects with peripheral neuropathy, diabetes, a history of hepatitis or malignancy were excluded, as were subjects chronically or recently using analgesics (opioids, non-opioids, NSAIDs, acetaminophen) or agents with analgesic potential (SSRIs, gabapentin, pregabalin, or duloxetine).\(^2\)

On Day 1, each subject underwent bunionectomy under midazolam and/or propofol sedation followed by a Mayo block using a maximum of 25 mL of 2% lidocaine without epinephrine. At least 30 minutes after the
lidocaine was injected, a single dose of EXPAREL 106 mg or saline placebo was administered intraoperatively by local infiltration. Postsurgical rescue analgesia consisted of 1-2 tablets of oxycodone/acetaminophen 5/325 mg every 4 to 6 hours, as needed, to a maximum of 12 tablets per day. Over the first 24 hours (i.e., prior to discharge), a second rescue consisting of a single IV dose of ketorolac 15 to 30 mg could be administered if the subject required it. No other analgesic agents were allowed during the 72-hour observation period. Subjects were discharged after their final scheduled (24-hour) inpatient assessment; after discharge, pain scores, rescue and other concomitant medications, and AEs were recorded in diaries. Staff called subjects at approximately 36, 48, 60, and 72 hours to remind them of the need to assess pain intensity at these time points and to record the use of any medications. Patients then attended a follow-up visit at the study center 72±8 hours after surgery.²

The primary efficacy endpoint for EXPAREL was compared to placebo using analysis of covariance (ANCOVA) with treatment and site as main effects and the baseline NRS score as a covariate. Secondary efficacy endpoints were compared using ANCOVA, ANOVA, CMH tests, and log-rank tests for continuous and categorical endpoints where appropriate. Missing values were imputed using the worst observation prior to receiving rescue medication (wWOCF) or LOCF.² Overall, 193 subjects were randomized; all had at least 2 postbaseline NRS scores, so comprised the safety and full analysis data set. Patients were aged 18-72 (mean 43) years, 82% were female and 71.5% white. Demographic and surgical characteristics were similar in the 2 groups.²

Pain intensity over the first 24 hours (the primary endpoint; AUC₀‐2₄ of NRS scores) was significantly lower with EXPAREL (mean 124.9) than placebo (146.4; P=0.0005). NRS AUC₀‐3₆ was also significantly lower in the EXPAREL than placebo group (196.9 vs 220.3; P=0.023), but NRS AUCs at other time points (48, 60 or 72 hours) were not significantly different.² The percentage of subjects who were pain-free was significantly higher with EXPAREL than placebo at 2, 4, 8, and 48 hours (P<0.05), as was the proportion of patients who received no rescue pain medication through 8, 12, 16, 20 and 24 hours (Figure 6).² The total amount of oxycodone/acetaminophen consumed in the first 24 hours postsurgically was significantly lower in the EXPAREL than placebo group (3.8 vs 4.7 tablets, P=0.0077).² Median time to first oxycodone/acetaminophen was 7.25 hours in the EXPAREL group vs 4.3 hours in the placebo group (P<0.0001).²
Figure 6. Proportion of subjects receiving no rescue medication over time after infiltration of bunionectomy wounds with EXPAREL or placebo\(^2\) \(* P \leq 0.0003\) vs placebo; \(\dagger P < 0.05\) vs placebo

There was no statistically significant difference between groups in the distribution of subjects across the assessment categories for any of the wound assessments (erythema, drainage, edema, and induration). Mean scores for overall satisfaction with wound healing were not statistically significantly different between groups. EXPAREL was well tolerated in subjects who received postsurgical treatment for pain following bunionectomy. No subjects demonstrated any evidence of malunion or nonunion on their routine podiatric follow-up visits.\(^2\)
3.1.1.3 Other Studies in Wound Infiltration

In addition to the pivotal Phase 3 studies (316 and 317) described above, a number of other studies have been conducted that support the efficacy of EXPAREL in surgical wound infiltration.

3.1.1.3.1 Phase 3 Breast Augmentation Studies

SIMPLE Breast Augmentation 315: A Phase 3, multicenter, randomized, double-blind, parallel-group, active-control study to evaluate the safety and efficacy of local administration of EXPAREL for prolonged postoperative analgesia in subjects undergoing bilateral, cosmetic sub-muscular breast augmentation (NCT 00813111 on www.clinicaltrials.gov)\(^8,109,111\)


This Phase 3 study was conducted at 11 plastic surgery sites in the United States between November 18, 2008, and February 25, 2009. This study was discontinued early, after results became available from 2 active-controlled Phase 3 studies comparing EXPAREL with bupivacaine HCl in a multimodal surgical setting in which subjects received concomitant analgesics postsurgically.

The primary objective was to demonstrate the superiority of EXPAREL compared with bupivacaine HCl with respect to the extent and duration of the analgesic effect achieved by local administration of the study drug into the implant pocket of each breast in subjects undergoing bilateral cosmetic, submuscular breast augmentation under general anesthesia. The primary outcome measure used to demonstrate this was the AUC of pain scores with activity using a standard NRS for pain with activity (NRS-A) through 72 hours.\(^110\) Approximately 240 subjects older than 18 years of age were to be randomized in a 1:1 ratio to either EXPAREL or bupivacaine HCl. The study was discontinued after randomization and treatment of 136 subjects aged 19 to 48 (mean age 31) years, 66 to EXPAREL and 70 to bupivacaine HCl.\(^111\) Study drug (either EXPAREL 266 mg or bupivacaine HCl 100 mg) was administered locally into each breast implant pocket of each subject at the end of surgery (total dose per patient of EXPAREL 532 mg or bupivacaine HCl 200 mg per patient). After surgery, subjects received standard treatment with acetaminophen 1000 mg 3 times daily and rescue analgesia with oxycodone as needed, for breakthrough pain.\(^111\)

For the primary efficacy endpoint of AUC for NRS-A scores through 72 hours, EXPAREL was compared to bupivacaine HCl using analysis of variance (ANOVA) with treatment and site as main effects. Sensitivity analyses of AUC of NRS-A through 72 hours were to be performed in support of the primary efficacy analysis: WWOCF+mWOCF, WWOCF on Completers, and LOCF (WWOCF=windowed worst observation carried forward, mWOCF=modified worst observation carried forward, and LOCF=last observation carried forward). Comparisons of EXPAREL to bupivacaine HCl for the secondary efficacy endpoints used ANOVA, analysis of covariance (ANCOVA), Cochran-Mantel-Haenszel (CMH) tests, and log-rank tests.\(^109,111\)
Of the 136 subjects randomized and treated (safety population), 122 made up the full analysis set of subjects who had sufficient postsurgical data to analyze the primary endpoint. The mean NRS-A AUC0–72 was similar in the 2 groups (441.0 with EXPAREL vs 467.2 with bupivacaine HCl), and this was consistent in the sensitivity analyses of the wWO CF completers and LOCF. Similarly, mean AUCs for NRS-A and NRS-R scores were similar at postdose assessments (12, 24, 36, 48, 60, 72, 84 and 96 hours postdose). Mean NRS-A scores were significantly lower in the EXPAREL than bupivacaine HCl group at 8 (P=0.0016) and 12 hours (P=0.0143) postdose, and mean NRS-R scores were significantly lower at 8 hours postdose (P=0.0027), but were not statistically significantly different at any other time point from first awakening to 96 hours.

Postsurgical opioid consumption (in morphine equivalents) was consistently lower in the EXPAREL than the bupivacaine HCl groups at 12, 24, 36, 48, 60, 72, 84, and 96 hours post-dose, and the differences were statistically significant at 24 hours (6.1 vs 9.3 mg equianalgesic parenteral morphine equivalents; P=0.0211) and 48 hours (11.0 vs 16.4 mg; P=0.0459).

However, the proportion of subjects needing supplemental opioid analgesia was similar in the 2 groups at all time points, and there was no significant difference in the median time to first opioid use (2.9 vs 2.5 hours for EXPAREL vs bupivacaine HCl). An integrated assessment of NRS-A scores and opioid usage significantly favored EXPAREL at 12 hours (P=0.0039) and 48 hours (P=0.0434). Similarly, an integrated assessment of cumulative pain intensity (NRS-A AUC) and opioid usage significantly favored EXPAREL at all postsurgical assessments between 12 and 72 hours and at 96 hours (p≤0.0430). Integrated assessment of NRS-R scores and opioid usage significantly favored EXPAREL at 12 hours (P=0.0235), 48 hours (P=0.0289), and 60 hours (P=0.0358). In the integrated analysis of NRS-R AUC and opioid usage, significant differences favoring EXPAREL were seen at 72 hours (P=0.0373) and 96 hours (P=0.0439).

Overall, 80% of subjects in the EXPAREL group vs 74.2% in the bupivacaine HCl group rated their satisfaction with postsurgical analgesia as “extremely satisfied” or “satisfied” (not significant). Patients in the bupivacaine HCl group showed higher rates of discharge readiness at 1, 2 and 3 hours on the MPADSS scale, and the differences were significant at 1 hour (75.8% with bupivacaine HCl vs 60.0% with EXPAREL; P=0.498) and 3 hours (79.0% vs 61.7%; P=0.0305).
On the BPI questionnaire, there were some statistically significant differences favoring EXPAREL (but none favoring bupivacaine HCl). These were:

- Question 3 – worst pain in the last 24 hours; significant on Day 8 ($P=0.0152$)
- Question 4 – least pain the last 24 hours; significant at 72 hours ($P=0.0107$), 96 hours ($P=0.0039$), and day 8 ($P=0.0018$)
- Question 5 – average pain; significant at 24 hours ($P=0.0432$), 72 hours ($P=0.0201$), and 96 hours ($P=0.0133$)
- Question 6 – pain right now; significant at 48 hours ($P=0.0274$), 72 hours ($P=0.0032$), and 96 hours ($P=0.0109$)
- Question 9b – pain interferes with mood; significant at 72 hours ($P=0.0456$), and Day 8 ($P=0.0427$).\(^{109}\)

Because this study was terminated early, it was not powered to detect a difference between the groups in the primary endpoint. However, the data indicate that EXPAREL was generally at least as effective as, if not more effective than, bupivacaine HCl for postsurgical analgesia in the setting of cosmetic breast augmentation surgery.

**Study 318: An observational study to assess the long-term follow-up of subjects who had participated in breast augmentation studies\(^9,^{112}\)**


This multicenter, observational study was conducted at 11 centers in the United States between February 2010 and March 30, 2010. The aim was to investigate the long-term safety of EXPAREL administered during breast augmentation, defined as changes to the silicone shell of the implant after exposure to the study drug. Patients who had participated in study 210 and study 315 were eligible for inclusion. In prior studies, subjects had received either a total of 532 mg of EXPAREL or 200 mg of bupivacaine HCl divided equally into each breast pocket (in the study 315 subjects) or 75 mg bupivacaine HCl in one breast pocket/133 mg EXPAREL in the other or 75 mg bupivacaine HCl in one breast pocket/266- mg EXPAREL in the other (in the study 210 subjects). In the present follow-up study (318), participating sites identified all subjects who had received study drug in a prior EXPAREL breast augmentation study (210 or 315). Both investigators and subjects remained blind to what treatment the subjects had received.\(^9,^{112}\)

At the office visit (Day 0), subjects reviewed and signed the informed consent, if they agreed to participate. Within the next 21 days (day 0 to 21), subjects were asked to complete a questionnaire regarding their perception of how well they had healed since their implant surgery and, on that day, were expected to undergo a focused physical exam by a physician or designate (if possible, by the plastic surgeon who performed the surgery) assessing postsurgical healing and implant integrity. The questionnaire asked
specifically about breast pain, tenderness, tingling, numbness, burning, and changes in sensation, as well as relevant life events that may have had an impact on the implants (e.g., chest wall surgery at the augmentation scar). The focused physical exam assessed sequelae of implant rupture or deflation, including decreased breast size, hard knots, uneven appearance of the breasts, and swelling. The end of the study occurred when both the questionnaire and the focused physical exam had been completed.9

All study centers participating in prior EXPAREL breast augmentation studies that had administered study drug to at least one subject were invited to participate. Four centers (with 27 subjects) declined to participate, so the maximum number of potential follow-up subjects was 148. Of these, 94 consented to participate in the long-term follow-up, 63 (47%) from study 315, and 31 (78%) from study 210.9

The subjects in the different treatment groups were similar with respect to age and race; there was a higher percentage of Hispanic or Latino subjects in study 210 than in study 315. Mean age was 31.5 years, and 87.2% of subjects were white. All subjects were in ASA class 1 (88.3%) or 2 (10.6%); ASA class data were missing for one subject (1.1%). Mean implant volume was 378 to 379 cc in each breast. Subjects were enrolled in the present study a mean of 15 months after treatment with EXPAREL or bupivacaine HCl in study 315 and a mean of 21 months after treatment in study 210 (overall mean of 17 months).9

More than 90% of subjects in all groups had no change in breast size or shape or changes in skin or nipple (Table 11). When changes in breast size or shape were noted, they were most commonly attributed to scar contracture. There were no reports of palpable hard knots or swelling, and only one report of signs of irritation or implant leakage (in the 75 mg bupivacaine HCl group).9
Table 11. Abnormal findings on physical examination or subject questionnaire in study 318\textsuperscript{112}

<table>
<thead>
<tr>
<th>Sign, n (%)</th>
<th>Study 315</th>
<th>Study 318</th>
<th>Study 210</th>
<th>Study 210</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EXPAREL 532 mg (n=31)</td>
<td>Bupivacaine HCl 200 mg (n=32)</td>
<td>Breast with EXPAREL 133 mg (n=17)</td>
<td>Breast with EXPAREL 266 mg (n=14)</td>
</tr>
<tr>
<td>Changes in breast size/shape</td>
<td>3 (9.7%)</td>
<td>3 (9.4%)</td>
<td>0</td>
<td>1 (7.1%)</td>
</tr>
<tr>
<td>Uneven appearance of breasts</td>
<td>5 (16.1%)</td>
<td>2 (6.3%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Changes in skin or nipple</td>
<td>1 (3.2%)</td>
<td>2 (6.3%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Palpable hard knots</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Palpable swelling</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Signs of irritation or implant leakage</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Subject questionnaire</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Numbness</td>
<td>15 (48.4%)</td>
<td>15 (46.9%)</td>
<td>5 (29.4%)</td>
<td>4 (28.6%)</td>
</tr>
<tr>
<td>Breast pain</td>
<td>3 (9.7%)</td>
<td>3 (9.4%)</td>
<td>3 (17.6%)</td>
<td>2 (14.3%)</td>
</tr>
<tr>
<td>Tenderness</td>
<td>6 (19.4%)</td>
<td>6 (18.8%)</td>
<td>2 (11.8%)</td>
<td>1 (7.1%)</td>
</tr>
<tr>
<td>Tingling</td>
<td>7 (22.6%)</td>
<td>2 (6.3%)</td>
<td>0</td>
<td>3 (21.4%)</td>
</tr>
<tr>
<td>Burning</td>
<td>2 (6.5%)</td>
<td>3 (9.4%)</td>
<td>0</td>
<td>1 (7.1%)</td>
</tr>
<tr>
<td>Other changes in sensation*</td>
<td>3 (9.7%)</td>
<td>7 (21.9%)</td>
<td>0</td>
<td>3 (21.4%)</td>
</tr>
</tbody>
</table>

*Increased sensitivity (n=5), decreased sensitivity (n=7), vibration (n=1), nipple “still not as before” (n=1), unknown (n=1).

Of 94 subjects, only one subject had an implant removed. This subject from study 315 had received bupivacaine HCl 200 mg in both breast pockets. She had her right implant removed when she underwent a mastectomy for breast cancer, 15 months after receiving the study drug. Grade 2 capsule contracture in the left breast was also noted. A safety committee reviewed the study data and determined that the malignancy was not related to study drug. Attempts to obtain a medical release from the subject, and therefore to obtain further information, were unsuccessful.\textsuperscript{9}

The majority of subjects reported no breast pain, tenderness, tingling, numbness, burning, other changes in sensation, chest wall surgery or trauma, or other life events impacting the implant. Numbness was the most commonly reported sensation in both groups, generally experienced in the
first few months after surgery. The incidence of numbness was similar in the EXPAREL and bupivacaine HCl groups. Overall, there was no clear signal that either bupivacaine HCl or EXPAREL was associated with changes in sensation or any other abnormal finding evaluated in this long-term follow-up study.

3.1.1.3.2 Cardiac Safety Analyses

**Study 105:** Evaluation of the effects of therapeutic and supra-therapeutic single doses of EXPAREL given as subcutaneous injection on the QT/QTc interval in young healthy volunteers. A prospective, randomized, placebo- and positive-controlled double-blind, single-center, crossover Phase I study

**Study 107:** Evaluation of the effects of single doses of EXPAREL 532 mg and EXPAREL 665 mg as subcutaneous injections on the QT/QTc interval in young healthy volunteers. A prospective, sequential dose, open label, single-center, Phase I study


Because bupivacaine HCl is capable of impacting the QT interval, an analysis was undertaken in 2 parts in healthy volunteers to examine the impact of EXPAREL on the QT interval. The study was performed in 2 parts: part 1 examined the effect of EXPAREL 266 mg and 399 mg SC on the QTc interval in healthy individuals compared to placebo. The maximum dose was set for safety reasons, taking into account the maximum recommended dose of 355 mg over 24 hours. However, an exploratory arm (part 2) was added to investigate higher doses of EXPAREL (532 and 655 mg SC) when plasma levels were found to be lower than anticipated in the lower doses. In part 1 only, 400 mg moxifloxacin was used as a positive control to confirm assay sensitivity.

The study population for part 1 consisted of 49 healthy, nonsmoking, male and female participants. Participants were excluded if they had a history or presence of clinically significant conditions (including cardiovascular disease, a clinically significant history or family history of congenital long QT syndrome) or had an abnormal electrocardiogram (ECG; PR consistently <120 or >230 ms, QRS consistently >120 ms, QTcB >430 ms for men and >450 ms for women) or were using concomitant medication. For part 2 of the study, 16 of the 49 participants were available. All participants provided written informed consent prior to any study-specific procedures being undertaken.

Measurement of the QT interval was performed automatically with subsequent manual on-screen over-reading using electronic calipers (MUSE CV® Interval Editor; GE Healthcare). The effect on the QT/QTc interval was analyzed using the largest time-matched mean difference between moxifloxacin/EXPAREL and placebo. All on treatment values were corrected using time matched baseline values. Under blinded conditions, QTcI was determined to be the best correction formula.
A total of 49 participants were included in the first part of the study and randomized to a sequence of 4 treatments. Of the participants, 69.4% were men and 30.6% were women. The mean (SD) age was 26 (5) years, with body mass index (BMI) ranging from 19.1 to 29.0 kg/m². With the exception of participants who were on contraception, no concomitant medication was administered during the study. Three participants did not complete the study because of personal or family reasons. Sixteen of the 46 participants completing part 1 were available for inclusion in part 2; 62.5% were men and 37.5% were women, with a mean (SD) age of 27 (6) years and BMI values ranging from 20.3 to 27.1 kg/m². Two participants received concomitant medication during the study: 1 received paracetamol for fever and tonsillitis and the other ibuprofen for thrombophlebitis. All 16 participants completed the study.

No prolongation of mean QTcI was observed in participants receiving EXPAREL 266 and 399 mg compared to placebo. Similarly, no prolongation of mean QTcI was observed in the 16 participants receiving EXPAREL 532 and 665 mg compared with placebo. In contrast, mean QTcI was prolonged in participants receiving moxifloxacin 400 mg compared with placebo (Figure 7).

**Figure 7.** Mean QTcI change from baseline against time for moxifloxacin 400 mg, and EXPAREL 266 mg, 399 mg, 532 mg and 665 mg.
No participants receiving EXPAREL 266 mg or 399 mg in part 1 or EXPAREL 532 mg or 665 mg in part 2 had a maximum QTcI value greater than 500 msec during the study. No changes from baseline in QTcI were greater than 60 msec at any measured time point.\textsuperscript{44}

The changes in QTcI noted with moxifloxacin were consistent with those in previous studies, indicating that this was a valid assay for QT evaluation.

\textbf{3.1.1.3.3 Phase 2 Hemorrhoidectomy Study}

\textit{Study 209: A multicenter, randomized, double-blind, parallel-group, active-control, dose-ranging study to evaluate the safety and efficacy of a single administration of EXPAREL for prolonged postoperative analgesia in subjects undergoing hemorrhoidectomy (NCT00529126 on www.clinicaltrials.gov)\textsuperscript{3-5,95}}


A randomized, parallel-group, double-blind study was carried out at 6 hospitals in the United States and 3 in the Republic of Georgia between July 2007 and January 2008 to evaluate three dose levels of EXPAREL compared with bupivacaine HCl, with respect to the extent and duration of the analgesic effect achieved by a single administration of the study drug via local infiltration in subjects undergoing hemorrhoidectomy.\textsuperscript{3} Approximately 100 subjects were enrolled into 2 consecutive cohorts.\textsuperscript{3} Forty-five subjects in Cohort 1 received 66 or 199 mg EXPAREL or 75 mg bupivacaine HCl in a 1:1:1 ratio (15 subjects per treatment group). Randomization was centralized, with an Interactive Voice Response System used to generate unique subject identification numbers. Based on findings from Cohort 1, an unblinded committee selected a third EXPAREL dose level (266 mg) for evaluation in Cohort 2. In Cohort 2, 55 subjects were enrolled and randomized, as follows: 10 subjects to receive 75 mg bupivacaine HCl, 10 subjects to 66 mg EXPAREL, 10 subjects to 199 mg EXPAREL, and 25 subjects to 266 mg EXPAREL.\textsuperscript{95}

Treatments were prepared and administered by unblinded study personnel who took no part in the postsurgical blinded assessments. A total of 30 mL of the study drug containing either EXPAREL or bupivacaine HCl (Marcaine\textsuperscript{®} 0.25% with epinephrine 1:200,000) was injected at the end of surgery as described for study 316 (see section 3.1.1.1 on page 38). All subjects received postsurgical analgesia with a single IV dose of 30 mg ketorolac, and then, when able to take oral medications, 1000 mg acetaminophen 3 times daily, for 96 hours after the study drug administration. Rescue analgesia consisted of 5 to 10 mg oxycodone orally every 4 to 6 hours, as needed (United States) or 2.5 to 5 mg injectable morphine, parenteral administration, every 4 to 6 hours, as needed (Republic of Georgia).\textsuperscript{4}

For analyses of efficacy and safety, the results from Cohort 1 and Cohort 2 at the same EXPAREL dose level were combined. All bupivacaine HCl subjects were also combined. Comparisons of EXPAREL doses to bupivacaine HCl for efficacy measures used analysis of variance (ANOVA), Cochran-Mantel-Haenszel (CMH)
tests, and log-rank tests.

One hundred subjects received study drug and had at least one postbaseline pain score, making up the Full Analysis Set (FAS). This included 25 subjects in the 199 mg and 266 mg EXPAREL groups, 24 in the 66 mg EXPAREL group and 26 in the 75 mg bupivacaine HCl group. The mean age was 43 years (range 21 to 69), and 94% of the subjects were white. Demographic and surgical characteristics were similar in each group.

Pain intensity, as reflected by the mean cumulative pain scores (AUC of NRS-R), was significantly lower in the EXPAREL 199 and 266 mg groups compared with the bupivacaine HCl group through 72 hours after administration of study medication. The greatest between-group difference occurred in the EXPAREL 266 mg group compared with the bupivacaine HCl 75 mg group. Differences in cumulative pain scores remained statistically significant for the EXPAREL 199 and 266 mg groups compared with bupivacaine HCl through 96 hours (EXPAREL 66 mg, 95% CI for difference vs bupivacaine HCl, -302, 11, P=0.023; 199 mg, 95% CI for difference, -363, -52, P=0.001; 266 mg, 95% CI for difference, -373, -60, P<0.001 vs. bupivacaine HCl). Pain intensity scores at first BM (NRS-BM) were significantly lower in the EXPAREL 199 mg (mean [SD], 4.5 [3.0], P=0.01) and 266 mg (mean [SD], 4.1 [2.1], P=0.003) groups compared with the bupivacaine HCl group (mean [SD], 6.7 [2.7]). Average NRS-BM scores in the three EXPAREL groups were not statistically different than scores in the bupivacaine HCl group. The mean time to first bowel movement (BM) ranged from 55 to 64 hours across the four treatment groups with no significant differences observed. A smaller proportion of patients in each of the three EXPAREL groups required rescue opioid medication compared with the bupivacaine HCl group between the 8-72 hours following surgery.

In the EXPAREL 266 mg group, eight of 25 patients (32%) were opioid-free through 72 hours postsurgery versus two of 25 (8%) in the bupivacaine HCl group (P=0.074). The median (range) time to first use of postsurgical rescue opioid medication was 8 (0.3–96.0) hours in the bupivacaine HCl group compared with 9 (0.1–96.0) hours in the EXPAREL 66 mg group, 11 (0.2–96.0) hours in the 199 mg group, and 19 (0.1–96.0) hours in the 266 mg group (P=0.005 for the 266 mg group vs. bupivacaine HCl). The differences in the total amount of rescue opioid medication used were statistically significant for the EXPAREL 266 mg group compared with bupivacaine HCl 75 mg through 48, 60, 72, 84, and 96 hours after surgery. The ratios of EXPAREL 266 mg to bupivacaine HCl at these time points were 0.39 (P=0.015), 0.037 (P=0.011), 0.34 (P=0.007), 0.32 (P=0.004), and 0.31 (P=0.004). A post-hoc analysis assessed the difference in opioid consumption from 0 to 12 hours postdose compared with 12 to 72 hours postdose. During the first 12 hours postdose, when both the EXPAREL and bupivacaine HCl formulations are presumed to be active, the total amount of rescue opioid medication used was not statistically different across the treatment groups, although the amount used was less in patients who had received EXPAREL. Between 12–72 hours post-infiltration, when EXPAREL is presumed to be active but bupivacaine HCl is not, a statistically significantly lower total amount of opioids were used in the EXPAREL 266 mg group (3.7 vs 10.2 mg, P=0.019). Because this was a post-hoc analysis, the Bonferroni correction was not applied.
Mean (SD) scores for the blinded care provider’s satisfaction with postsurgical analgesia assessment were 6 (2), 7 (2), and 7 (2) in the EXPAREL 66, 199, and 266 mg groups, respectively, compared with 6 (2) in the bupivacaine HCI group (P=0.03 for EXPAREL 266 mg vs. bupivacaine HCl). At baseline, the EQ-5D QOL mean (SD) assessment scores were 72 (18), 74 (18), 68 (18), and 67 (24) in the EXPAREL 66 mg, 199 mg, 266 mg, and bupivacaine HCI groups, respectively. Significant improvement was observed in the mean scores for the EXPAREL 266 mg group compared with the bupivacaine HCl group at 48 and 72 hours after administration of study medication (P=0.006 and < 0.001 at 48 and 72, respectively). By the end of the study, 96% of patients treated with EXPAREL 266 mg had returned to work or normal daily activities compared with 83% of the bupivacaine HCl patients (P=0.19). There were no significant differences between the treatment groups in terms of the number of subjects who met the discharge criteria at 1, 2, and 3 hours after surgery.3

Looking specifically at opioid related adverse events (ORAEs), a post-hoc analysis was conducted in a blinded manner using a definition of ORAEs similar to one already agreed to by the FDA (nausea, vomiting, constipation, pruritis, somnolence, urinary retention, respiratory depression). When comparing the EXPAREL 266 mg to the bupivacaine HCl group, patients receiving EXPAREL had a decrease in ORAEs of 89% (P<0.05). In sum, when compared through 72 hours to patients who received bupivacaine HCl 75 mg, patients who received EXPAREL 266 mg had a decrease in cumulative pain score of 47%, a decrease in total opioids used of 66%, and a decrease in opioid related adverse events of 89% (P<0.05 for all three).3

3.1.1.3.4 Phase 2 Study in Total Knee Arthroplasty

Study 208. A multicenter, randomized, double-blind, parallel-group, active-control, dose- ranging study to evaluate the safety, efficacy, and comparative systemic bioavailability of a single administration of EXPAREL via local infiltration for prolonged postoperative analgesia in subjects undergoing total knee arthroplasty (NCT00485693 on www.clinicaltrials.gov)11,12,40


This Phase 2 study was similar in design to study 209 in hemorrhoidectomy subjects described earlier (see page 48), except that there were 3 cohorts of subjects instead of 2. It was conducted at 10 centers in the United States and the Czech Republic between October 2007 and November 2008.11 In brief, 55 subjects were randomized 1:1:1 in cohort 1 to EXPAREL 133 or 266 mg or bupivacaine HCl, 65 were randomized in a 2:2:5:2 ratio in cohort 2 to EXPAREL 133, 266, 399 mg or bupivacaine HCl, and 44 subjects were randomized in a 5:2 ratio to EXPAREL 532 mg or bupivacaine HCl. A single dose of the study drug was administered intraoperatively via local infiltration on Day 1. All subjects received standard, around-the-clock perioperative treatment with acetaminophen and a single IV dose of 30 mg ketorolac (or equivalent NSAID) at the end of surgery. Postsurgical rescue analgesia initially consisted of parenteral opioid medication (i.e., morphine), generally via PCA pump, followed by oral opioid medication (i.e., immediate-
release oxycodone), as needed. Overall, 138 subjects aged 42 to 75 (mean 62) years undergoing TKA under general anesthesia made up the full-analysis set; 62% of the subjects were female and 92% were white.\textsuperscript{11}

The primary endpoint of NRS-A (during knee flexion) AUC through day 4 showed similar reduction in pain intensity with all doses of EXPAREL and bupivacaine HCl. In addition, a similar proportion of subjects in each treatment group required no supplemental opioid medication postsurgically, and the total postsurgical opioid consumption did not differ between groups.\textsuperscript{11}

However, statistically significant differences were observed in the NRS-R scores at the following time points:

- End of anesthesia in the 399 mg group ($P=0.004$)
- At first opioid in the 399 mg ($P=0.0057$) and 300 mg group ($P=0.0148$)
- At Day 1 in the 532 mg group ($P=0.0271$)
- On the morning of Day 5 in the 532 mg group ($P=0.0397$)
- In the evening of Day 5 in all EXPAREL groups, 133 mg ($P=0.0023$), 266 mg ($P=0.0112$), 399 mg ($P=0.0149$), 532 mg ($P=0.0023$).

Significant between-group differences favoring EXPAREL 532mg over bupivacaine HCl were seen in the NRS at rest AUC through Day 2 ($P=0.0013$), Day 3 ($P=0.0073$), Day 4 ($P=0.0125$) and Day 5 ($P=0.0143$).\textsuperscript{11} EXPAREL at doses of 266 mg or 399 mg significantly delayed the time to first opioid medication ($P\leq0.005$), as well as the time to first occurrence of PONV ($P<0.05$), relative to bupivacaine HCl. EXPAREL 532 mg received a higher mean score for the blinded care provider’s satisfaction with analgesia compared with bupivacaine HCl (9.2 vs 8.3; $P=0.04$). Bupivacaine HCl was significantly more effective than EXPAREL 133 mg in the integrated analysis of NRS evaluations + supplemental opioid use ($P<0.05$), and this was the case when the NRS-A or NRS-R evaluations were used in the analysis. No significant between-group differences were seen in other secondary endpoints: individual NRS-A scores at any time point, QOL scores on EQ-5D, number of postsurgical antiemetic doses, clinically meaningful physical rehabilitation, and time from surgery to first bowel movement, or return to daily activities.\textsuperscript{11}

Overall, these results indicate that EXPAREL is at least as effective as bupivacaine HCl for postsurgical analgesia, and has a greater extent and duration of postsurgical pain relief than bupivacaine HCl at specific time points with higher doses.

### 3.1.1.3.5 Phase 3 Study in Total Knee Arthroplasty

**Study TKA 311: A Phase 3, multicenter, randomized, double-blind, parallel-group, active-control study to evaluate the safety and efficacy of a single intraoperative administration of EXPAREL for prolonged postoperative analgesia in subjects undergoing total knee arthroplasty (TKA) [NCT00745290 on www.clinicaltrials.gov]\textsuperscript{116}**

In this Phase 3 study, 245 subjects undergoing TKA under general or spinal anesthesia were randomized 1:1
to receive EXPAREL 532 mg (n=122) or bupivacaine HCl 200 mg (n=123), infiltrated into the capsulotomy incision (15 mL) and deep tissues of the surgical field (55 mL) before prosthesis implantation and into the SC tissue around the skin incision (10 mL) before surgical closure using a moving-needle technique. Exclusion criteria were consistent with the other Phase 2 and 3 studies in subjects undergoing surgical site infiltration, outlined in Table 10. Subjects received opioid rescue medication, as needed, to control postsurgical pain, as part of a multimodal analgesic regimen consisting of local infiltration with the study drug (EXPAREL or bupivacaine HCl), around-the-clock acetaminophen (1000 mg orally 3 times daily for 96 hours), and rescue opioid pain medication (morphine by PCA pump).13

Overall, 245 subjects were treated (safety population) and 218 comprised the full analysis set (i.e., those who had sufficient data to calculate the primary endpoint of NRS-A AUC0-72). Patients were aged 34 to 86 (mean 66) years; 156 (64%) were female and 206 (84%) white.

Mean NRS-A AUC0-72 scores were similar in subjects receiving EXPAREL 532 mg (mean 359.4) and bupivacaine HCl (mean 334.9; P=0.1266). With the exception of a higher mean NRS-A score in the EXPAREL than bupivacaine HCl group at 48 hours (mean 5.9 vs 5.2; P=0.0363), no other statistically significant differences between treatment groups were seen in any of the other efficacy assessments:

- Postsurgical consumption of supplemental opioid medication
- Pain scores (NRS-A or NRS-R)
- AUC of pain scores
- QOL (EQ-5D)
- Time to first PONV occurrence/number of postsurgical antiemetic doses
- Time to physical recovery (adequate joint flexion/extension, walking and transferring in/out of bed independently)
- Bowel movements
- Return to daily activities
- Subject’s overall satisfaction with postsurgical analgesia at 96 hours.

The trial was not one of the pivotal trials to determine the efficacy of EXPAREL. In this trial there was an unexpectedly high comparator response. For this reason and sample size limitation, this study did not demonstrate a statistically significant difference from the comparator. This trial was a bupivacaine active-control trial where all patients also received ketorolac and APAP with opioid rescue. The results of this study influenced some of the inclusion and exclusion criteria and protocol-specified measures used in the pivotal Phase 3 clinical trials that led to the FDA approved indication for EXPAREL.

3.1.1.3.6 Phase 2 Study in Inguinal Hernia Repair

Study 201: A Phase 2, multicenter, randomized, double-blind, dose-escalating/de-escalating study to evaluate the safety, efficacy, and pharmacokinetics of a single dose of EXPAREL in the management of
postoperative pain in subjects undergoing inguinal hernia repair (NCT01203644 on www.clinicaltrials.gov)\textsuperscript{6,7,108}


This study evaluated the safety, efficacy, and PK of EXPAREL compared with a 100 mg dose of bupivacaine HCl for the treatment of postsurgical pain in subjects undergoing unilateral inguinal hernia repair. Study drug was administered by surgical wound infiltration at the end of the hernia repair procedure. In the first cohort, subjects were randomized 1:1 to EXPAREL 155 mg or bupivacaine HCl. In all subsequent cohorts, randomization was approximately 4:1 to EXPAREL (200, 266 or 310 mg) or bupivacaine HCl administered in a dose-escalating/de-escalating fashion. The use of opioid pain medication was prohibited during the 7-day period preceding the administration of study drug; intraoperative morphine was prohibited and IV fentanyl was limited to no more than 250 μg.

Seventy-six subjects aged 19 to 85 years were randomized, 50 to the 4 EXPAREL dose groups and 26 to bupivacaine HCl; mean age was 55 years across the 3 EXPAREL cohorts and 51 years in the bupivacaine HCl cohort. All subjects were male and 71 (93%) were white. All subjects could be evaluated for safety and efficacy. Demographic and surgical characteristics were similar across the treatment groups.

There were no statistically significant differences between any EXPAREL group and the bupivacaine HCl group in median time to first use of supplemental (opioid or non-opioid) medication. The 155 mg EXPAREL group had the longest median time to first use of supplemental pain medication (13.75 hours), approximately 3-fold longer than the 200 mg EXPAREL (3.94 hours) and bupivacaine HCl groups (4.16 hours), and 2-fold longer than the EXPAREL 266 mg (5.23 hours) and 310 mg (5.48 hours) groups. The median time to first use of supplemental opioid medication was longer in the EXPAREL groups (96 hours in each group) than in the bupivacaine HCl group (65 hours), but the informative value of this endpoint is limited by the small number of subjects taking opioid medication (16.7% to 50% of subjects in each treatment group did not receive opioids). A cumulative analysis of subjects taking pain medication at the 12-, 24-, 36-, 48-, 60-, 72-, 84-, and 96-hour assessments showed that 2- to 3-fold fewer subjects in the EXPAREL groups than the bupivacaine HCl group took supplemental opioid and non-opioid pain medication (differences not statistically significant), and fewer subjects in the EXPAREL groups vs bupivacaine HCl group took supplemental opioid pain medication (differences not statistically significant). The quantity of opioid supplemental medication used postsurgically was 2 to 3 times lower in the EXPAREL groups (adjusted geometric mean dose 1.38 to 2.02 mg of morphine equivalents) compared with the bupivacaine HCl group (4.42 mg); these differences were statistically significant.

The mean pain intensity scores at rest and with activity (VAS-R and VAS-A) were generally lower in the
EXPAREL groups than the bupivacaine HCl group. For VAS-A, the differences between all the EXPAREL groups and the bupivacaine HCl group were more pronounced and statistically significant from 8 to 24 hours after the study drug administration. Overall, the mean integrated pain intensity and supplemental opioid pain medication use was lower (indicating a better response) in all EXPAREL groups compared with the bupivacaine HCl group, at rest and with activity, at all time points. The differences in scores with activity were statistically significant for each EXPAREL group, compared with bupivacaine HCl, during at least 2 postsurgical time points.

Pain intensity scores with activity (CAT-A) were statistically significantly lower in most of the EXPAREL groups compared with the bupivacaine HCl group from 4 to 24 hours after administration. Mostly, fewer subjects in the EXPAREL groups than the bupivacaine HCl group had moderate or severe pain with activity, and differences were statistically significant from 4 to 24 hours after study drug administration. Across all treatment groups, the adequacy of pain control was rated as good or very good by most subjects and most study personnel. The difference in the study personnel ratings of pain control between the 200 mg EXPAREL group and the bupivacaine HCl group was statistically significant at 24 hours; however, there were no other statistically significant differences in ratings between any EXPAREL group and the bupivacaine HCl group at any time point.

No formal analysis was conducted for dose response; however, it appears from a review of the efficacy data that there was no dose response for most efficacy parameters evaluated.

3.1.1.3.7 Phase 2 Study in Breast Augmentation

Study 210: A randomized, double-blind, active-control study to evaluate the safety and efficacy of a single local administration of EXPAREL for prolonged postoperative analgesia in subjects undergoing augmentation mammoplasty (NCT01206608 on www.clinicaltrials.gov) 9,6


This study was conducted at four US centers between March 20, 2008 and August 25, 2008. The primary objective of this study was to demonstrate the superiority of EXPAREL over commercially available bupivacaine HCl with respect to the duration of the analgesic effect achieved by a single local administration of the study drug. The secondary objectives were to evaluate additional dose-response efficacy and safety, and to characterize the local safety of EXPAREL in comparison with bupivacaine HCl.

In this study, 40 women age 18 to 40 years (mean of 29.6 years) undergoing bilateral, cosmetic, or submuscular augmentation mammoplasty were randomized 1:1 to receive:

- EXPAREL 133 mg in one side and bupivacaine HCl 75 mg in the contralateral side
- EXPAREL 266 mg in one side and bupivacaine HCl 75 mg in the contralateral side.
The study drugs were administered into the breast implant pocket at the end of surgery, and subjects 
received standard treatment with acetaminophen 1000 mg three times daily and rescue analgesia with 
immediate-release oxycodone as needed for breakthrough pain.

The statistical analyses were reported using summary tables, figures, and data listings. All statistical tests 
were 2-sided and based on a significance level of 0.05. No adjustments of the significance levels were 
made. Paired t-tests were used to compare EXPAREL (133 mg and 266 mg) with bupivacaine HCl, and 2-
sample t-tests were used to compare 133 mg EXPAREL with 266 mg EXPAREL at each assessment time 
point for NRS-A and NRS-R scores. Missing data for NRS scores were imputed using LOCF. Other missing 
scores were imputed using linear interpolation between the closest non-missing score before and after 
the missing data point. The safety set included all randomized subjects who received the study drug 
(EXPAREL or bupivacaine HCl). The full analysis set included all subjects in the safety subset who had at 
least one postsurgery pain measurement for each breast at the same time point.

All efficacy analyses were performed on the subjects in the FAS and all safety analyses were performed on 
the subjects in the safety subset.

Postsurgical NRS scores were consistently lower with EXPAREL 133 or 266 mg compared with bupivacaine 
HCl at almost every time point, and some of the between-group differences were statistically significant 
(Table 12). Cumulative pain intensity at rest (NRS-R AUC) was significantly lower with EXPAREL 133 mg vs 
bupivacaine HCl at all assessments from 36 through 96 hours, and NRS-A AUC was also significantly lower 
through 60 hours. There were no statistically significant differences between EXPAREL 133 and 266 mg.

More opioid doses were required for pain in the breast that received bupivacaine HCl than the one that 
received EXPAREL (4 doses each for breasts receiving EXPAREL 133 mg or 266 mg vs 11 or 7 doses for the 
contralateral breasts receiving bupivacaine HCl). The number of subjects receiving no supplemental opioid 
pain medication postsurgically was consistently higher at every assessment for the 266 mg vs 133 mg 
EXPAREL group, but these differences were not statistically significant. Total opioid consumption (in 
morphine equivalents) also tended to be lower in the 266 mg group, with statistically significantly lower 
total opioid consumption through 48 to 84 hours (P<0.05) compared with EXPAREL 133 mg. No other 
between-group differences were observed in the frequency of PONV, antiemetic consumption (except at 24 
hours when more subjects required antiemetics in the EXPAREL 266 mg vs 133 mg group; P<0.05), discharge 
readiness, time-to-first bowel movement, blinded caregiver’s satisfaction with postsurgical analgesia, time 
to return to work or daily activities.
### Table 12. Postsurgical assessments of pain intensity during activity (NRS-A) or at rest (NRS-R). Bold font indicates a statistically significant difference vs bupivacaine HCl in the contralateral side\(^9\)

<table>
<thead>
<tr>
<th>First opioid</th>
<th>Postsurgical assessment time (h)</th>
<th>1</th>
<th>2</th>
<th>4</th>
<th>8</th>
<th>12</th>
<th>24</th>
<th>36</th>
<th>48</th>
<th>60</th>
<th>72</th>
<th>84</th>
<th>96</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mean NRS-A score</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exp 133 mg</td>
<td></td>
<td>5.5</td>
<td>4.6</td>
<td>5.3</td>
<td>4.7*</td>
<td>5.1</td>
<td>5.7</td>
<td>4.1*</td>
<td>3.7</td>
<td>2.4</td>
<td>2.3</td>
<td>2.0</td>
<td>1.7</td>
</tr>
<tr>
<td>Bupi</td>
<td></td>
<td>5.6</td>
<td>4.2</td>
<td>5.9</td>
<td>6.3</td>
<td>5.9</td>
<td>6.3</td>
<td>5.4</td>
<td>4.4</td>
<td>3.5</td>
<td>3.0</td>
<td>2.8</td>
<td>2.3</td>
</tr>
<tr>
<td>Exp 266 mg</td>
<td></td>
<td>3.5</td>
<td>3.5</td>
<td>3.9</td>
<td>4.1</td>
<td>4.1</td>
<td>4.3</td>
<td>4.0</td>
<td>3.1</td>
<td>2.8</td>
<td>1.8</td>
<td>2.1</td>
<td>1.3</td>
</tr>
<tr>
<td>Bupi</td>
<td></td>
<td>3.7</td>
<td>3.9</td>
<td>4.4</td>
<td>4.8</td>
<td>4.8</td>
<td>4.8</td>
<td>4.0</td>
<td>3.2</td>
<td>2.9</td>
<td>2.1</td>
<td>1.8</td>
<td>1.8</td>
</tr>
<tr>
<td><strong>Mean NRS-A score</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exp 133 mg</td>
<td></td>
<td>5.7</td>
<td>4.6</td>
<td>4.1</td>
<td>3.6</td>
<td>4.1</td>
<td>3.7</td>
<td>4.5</td>
<td>3.4*</td>
<td>3.0</td>
<td>1.9*</td>
<td>1.9</td>
<td>1.6</td>
</tr>
<tr>
<td>Bupi</td>
<td></td>
<td>5.7</td>
<td>4.6</td>
<td>4.4</td>
<td>4.7</td>
<td>4.7</td>
<td>4.1</td>
<td>4.9</td>
<td>4.2</td>
<td>3.9</td>
<td>2.9</td>
<td>2.6</td>
<td>2.0</td>
</tr>
<tr>
<td>Exp 266 mg</td>
<td></td>
<td>5.3</td>
<td>3.9</td>
<td>3.3</td>
<td>2.9</td>
<td>3.2</td>
<td>3.8</td>
<td>3.4</td>
<td>2.7</td>
<td>2.0</td>
<td>1.8</td>
<td>1.3</td>
<td>1.3</td>
</tr>
<tr>
<td>Bupi</td>
<td></td>
<td>5.6</td>
<td>3.2</td>
<td>3.5</td>
<td>3.2</td>
<td>3.6</td>
<td>3.9</td>
<td>3.6</td>
<td>2.7</td>
<td>2.1</td>
<td>1.9</td>
<td>1.5</td>
<td>1.4</td>
</tr>
<tr>
<td><strong>Mean NRS-A AUC (cumulative pain intensity)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exp 133 mg</td>
<td></td>
<td>57.6*</td>
<td>122.8</td>
<td>181.8</td>
<td>228.3</td>
<td>264.9*</td>
<td>292.7</td>
<td>318.2</td>
<td>340.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bupi</td>
<td></td>
<td>67.2</td>
<td>140.0</td>
<td>209.8</td>
<td>267.9</td>
<td>315.8</td>
<td>354.1</td>
<td>388.2</td>
<td>418.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exp 266 mg</td>
<td></td>
<td>44.9</td>
<td>94.4</td>
<td>144.0</td>
<td>186.0</td>
<td>221.3</td>
<td>249.5</td>
<td>273.2</td>
<td>293.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bupi</td>
<td></td>
<td>51.6</td>
<td>109.4</td>
<td>162.3</td>
<td>205.0</td>
<td>241.0</td>
<td>270.4</td>
<td>293.4</td>
<td>315.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mean NRS-R AUC (cumulative pain intensity)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exp 133 mg</td>
<td></td>
<td>45.4</td>
<td>94.2</td>
<td>141.3*</td>
<td>178.9*</td>
<td>207.6*</td>
<td>229.6*</td>
<td>250.2*</td>
<td>267.7*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bupi</td>
<td></td>
<td>50.7</td>
<td>104.2</td>
<td>158.8</td>
<td>206.7</td>
<td>247.9</td>
<td>280.2</td>
<td>307.6</td>
<td>329.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exp 266 mg</td>
<td></td>
<td>37.8</td>
<td>80.6</td>
<td>116.9</td>
<td>144.5</td>
<td>167.3</td>
<td>185.6</td>
<td>201.1</td>
<td>214.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bupi</td>
<td></td>
<td>40.2</td>
<td>84.8</td>
<td>122.7</td>
<td>151.0</td>
<td>174.7</td>
<td>194.7</td>
<td>211.8</td>
<td>228.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Exp=EXPAREL; Bupi=bupivacaine HCl

*P<0.05 vs bupivacaine HCl in the contralateral side.
Blank cells indicate that no assessment was undertaken at this time.

Although small, this study provided evidence that EXPAREL provides postsurgical analgesia at least as, or more, effective than bupivacaine HCl. Variability was limited by subjects acting as their own controls, but this prevented a comparison of opioid requirements between groups. Cumulative pain intensity at rest (NRS-R AUC) was significantly lower with EXPAREL 133 mg vs bupivacaine HCl at all assessments from 36 through 96 hours, and NRS-A AUC was also significantly lower through 60 hours. There were no statistically significant differences between EXPAREL 133 and 266 mg.
3.1.1.3.8 Phase 3 Study in Hemorrhoidectomy

**SIMPLE Hemorrhoidectomy Study 312:** A Phase 3, multicenter, randomized, double-blind, parallel-group, active-control study to evaluate the safety and efficacy of a single administration of EXPAREL for prolonged postoperative analgesia in subjects undergoing hemorrhoidectomy (NCT00529126 on www.clinicaltrials.gov).116

This randomized, parallel-group, double-blind study was performed at 19 hospitals in the United States between July 28, 2008 and February 24, 2009. The objective was to demonstrate the superiority of a single dose of 266 mg EXPAREL compared with bupivacaine HCl in subjects undergoing hemorrhoidectomy under general or spinal anesthesia. Patients were eligible for inclusion if they met the inclusion criteria outlined in Table 10, were undergoing hemorrhoidectomy under general or spinal anesthetic using the Milligan-Morgan or Ferguson-type techniques (including modified approaches with specialized instruments, such as Ligasure™ or harmonic scalpel), and were in ASA physical class 1-4 (although no class 4 subjects were enrolled). In addition to the exclusion criteria in Table 10, subjects were excluded if they used a long-acting opioid within 3 days prior to surgery or any opioid medication within 24 hours prior to surgery; had a history of hypersensitivity or idiosyncratic reactions to any ingredients in the active treatment (e.g., sulfites in Marcaine with epinephrine), or a contraindication to epinephrine or to any of the pain-control agents planned for postsurgical use (acetaminophen, oxycodone, morphine, or NSAIDs); or if they had conditions where the exacerbation of tachycardia could prove fatal or a condition that may be aggravated by the effects of epinephrine.

An unblinded research designee randomized subjects 1:1 to receive EXPAREL or bupivacaine HCl using a centralized randomization system to obtain a unique random subject identifier. Randomization was stratified by the study site and modality of anesthesia. EXPAREL and placebo are visually distinguishable, so an unblinded person prepared the study drugs and administered them. Staff members conducting study-specific, postsurgical assessments and the subjects and caregivers remained blinded to treatment assignment throughout the study.

At the end of surgery, subjects received a total of 40 mL of study drug containing either EXPAREL 266 mg or bupivacaine HCl 100 mg (Marcaine 0.25% with epinephrine 1:200,000) by injection as described earlier. At the end of surgery, all subjects received a single IV dose of ketorolac 30 mg (or appropriate substitute, such as ketoprofen or diclofenac). Beginning as soon as they could tolerate oral intake, subjects received standard treatment with acetaminophen 1000 mg 3 times daily for 96 hours after study drug administration. Rescue analgesia for breakthrough pain was provided with opioid analgesics, as needed.

The sample size estimate was based on results of the Phase 2 hemorrhoidectomy study (Study 209) using the AUC of NRS-R. Based on a 2-sided t-test with a significance level of 0.05 and a combined SD of 235, with 100 subjects per treatment group, the study had 96% power to detect a difference of 100.

A total of 220 subjects undergoing hemorrhoidectomy were randomized, but 16 (8 in each group) did not receive study drug. The mean age was 50 years (range 20 to 83 years); 106 subjects (52%) were
male. Demographic and surgical characteristics were similar in each group. Of the 220 subjects randomized, 204 received the study drug and made up the safety population. A further 6 subjects (2 from the EXPAREL and 4 from the bupivacaine HCl group) were excluded from the FAS because they did not have sufficient data to compute the primary endpoint (at least 4 NRS-R pain scores after surgery). All subjects in the EXPAREL group (n=101) completed the study including the 30-day assessment, but 6 subjects in the bupivacaine HCl group did not complete the study because they were lost to follow-up. Subjects were required to have at least 4 NRS-R scores within 96 hours for calculation of the primary endpoint. Missing scores before the first non-missing score were replaced by the median score at the missing time point from other subjects in the same treatment group. Missing scores after the last non-missing score were replaced by the last non-missing score (last observation carried forward [LOCF]). Linear interpolation was used to replace missing scores between 2 non-missing scores.

Pain intensity through 96 hours, as measured by NRS-R AUC0-96 (primary endpoint), was not statistically significantly different between the EXPAREL and bupivacaine HCl groups (mean 395.6 vs 359.1; P=0.15). The mean pain intensity score was significantly higher with EXPAREL than bupivacaine HCl at 84 hours (4.3 vs 3.6; P=0.038), but there were no significant between-group differences in NRS-R scores at any other time points. Similarly, the mean integrated NRS-R pain intensity scores and supplemental opioid pain medication consumption favored bupivacaine HCl at the 84 hour time point (P=0.0266). There were no statistically significant differences between the EXPAREL and bupivacaine HCl group in terms of individual or total postsurgical consumption of supplemental opioid medication, the proportion of subjects receiving no supplemental opioid medication, or the time to first use of opioid medication. There were no statistically significant differences between groups in the mean values for other secondary endpoints, such as pain with BM, PONV, discharge readiness, and time to return to work or normal daily activities. Mean values for QOL (measured by EQ-5D) and subject and caregiver’s satisfaction with analgesia were not statistically significant between treatment groups.

Although EXPAREL performed as expected and continued to demonstrate its safety and tolerability, due to the unexpectedly positive results in the control arm, this trial did not meet its primary endpoint. The results of this study influenced some of the inclusion and exclusion criteria and protocol-specified measures used in the successful pivotal Phase 3 clinical trials described above.

3.1.2 Clinical Studies Supporting Off-label Indications (Administration Other Than by Wound Infiltration)

In addition to the studies supporting the efficacy of EXPAREL administered by surgical wound infiltration described above, a Phase 2 study has been conducted investigating EXPAREL administered as a nerve block for the management of pain after bunionectomy and following epidural administration. These two studies are briefly described below. Another Phase 2 study on intercostal injection of EXPAREL during thoracotomy was terminated early, and no efficacy results were analyzed.

3.1.2.1 Nerve Block/Epidural
Study 203: A Phase 2, multicenter, randomized, double-blind, dose-escalating/de-escalating study to evaluate the safety, efficacy, and pharmacokinetics of EXPAREL (Depo-Bupivacaine) administered as a nerve block in the management of postoperative pain in subjects undergoing bunionectomy (NCT01206595 on www.clinicaltrials.gov).10

Data on file.

This sequential-cohort designed study was performed at 11 sites in Europe and Australia between March 3, 2005, and March 9, 2006. The primary objective was to determine the appropriate dose of EXPAREL administered as a nerve block for the management of postsurgical pain after bunionectomy, and secondary objectives were to evaluate the efficacy and PK and safety of various doses of EXPAREL vs a 125 mg dose of bupivacaine HCl.

Patients were randomized in 5 consecutive cohorts. In cohort 1, subjects were randomized in a 1:1 ratio to receive EXPAREL 155 mg or bupivacaine HCl 125 mg. Based on safety, PK, and efficacy data observed in the previous cohort, EXPAREL dose was increased or decreased in subsequent cohorts, where subjects were randomized in a 3:1 ratio to EXPAREL (planned doses 200, 244, 279 and 310 mg) or bupivacaine HCl 125 mg.

Study drug was administered as an ankle block between 1 hour before the induction of general anesthesia and 20 minutes before the end of general anesthesia. The ankle block procedure consisted of five injections via three skin entries targeting the posterior tibial, sural, deep peroneal, superficial peroneal and saphenous nerves. Intravenous fentanyl (≤250 μg) was permitted during general anesthesia. Intraoperative use of morphine or infiltration of any local anesthetic/analgesic into the surgical wound was prohibited.

Patients were eligible for inclusion if they were aged at least 18 years, scheduled to undergo a primary unilateral first metatarsal bunionectomy repair under general anesthesia, ASA Physical class 1 or 2, able to comply with all study visits and procedures, and provided informed consent. Procedures associated with minimal bone excision or limited to soft tissue repair were not eligible for the study. In addition to the inclusion/exclusion criteria outlined in Table 10, subjects were excluded if they had significant ECG abnormalities, alpha 1-acid glycoprotein levels below normal, coagulation disorders, BMI >30 kg/m², and had received opioid medication in the 7-day period before study drug administration.

All statistical tests were performed against a 2-sided alternative hypothesis with a significance level of 5% (α=0.05), and all CIs calculated were 2-sided 95% CIs. With a sample size of 12 in each group, a 0.05 level 2-sided log-rank test for equality of survival curves has a 78% power to detect the difference between a median time in the EXPAREL group of 48 hours and a median time in the bupivacaine HCl group of 12 hours (hazard ratio of 4) when subjects are followed for 96 hours.

Fifty-eight subjects were enrolled into three cohorts: 12 subjects received EXPAREL 155 mg, 12 received 200 mg and 14 received 310 mg, and, overall, 20 subjects received bupivacaine HCl 125 mg. A log-rank test showed no statistically significant differences in the primary efficacy endpoint across the bupivacaine HCl cohorts, so these subjects were combined into one treatment group for all statistical analyses. The full
analysis set included all randomized subjects who underwent the planned surgical procedure, received the study drug, and for whom any data regarding the use of medication for the treatment of surgical pain was collected (58 subjects). Most subjects were white (>90%) and female (57 to 92%), with a mean age of 52 to 59 years.

The primary efficacy endpoint (median time to first use of supplemental postsurgical opioid or non-opioid pain medication for surgical pain) of 9.42 hours for bupivacaine HCl was not significantly different to EXPAREL 155 mg (1.94 hours) and 350 mg (2.43 hours), but was significantly longer than that for EXPAREL 200 mg (1.24 hours; \( P < 0.001 \)). Secondary endpoints assessed through 96 hours after study drug administration included median time to first supplemental postsurgical opioid medication for surgical pain, which was 96 hours for all treatment groups, except EXPAREL 200 mg (7.3 hours). Most subjects (>90%) used supplemental opioid or non-opioid medication for postsurgical pain. The proportions of subjects who did not take supplemental opioid medication for the treatment of postsurgical pain through 96 hours after study drug administration were not significantly different between the EXPAREL and bupivacaine HCl groups (33.3% to 64.3% of subjects vs 55.0% of subjects, respectively). For subjects treated with EXPAREL 310 mg, the quantity of supplemental opioid medication used postsurgically was lower than for subjects treated with EXPAREL 175 or 225 mg, and similar to the bupivacaine HCl treatment group, with an adjusted mean ratio of 0.86 (95% CI 0.25, 3.00) for EXPAREL 350 mg vs bupivacaine HCl. Pain intensity was evaluated at rest (VAS-R and CAT-R) and when attempting to move the big toe (VAS-A and CAT-A). Compared with bupivacaine HCl, mean VAS-A and VAS-R scores were higher in all EXPAREL groups for the first 12 hours, but were often lower in the EXPAREL 350 mg group from 24 to 96 hours. Analysis of data as an integrated rank assessment using the VAS-R and VAS-A scores and total opioid usage to account for the effect of opioid medication use on pain intensity showed a lower therapeutic effect for EXPAREL 155 mg and 200 mg vs bupivacaine HCl throughout the 96-hour assessment period. According to the integrated assessment, EXPAREL 310 mg was inferior to bupivacaine HCl during the first 12 hours, but it performed better after this time point. Overall, based on the integrated assessment’s AUC for the 96-hour study period, EXPAREL 310 mg was better (>4-fold greater AUC) than bupivacaine HCl at rest and slightly worse (25% lower AUC) with activity, but there were no statistically significant differences between the 2 treatment groups at any time point. Pain intensity using CAT scores also generally showed no significant differences between the bupivacaine HCl group and any of the EXPAREL treatment groups. Most subjects and study personnel rated pain control in all treatment groups as very good or good at 24 hours, 48 hours, 72 hours, and 96 hours. Compared with bupivacaine HCl, significantly more subjects treated with EXPAREL had good or very good pain control at 48 hours for the 310 mg dose as rated by study personnel (27.9% difference; 95% CI 3.0, 52.7), and at 72 hours for the 200 mg dose as rated by subjects (25.0% difference; 95% CI 6.0. 44.0), and study personnel (20.0% difference; 95% CI 2.5, 37.5).
Administration of ankle block involves precise placement of a needle at five nerves, misplacement of any of which would result in more intense postsurgical pain. Placement is potentially more critical for EXPAREL, which may not diffuse through tissue as easily as bupivacaine HCl. Overall, the results suggest that >70 mg of EXPAREL per nerve is required for sensory block at early time points and should be investigated in future nerve block studies.

**Study 103: Randomized, Double-Blind, Dose-Finding Study to Evaluate the Safety, Pharmacokinetic and Pharmacodynamic Profiles of EXPAREL Administered via a Single Epidural Injection to Healthy Volunteers**

Viscusi ER, Candiotto K. Duration of motor vs sensory blockade of EXPAREL™ (bupivacaine extended-release liposome injection) and bupivacaine HCl in a phase 1 epidural study. Poster presented at: *36th Annual ASRA Regional Anesthesia Meeting*; May 5-8, 2001; Las Vegas, NV.

In 29 healthy volunteers, the PK characteristics of EXPAREL following epidural administration were similar to those observed in the surgical subjects receiving EXPAREL by infiltration. Plasma bupivacaine concentrations peaked lower, later, and took longer to decline with EXPAREL compared to unencapsulated bupivacaine HCl. Importantly, doses of EXPAREL up to 266 mg administered in the epidural space resulted in plasma bupivacaine concentrations considerably lower than the levels associated with systemic toxicity and were safe and well tolerated by all recipients. In general, the PK of epidural EXPAREL appeared to be dose proportional (i.e., linear), as assessed by $C_{\text{max}}$, $AUC_{0-\text{tlast}}$, and $AUC_{0-\infty}$ (Table 13). 33

**Table 13. Bupivacaine PK following single, epidural doses of EXPAREL or unencapsulated bupivacaine HCl**

<table>
<thead>
<tr>
<th></th>
<th>EXPAREL</th>
<th>Bupivacaine HCl</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD) $C_{\text{max}}$, ng/mL</td>
<td>120 (47)</td>
<td>133 (54)</td>
</tr>
<tr>
<td>Mean $t_{\text{max}}$, h</td>
<td>9 (7)</td>
<td>20 (8)</td>
</tr>
<tr>
<td>Median $t_{\text{max}}$, h</td>
<td>7.3</td>
<td>24.3</td>
</tr>
<tr>
<td>Mean $AUC_{0-\text{tlast}}$, h • ng/mL</td>
<td>4064 (1325)</td>
<td>6387 (1708)</td>
</tr>
<tr>
<td>Mean $AUC_{0-\infty}$, h • ng/mL</td>
<td>4151 (1312)</td>
<td>6565 (1679)</td>
</tr>
<tr>
<td>Mean $t_{\frac{1}{2}}$, h</td>
<td>16 (6)</td>
<td>14 (5)</td>
</tr>
</tbody>
</table>

**Motor block:** The incidence of motor block was considerably lower in the EXPAREL groups compared with the bupivacaine HCl group. There was a direct dose response in the incidence of motor block for the various doses of EXPAREL. The duration of motor block was lower in the EXPAREL group compared with bupivacaine HCl group. Motor block in all subjects had resolved by 4 hours, except for one subject in the bupivacaine HCl group for whom the motor block resolved by 12 hours.
Ability to ambulate freely: A smaller proportion of subjects in the combined EXPAREL group lost their ability to ambulate freely compared with those in the bupivacaine HCl group. Among the EXPAREL groups, the 89 mg group had the lowest number of subjects unable to ambulate freely (n=0) and the 155 mg group had the highest (n=7; 87.5%). When including all subjects in the analysis, whether or not they had ambulatory impairment, the median duration of ambulatory deficit was lower in the combined EXPAREL groups (0.00 hours), compared with the bupivacaine HCl group (1.53 hours), although this difference was not statistically significant. The median time to recovery of ability to ambulate freely for subjects who experienced ambulatory deficit was comparable in all treatment groups.

Sensory Block: The onset of numbness to pinprick and cold was noted approximately 15 to 30 minutes after study drug administration in all groups, and the median time to onset of numbness to pinprick and cold was similar in all groups. The median duration of numbness to pinprick in the 266 mg EXPAREL group was 35.6 hours, which was approximately three times longer than the bupivacaine HCl group. Similarly, the median duration of numbness to cold in the 266 mg EXPAREL was greater than the bupivacaine HCl group, nearly six times longer (68.7 hours). When comparing the incidence of sensory blockade for cold in anatomical areas of interest for epidural analgesia (i.e., dermatomes S1=foot, L4=knee, L2=upper thigh, and T10-11=sub-umbilical), the 266 mg EXPAREL dose provided a notable effect after 24 hours and up to 72 hours.

Doses of EXPAREL up to 266 mg administered via the epidural route were safe and well tolerated. EXPAREL demonstrated a PK profile typical of an extended-release formulation. Maximum observed plasma bupivacaine concentrations after EXPAREL administration were similar to or lower than those attained with 50 mg of bupivacaine HCl and significantly below levels associated with systemic bupivacaine toxicity. EXPAREL doses investigated in this study did not cause significant motor block. The extent and duration of sensory blockade was dose dependent. Based on the pharmacodynamic profile, the 266 mg dose demonstrated the potential to provide effective postsurgical pain relief for up to 72 hours. The effect of this dose on surgical pain models needs to be further investigated in future clinical trials.

Other

Dasta J, Ramamoorthy S, Patou G, Sinatra R. Bupivacaine extended release liposome injection (DepoFoam® bupivacaine) vs. bupivacaine HCl: a meta-analysis of multimodal trials of doses up to and including 300 mg. Poster 198 presented at the American College of Clinical Pharmacy Annual Meeting, Pittsburgh, PA, Oct 16–19, 2011.115

This analysis of pooled efficacy and safety data from 5 double-blind, placebo- or active- (bupivacaine HCl) controlled multimodal analgesia studies of >700 patients was conducted to assess the comparative efficacy of liposome bupivacaine administered at doses up to 266 mg and bupivacaine HCl administered (both administered via infiltration at the end of the procedure) at doses up to 150 mg for postsurgical analgesia. Of the five studies, 3 different surgical procedures were represented including inguinal hernia repair (2), hemorrhoidectomy (2), total knee arthroplasty (1).
Outcome measures included area under the curve (AUC) of pain intensity scores assessed by a numeric rating scale (NRS) through 72 hours postsurgery, time to first use of rescue opioid medications, total amount (mg) of opioid medications used, and occurrence of opioid-related adverse events (ORAEs). Incidence of overall adverse events was also assessed.

The mean cumulative pain score (AUC of NRS scores through 72 hours) was statistically significantly lower with liposome bupivacaine (n=315) compared with bupivacaine HCl (n=427, p <0.0001). Median time from administration of study drug to first use of opioid rescue medication was significantly longer for liposome bupivacaine (10 hours vs. 3 hours, p < 0.0001). Liposome bupivacaine was associated with a significant reduction in opioid use (8 mg vs 16 mg; p < 0.0001), percentage of patients reporting ≥1 ORAE (24.6% vs 45.1%; p < 0.0001) and mean number of ORAEs per patient (.25 vs .46, p<0.0001) compared with bupivacaine HCl.

In this analysis, the use of liposome bupivacaine 266mg or less (in a multimodal treatment regimen) was associated with a lower cumulative pain score at 72 hours, delayed use of opioids, less consumption of opioid medications, and fewer ORAEs than bupivacaine HCl. Reductions of approximately 50% in both opioid use and opioid related adverse events were noted.


This analysis examined pooled efficacy data as reflected in cumulative pain scores from 9 randomized, double-blind liposome bupivacaine clinical studies (wound infiltration studies in patients undergoing hernia repair, total knee arthroplasty, hemorrhoidectomy, breast augmentation, or bunionectomy) in which the study drug was administered via local wound infiltration. In 823 patients liposome bupivacaine doses ranged from 66 mg to 532 mg in five surgical settings; 446 patients received bupivacaine HCl (dose: 75–200 mg) and 190 received placebo.

Pain intensity after surgery was measured using an 11-point numeric rating scale (NRS) where 0 = no pain and 10 = worst possible pain. The NRS was used in all studies except study 1, in which a 100 mm length visual analog scale (0 = no pain and 100 = most severe pain possible) was used to measure pain intensity. Pain intensity scores were collected through at least 72 hours after study drug administration. Cumulative pain score as reflected in the area under the curve (AUC) of NRS scores through the last timed assessment, and through other time points, were derived for each study.

In the analysis of cumulative pain intensity scores through 72 hours, liposome bupivacaine was associated with lower pain scores than the comparator in 16 of 19 treatment arms assessed, achieving statistically significant differences compared with bupivacaine HCl (P<0.05) in five of 17 treatment arms. The median time to first postsurgical use of rescue opioid medication was significantly longer with liposome bupivacaine (9.3 hours) compared with bupivacaine HCl (6.4 hours; P=0.013) and placebo (3.6 hours; P<0.0001). The adverse event profile for liposome bupivacaine was similar to bupivacaine HCl. Overall, 62% (n=508/823) of patients treated with liposome bupivacaine reported at least one adverse event compared with 75% (n=334/446) for
bupivacaine HCl and 43% (n=82/190) for placebo. The most frequently reported adverse events for patients who received liposome bupivacaine and bupivacaine HCl were nausea, vomiting and constipation; these were frequently reported in patients receiving opioid medications. Treatment with liposome bupivacaine resulted in lower pain scores and decreased opioid consumption in the first 72 hours in several surgical models.


An analysis was conducted of the previously reported double-blind placebo control study of adults undergoing excisional hemorrhoidectomy by Gorfine et al.1 The study consisted of 189 randomized individuals of whom 95 received liposome bupivacaine 266mg and 94 received placebo. This analysis set to determine that in the context of a placebo controlled trial where all patients were offered rescue opioids, pain scores alone were inadequate to assess the full efficacy of a drug. Rather, combining pain scores, opioid use, quality of post surgical function and recovery and subject satisfaction could provide a more comprehensive assessment of the analgesic efficacy of a new therapeutic modality rather than these factors taken into consideration separately and alone.

There was a statistically significant reduction in pain over 72 hours in the group receiving EXPAREL vs placebo as measured by the AUC of the NRS-R pain intensity scores through 72 hours (NRS-R AUC0-72; primary endpoint, Figure 5).1 Mean NRS-R AUC0-72 was 202.5 in the placebo group vs 141.8 in the EXPAREL group (P<0.0001) in the FAS population and in each individual country.1 Significantly lower cumulative pain scores (NRS AUC) were noted at all time points to 60 hours (secondary endpoints; Figure 5).

A significantly higher proportion of EXPAREL than placebo recipients required no supplemental opioid medication through 12, 24, 36, 48, 60 and 72 hours (P≤0.0007), and the median time to first supplemental opioid dose was 14 hours and 20 minutes with EXPAREL compared with 1 hour and 10 minutes with placebo (P<0.0001). Total opioid consumption was significantly reduced in the EXPAREL-treated vs placebo-treated group through 72 hours (P=0.0006).1

Liposome bupivacaine demonstrated 2 phases of therapeutic benefit; pain intensity scores were lower during the first 12 hours postsurgery and study subjects required less opioid use through 72 hours. Pain intensity scores showed progressive equalization over the first postoperative day. However, postsurgical opioid rescue medication use differences were statistically significant beginning at 12 hours and this difference was seen from 24 through 72 hours. This was supported by a persistent benefit recorded by individuals treated with liposome bupivacaine on the Brief Pain Inventory assessment at 24 and 72 hours postsurgery.

Looking solely at pain intensity scores could cause individuals to incorrectly assume that the benefit of liposome bupivacaine lasts only for up to 24 hours. This more complete analysis demonstrated that combining pain intensity scores with additional outcome measures (including use of postsurgical opioids and
patient satisfaction scores) may lead to more meaningful assessment that the benefit of liposome bupivacaine lasts through 72 hours.
### 3.1.3 Clinical Evidence Summary Table

#### Table 14. Clinical Evidence Summary

<table>
<thead>
<tr>
<th>Study no.</th>
<th>Drug regimens</th>
<th>N</th>
<th>Time</th>
<th>Demographics</th>
<th>Design</th>
<th>Endpoints/results/comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pivotal Phase 3 studies wound infiltration</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study 317 (Golf et al. 2011)²</td>
<td>EXPAREL 106 mg Placebo (saline)</td>
<td>193</td>
<td>72 hours</td>
<td>Adults (mean 43 y) undergoing primary unilateral first metatarsal osteotomy; 82% female, 71.5% white</td>
<td>MC, R, DB, PG</td>
<td>Primary: Mean NRS-R AUC₀₋₂₄ was 124.9 in the EXPAREL group vs 146.4 in the placebo group 0.0005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Lower NRS-R AUC₀₋₃₆ 0.023</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: More EXPAREL recipients required no rescue pain medication at 8, 12, 16, 20, and 24 h ≤0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Longer mean time to first rescue pain medication with EXPAREL (7.15 vs 2.28 h) &lt;0.0001</td>
</tr>
<tr>
<td>Study 316 (Gorfine et al. 2011)¹</td>
<td>EXPAREL 266mg Placebo (saline)</td>
<td>189</td>
<td>72 hours</td>
<td>Adults (mean age 48 y) undergoing hemorrhoidectomy under general anesthesia; 69% male, 100% white</td>
<td>MC, R, DB, PG</td>
<td>Primary: Mean NRS-R AUC₀₋₇₂ was 202.3 in the placebo group vs 141.6 in the EXPAREL group &lt;0.0001</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Lower NRS-R AUC at all time points to 60 h &lt;0.0001</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: More EXPAREL recipients pain-free (NRS-R of 0 or 1) at all time point to 24 h &lt;0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: More EXPAREL recipients required no supplemental opioids at 12, 24, 36, 48, and 60 h ≤0.0007</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Total opioid consumption lower with EXPAREL through 72 h 0.0006</td>
</tr>
</tbody>
</table>
### Other studies in wound infiltration

#### Phase 3 studies in breast augmentation

<table>
<thead>
<tr>
<th>Study</th>
<th>EXPAREL 266 mg in each side (total dose 532 mg) bupivacaine HCl 100 mg in each side (total dose 200 mg)</th>
<th>136</th>
<th>96 hours</th>
<th>Adults (mean 31 y) undergoing bilateral cosmetic, submuscular breast augmentation under general anesthesia</th>
<th>MC, R, DB, PG</th>
<th>Primary: NRS-A AUC(_{0-72}) similar (441.0 for EXPAREL and 467.2 with bupivacaine HCl); study terminated early so not powered to detect a difference in primary endpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: NRS-A and NRS-R AUCs similar among treatment groups at all post-dose assessments (12, 24, 36, 48, 60, 72, 84, 96 h)</td>
<td>&gt;0.05</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: NRS-A scores significantly lower for EXPAREL vs bupivacaine HCl at 8 h and 12 h, and NRS-R significantly lower at 8 h</td>
<td>&lt;0.05</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Postsurgical opioid consumption significantly lower for EXPAREL vs bupivacaine HCl at 24 h (9.73 vs 13.68 mg morphine equivalents) and 48 h (18.44 vs 55.69 mg)</td>
<td>&lt;0.05</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: No significant difference in median time to first opioid analgesia (2.9 vs 2.5 h for EXPAREL vs bupivacaine HCl)</td>
<td>&gt;0.05</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Integrated assessment of NRS-A scores and opioid usage significantly favored EXPAREL at 12 and 48 h, as did integrated assessment of NRS-A AUC and opioid usage between 12 and 72 h and at 96 h</td>
<td>&lt;0.05</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Integrated assessment of NRS-R scores and opioid usage significantly favored EXPAREL at 12, 48, and 60 h, as did integrated assessment of NRS-R AUC and opioid usage assessment at 72 and 96 h</td>
<td>&lt;0.05</td>
<td></td>
</tr>
</tbody>
</table>
Study 318 (Minkowitz et al., 2012)$^9$
Study 210: EXPAREL 133 mg or 266 mg in one breast pocket
  Bupivacaine HCl 75 mg in the contralateral side
Study 315: EXPAREL 266 mg in each side (total dose 532 mg)
  Bupivacaine HCl 100 mg in each side (total dose 200 mg)
  Adults (mean 31.5 y) who underwent bilateral cosmetic, submuscular breast augmentation in previous studies (studies 201 and 315 summarized above); 87.2% white
  MC, O

Long-term safety follow-up: Most (>90%) subjects had no change in breast size or shape or changes in skin or nipple. When noted, such changes were most commonly attributed to scar contracture.

In study 315, the incidence of uneven appearance of breasts was low (16.1% for EXPAREL and 6.3% for bupivacaine HCl; mean time to appearance 7.18 and 14.19 months, respectively), and the difference between the groups was not likely to be clinically significant. In study 210, one bupivacaine HCl recipient had uneven appearance of breasts at approximately 12 months. There were no reports of palpable hard knots or swelling, and one report of signs of irritation or implant leakage. There was no clear evidence that either EXPAREL or bupivacaine HCl was associated with changes in sensation or any other abnormal finding.

<table>
<thead>
<tr>
<th>Cardiac safety analyses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Studies 105 and 107 (Naseem et al. 2011, Bergese et al. 2012)$^{43,44}$</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

Page 67
<table>
<thead>
<tr>
<th>Study 209 (Haas, 2012; Onel et al. 2010; Miller et al. 2009)</th>
<th>EXPAREL 67 mg, 200 mg, or 266 mg bupivacaine HCl 75 mg</th>
<th>100</th>
<th>96 hours</th>
<th>Adults (mean 43 y) undergoing hemorrhoidectomy under general anesthesia; 94% white</th>
<th>MC, R, DB, PG</th>
<th>Primary endpoint: EXPAREL 266 mg contained greatest number of subjects receiving no supplemental opioid pain medication</th>
<th>&gt;0.05</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Significantly less opioid pain medication consumed by subjects in the EXPAREL 266 mg at 24, 36, 48, 72, 84, and 96 h</td>
<td>≤0.035</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: AUC of NRS-R scores significantly reduced in all EXPAREL treatment groups compared with bupivacaine HCl through 12, 24, 36 (75 mg group was not significant), 48 (75 mg group was not significant), 60 (75 mg group was not significant), 72, 84, and 96 h</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Significant improvements in integrated analysis of AUC NRS-R scores and supplemental opioid pain medication usage observed in the EXPAREL 200 mg and 266 mg groups over 12, 24, 36, 48, 60, 84 and 96 h, and in the EXPAREL 75-mg group over 72 and 96 h vs bupivacaine HCl</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Significant improvements in subject QOL (VAS score) observed at 48 h in the 266 mg EXPAREL treatment group, at 72 h in the 67, 200, and 266 mg EXPAREL treatment groups, and at 96 h in the 266 mg EXPAREL treatment group, compared with bupivacaine HCl group</td>
<td>≤0.029</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Over the first 3 postsurgical days, EXPAREL 266 mg significantly reduced pain intensity by 47%, opioid use by 66%, and opioid-related side effects by 89%, relative to bupivacaine HCl 75 mg</td>
<td>&lt;0.05 for all</td>
</tr>
<tr>
<td>Study</td>
<td>EXPAREL 133 mg, 266 mg, 399 mg, or 532 mg bupivacaine HCl 150 mg</td>
<td>138</td>
<td>5 days</td>
<td>Adults (mean 62 y) undergoing TKA under general anesthesia, 62% female, 92% white</td>
<td>MC, R, DB, PG</td>
<td>Primary: Comparable pain intensity during activity (NRS-A AUC_{0-4d}) in each group</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>-------</td>
<td>---------------------------------------------------------------</td>
<td>------</td>
<td>--------</td>
<td>--------------------------------------------------------------------------------</td>
<td>----------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Comparable proportion of subjects in each group required no supplemental opioid</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>medication postsurgically, and the total postsurgical opioid consumption did not differ between groups</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Significantly lower cumulative pain intensity at rest (AUC NRS-R) with EXPAREL 532 mg vs bupivacaine HCl through Day 2, 3, 4 and 5</td>
<td>≤0.015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Bupivacaine HCl more effective than EXPAREL 133 mg in integrated analysis of cumulative pain intensity during activity or rest + supplemental opioid use</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: EXPAREL 266 mg or 399 mg significantly delayed time to first opioid medication vs bupivacaine HCl</td>
<td>≤0.005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: EXPAREL 266 mg or 399 mg significantly delayed time to first occurrence of PONV vs bupivacaine HCl</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study</th>
<th>EXPAREL 532 mg bupivacaine HCl 200 mg</th>
<th>218</th>
<th>96 hours</th>
<th>Adults (mean 66 y) undergoing TKA under general or spinal anesthesia, 64% female, 84% white</th>
<th>MC, R, DB, PG</th>
<th>Primary: Comparable pain intensity during activity (NRS-A AUC_{0-96}) in each group</th>
<th>0.1266</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Higher mean NRS-A score with EXPAREL vs bupivacaine HCl at 48 h</td>
<td>0.363</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Comparable total postsurgical opioid consumption in both groups</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Comparable pain scores (NRS-1 or NRS-R) at all time points and AUCs of pain scores in both groups</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Comparable QOL scores (EQ-5D) in both groups</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Comparable time to physical recovery and return to daily activities in both groups</td>
<td>&gt;0.05</td>
</tr>
</tbody>
</table>
### Phase 2 study in breast augmentation

<table>
<thead>
<tr>
<th>Study</th>
<th>EXPAREL 133 mg or 266 mg in breast pocket bupivacaine HCl 75 mg in the contralateral side</th>
<th>40</th>
<th>96 hours</th>
<th>Adults (mean 29.6 y) undergoing bilateral cosmetic, submuscular breast augmentation mammoplasty</th>
<th>MC, R, DB, PG</th>
<th>Primary: Postsurgical NRS scores (NRS-R and NRS-A) consistently lower with EXPAREL 133 mg or 266 mg vs bupivacaine HCl</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: NRS-R AUC significantly lower with EXPAREL 133 mg vs bupivacaine HCl at assessments from 36 through 96 hours, and NRS-AUC significantly lower at 12 and 60 hours</td>
<td>&gt;0.05 at most assessments, including 96 hours</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: More opioid doses required with bupivacaine HCl vs EXPAREL (4 doses each for EXPAREL 133 mg or 266 mg vs 11 or 7 doses for bupivacaine HCl)</td>
<td>&gt;0.05</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Number of subjects receiving no supplemental postsurgical opioid pain medication consistently higher for EXPAREL 266 mg vs 133 mg</td>
<td>&gt;0.05</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Total opioid consumption significantly lower for EXPAREL 266 mg vs 133 mg through 48 to 84 hours</td>
<td>&gt;0.05</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>

### Phase 3 study in hemorrhoidectomy

<table>
<thead>
<tr>
<th>Study</th>
<th>EXPAREL 266 mg bupivacaine HCl 100 mg</th>
<th>204</th>
<th>96 hours</th>
<th>Adults (mean age 50 y) undergoing hemorrhoidectomy under general or spinal anesthesia, 52% male</th>
<th>MC, R, DB, PG</th>
<th>Primary: Comparable NRS-R AUC$_{0-96}$ with EXPAREL vs bupivacaine HCl (395.6 vs 359.1)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: No difference in proportion of subjects requiring no supplemental opioid medication</td>
<td>&gt;0.05</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: No difference in total consumption of supplemental opioid medication</td>
<td>&gt;0.05</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: No difference in time to first supplemental opioid medication</td>
<td>&gt;0.05</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>
### Phase 2 study in inguinal hernia repair

<table>
<thead>
<tr>
<th>Study</th>
<th>EXPAREL 155 mg, 200 mg, 266 mg, or 310 mg bupivacaine HCl 100 mg</th>
<th>76</th>
<th>5 days</th>
<th>Adults (mean 51 to 55 y) undergoing inguinal hernia repair under general anesthesia, 100% male, 93% white</th>
<th>MC, R, DB, PG</th>
<th>Primary: No significant difference in median time to first supplemental (opioid or nonopioid) pain medication</th>
<th>&gt;0.05</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Longer median time to first opioid pain medication with EXPAREL vs bupivacaine HCl (96 vs 65 h)</td>
<td></td>
<td>Secondary: quantity of opioid supplemental medication used postsurgically was 2- to 3-fold lower in EXPAREL groups vs bupivacaine HCl group (adjusted geometric mean dose 1.38 to 2.02 mg vs 4.42 mg of morphine equivalents)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Mean pain intensity scores at rest and with activity (VAS-R and VAS-A) generally lower in the EXPAREL groups than bupivacaine HCl group. For VAS-A, the differences between all the EXPAREL groups and bupivacaine HCl group were more pronounced and were statistically significant from 8 to 24 h after study drug administration</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: mean integrated pain intensity and supplemental opioid pain medication use was lower in all EXPAREL groups compared with the bupivacaine HCl group, at rest and with activity, at all time points</td>
<td>&lt;0.05 for at least 2 postop times in each EXPAREL group</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: fewer subjects in the EXPAREL groups had moderate or severe pain with activity compared with the bupivacaine HCl group</td>
<td>&lt;0.05 from 4 to 24 h after drug admin</td>
</tr>
<tr>
<td>Nerve block Study 203 (Data on file)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EXPAREL 155 mg, 200, 244, 279 mg or 310 mg or bupivacaine HCl 125 mg</td>
<td>58</td>
<td>96 hours</td>
<td>MC, R, DB, PG</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adults (mean 52 to 59 years) undergoing a unilateral first metatarsal bunionectomy repair under general anesthesia, &gt;90% white and 57% to 92% female</td>
<td></td>
<td></td>
<td>Primary: Median time to first use of supplemental postsurgical pain medication (opioid or nonopioid) significantly longer for bupivacaine HCl vs EXPAREL 200 mg (9.42 vs 1.24 h); no significant difference vs EXPAREL 155 mg (1.94 h) and 310 mg (2.43 h)</td>
<td>&lt;0.001; &gt;0.05</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Secondary: Median time to first supplemental postsurgical opioid medication was 96 hours for all treatment groups except EXPAREL 200 mg (7.3 h)</td>
<td>&gt;0.05</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Secondary: 33.3% to 64.3% of EXPAREL recipients and 55% of bupivacaine HCl recipients did not take supplemental opioid medication</td>
<td>&gt;0.05</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Secondary: The quantity of supplemental opioid medication used postsurgically was similar for EXPAREL 310 mg vs bupivacaine HCl, with an adjusted mean ratio of 0.86 (95% CI 0.25, 3.00). Adjusted mean ratios for EXPAREL 155 mg and 200 mg vs bupivacaine HCl were 1.37 (95% CI 0.37, 5.37) and 2.56 (95% CI 0.69, 9.49), respectively.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Secondary: VAS-A and VAS-R scores higher in all EXPAREL groups vs bupivacaine HCl for the first 12 h, but generally lower with EXPAREL 310 mg vs bupivacaine HCl from 24 to 96 h</td>
<td>&gt;0.05</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Secondary: Integrated assessment of VAS scores and total opioid usage showed a lower effect for EXPAREL 155 mg and 200 mg vs bupivacaine HCl throughout the 96-h assessment period, and a better effect for EXPAREL 310 mg vs bupivacaine HCl after 12 h; integrated assessment AUC_{96} for EXPAREL 310 mg was better (&gt;4-fold greater) than bupivacaine HCl at rest and slightly worse (25% lower AUC) with activity, but no significant differences between the 2 treatment groups at any time point.</td>
<td>&gt;0.05</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Epidural injection
Study 103 Epidural injection (Viscusi et al. 2009)\textsuperscript{33,34}

| Dose ranging Study assessing PK profile and onset and duration of sensory block | 29 | 96 hours | Adults- healthy volunteers EXPAREL epidural injection (89, 155, 266 mg) vs. 50 mg Bupivacaine | $T_{1/2}$ 3x longer in EXPAREL group compared to Bupivacaine group
266 mg dose provided longer duration of sensory block
Incidence and duration of motor block was less with EXPAREL group
266 mg dose of EXPAREL identified as likely dose for follow on epidural studies | 95% CI did not include 0

Secondary: Significantly more subjects treated with EXPAREL vs bupivacaine HCl had good or very good pain control at 48 h for the 310 mg dose as rated by study personnel (27.9% difference; 95% CI 3.0, 52.7), and at 72 h for the 200 mg dose as rated by subjects (25.0% difference; 95% CI 6.0. 44.0), and study personnel (20.0% difference; 95% CI 2.5, 37.5).

MC=multicenter; R=randomized; DB=double-blind; PC=placebo-controlled; PG=parallel group; CO=crossover; NRS-R=pain intensity score at rest; NRS-A=pain intensity score during activity; NRS AUC=cumulative pain intensity score; QOL=quality of life; Seq=sequential; VAS=visual analog scale; h=hours.
3.1.4 Summarizing of Evidence from Secondary Sources

3.1.5 Integrated Analysis of Efficacy and Safety

An integrated analysis was undertaken of the 9 randomized, parallel-group studies in which EXPAREL was administered by wound infiltration,\(^{14,15,116}\) described in section 3, starting on page 33. Seven of these studies had a bupivacaine HCl control and the 2 pivotal Phase 3 studies had a placebo control. These studies were conducted in subjects undergoing 5 different surgical procedures: hemorrhoidectomy (3 studies), bunionectomy (1 study), TKA (2 studies), hernia repair (2 studies) and breast augmentation (1 study). Overall, 823 subjects were exposed to EXPAREL at doses of 66 to 532 mg, 446 subjects received bupivacaine HCl at doses of 75 to 200 mg, and 190 received placebo. In all studies, efficacy could be evaluated on the basis of the NRS AUC over time; the primary endpoints of the integrated analysis were NRS AUC\(_{0-72}\) and NRS AUC\(_{0-24}\).

3.1.5.1 Pivotal Phase 3 Studies

The two Phase 3 pivotal trials were conducted to demonstrate the efficacy and safety of EXPAREL administered intraoperatively via local infiltration at the end of the procedure. Both trials were multicenter, randomized, double-blind, parallel-group, placebo-controlled and met their respective primary efficacy endpoint of pain reduction as assessed by AUC of the NRS at rest (NRS-R). In both trials (hemorrhoidectomy and bunionectomy), EXPAREL met its primary endpoint in demonstrating a statistically significant reduction in pain intensity as measured by AUC of NRS-R compared to placebo \((P \leq 0.0005)\). In both trials, EXPAREL also demonstrated statistically significant reduction in opioid usage, specifically:

- Delay in the need for opioids
- Decrease in the amount of opioids required
- Increase in the number of subjects able to avoid opioids entirely

Table 15 describes the statistical significance of the between-group differences favoring EXPAREL for the primary and secondary endpoints in these studies.
Table 15. Statistical significance of between-group differences favoring EXPAREL for primary and secondary endpoints in the pivotal Phase 3 studies (316 and 317)\textsuperscript{15}

<table>
<thead>
<tr>
<th></th>
<th>Hemorrhoidectomy (at 72 hours)</th>
<th>Bunionectomy (at 24 hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary endpoint</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reduction in pain</td>
<td>$P&lt;0.0001$</td>
<td>$P=0.0005$</td>
</tr>
<tr>
<td><strong>Opioid-related secondary endpoints</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total avoidance of opioid rescue</td>
<td>$P=0.0007$</td>
<td>$P=0.0404$</td>
</tr>
<tr>
<td>Reduced total consumption of opioid rescue</td>
<td>$P=0.0006$</td>
<td>$P=0.0077$</td>
</tr>
<tr>
<td>Delayed use of opioid rescue</td>
<td>$P&lt;0.0001$</td>
<td>$P&lt;0.0001$</td>
</tr>
<tr>
<td><strong>Patient satisfaction secondary endpoint</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Improved patient satisfaction</td>
<td>$P=0.0007$</td>
<td>$P=0.08$</td>
</tr>
</tbody>
</table>

3.1.5.2 Phase 2 and 3 Clinical Trial Program

There were 17 treatment arms comparing EXPAREL with bupivacaine HCl in active-controlled trials.

- In the AUC\textsubscript{0-72} analysis for 5 of these groups, EXPAREL was statistically significantly superior to bupivacaine HCl ($P<0.05$), in 8 groups there was a trend favoring EXPAREL, 3 groups failed to show a difference, and one group demonstrated a trend favoring bupivacaine HCl (Figure 8).

- Similar results were seen in the AUC\textsubscript{0-24} analysis: 5 comparisons showed statistically significant superiority of EXPAREL over bupivacaine HCl ($P<0.05$), 8 showed a trend favoring EXPAREL, and 5 failed to show a difference (Figure 9).
Figure 8. Cumulative pain score (AUC₀-72 of NRS)¹⁴,¹¹⁶

DB=DepoFoam bupivacaine; TKA=total knee arthroplasty.
The combined safety analysis showed a rate of TEAEs of 62% with EXPAREL, 75% with bupivacaine HCl, and 43% with placebo. The common TEAEs with EXPAREL were nausea, constipation, and vomiting. One death each occurred in the EXPAREL and bupivacaine HCl groups; neither was considered by the investigator to be related to the study drug.14,116

The cumulative body of evidence from this analysis indicates the EXPAREL provides prolonged postsurgical analgesia for up to 72 hours after intraoperative administration in a range of surgical models.

### 3.1.6 Integrated Cardiac Safety Analysis

Because bupivacaine HCl may cause cardiovascular changes at high doses, an analysis of QT and QTc changes from a Phase 2 study of EXPAREL in patients undergoing TKA was undertaken, as well as a thorough review of all potential cardiotoxicity-related AEs with EXPAREL in the overall clinical trial program.43
The Phase 2 study in patients undergoing TKA has been previously described in this document (see section 3.1.1.3.4 on page 51). Briefly, subjects undergoing TKA were randomized in 3 consecutive cohorts to receive either bupivacaine HCl 150 mg or EXPAREL at a dose level of 133, 266, 399, or 532 mg. Electrocardiograms (ECGs) were assessed at baseline and at 4, 8, 12, 24, 36, 48, 60, 72, 84, and 96 hrs postdose and before or 30 min after pain assessments, physical therapy, PK sampling, or other invasive procedure. The measured QT interval was corrected for heart rate (HR) using Bazett formula (QTcB): QTcB = QT/(RR)^1/2 and Fridericia formula (QTcF): QTcF = QT/(RR)^1/3.43

The mean change from baseline in QTcF duration across EXPAREL dose levels ranged from −7 to −10 msec compared with −6 msec for bupivacaine HCl. QTc outlier analysis showed 1 patient met the new greater than 500 msec absolute QTcF duration criteria in the EXPAREL 266 mg group. One patient in the EXPAREL 266 mg group and 1 in the bupivacaine HCl group met the greater than 60 msec change in QTcF criteria. The proportion of patients meeting the nonspecific outlier criterion (a 30 to 60 msec change from baseline) ranged from 12% to 17% across the EXPAREL groups; 10% met the criterion in the bupivacaine HCl group.43

Two patients experienced new atrial fibrillation (1 receiving EXPAREL 266 mg and 1 receiving 399 mg), 3 patients displayed right bundle-branch block in the EXPAREL 266 mg group; and 1 patient displayed bifascicular block in the EXPAREL 532 mg group. These occurrences of atrial fibrillation and bundle-branch block resolved spontaneously. Nonspecific ST-T wave abnormalities were observed in 4% of patients in the EXPAREL 266 mg group and 9% in the bupivacaine HCl group. Nonspecific T-wave abnormalities alone occurred in 32% to 52% of patients receiving EXPAREL and 31% of patients receiving bupivacaine HCl. There did not appear to be a dose-related trend in QTc effect or morphology changes, although statistical analyses were not conducted; the small sample size limits interpretation of these data.43

Among 93 healthy volunteers participating in 4 Phase 1 studies with EXPAREL, there were no clinically significant ECG changes or cardiac AEs.43 In a Phase 2 dose-ranging study of EXPAREL and bupivacaine HCl in 76 patients undergoing inguinal hernia repair, 3 patients treated with EXPAREL had abnormal ECGs both before and after the study drug was administered; no drug-related cardiac AEs were reported during the study.43

Among 823 patients receiving EXPAREL during the Phase 2 or 3 clinical trial program, 53 (6.4%) had a cardiac AE compared with 26/446 (5.8%) receiving bupivacaine HCl and none receiving placebo. Of the cardiac AEs in the EXPAREL groups, 7 patients experienced an event that was assessed by the investigators as related to study drug (5 patients experienced bradycardia, and 2 patients experienced tachycardia). There was no apparent relationship to the dose, and all of these AEs were mild or moderate in severity. None of the patients in the bupivacaine HCl or placebo groups experienced a cardiac AE that was deemed related to treatment by the investigators.43

Adverse events of HR changes (both bradycardia and tachycardia) in patients participating in wound
infiltration studies that included PK assessments following EXPAREL doses of greater than 266 mg were analyzed. In total, 12 patients experienced bradycardia or tachycardia in these studies; 6 exhibited a $C_{\text{max}}$ of greater than 1000 ng/mL, and 6 exhibited a $C_{\text{max}}$ of less than 1000 ng/mL. Thus, there did not appear to be a relationship between $C_{\text{max}}$ levels and HR changes. In all but 1 of these cases, HR changes were considered to be associated with clinical events or conditions (e.g., fever or acute blood loss) that were not related to study drug. Adverse event profiles of all patients who exhibited a $C_{\text{max}}$ of greater than 1000 ng/mL were reviewed, and no consistent cardiac profile emerged.\textsuperscript{43}

Treatment-emergent central nervous system disorders are often precursors to cardiac AEs. Across all wound infiltration studies, 2 EXPAREL-treated patients (0.2%) reported syncope, compared with 4 patients (0.9%) receiving bupivacaine HCl and none receiving placebo. No patients in active treatment groups experienced loss of consciousness, compared with 1 patient (0.5%) receiving placebo. In a Phase 1 study, a healthy volunteer experienced a tonic-clonic seizure after subcutaneous injections of EXPAREL 15 mg and bupivacaine HCl 2.5 mg in the right and left forearms, respectively, followed by a 5-mm incision on the right forearm. Immediately after the incision, the subject complained of nausea, appeared to have a vasovagal reaction, and had a tonic-clonic seizure lasting approximately 15 seconds. The event resolved and was classified by the investigator as unlikely related to the study drug.\textsuperscript{43}

The limitations of these analyses are its retrospective nature and the possibility that the small size of the subject populations in these studies was not large enough to allow cardiac or central nervous system toxicities to be detected. In addition, no between-group statistical comparisons were undertaken, which limited interpretation of the data. Nevertheless, no changes were detected in clinical profiles or ECG results that would raise a question of cardiac safety in the study populations that were assessed, and evaluation of the AE database did not uncover signs of clinically important cardiac AEs associated with the use of EXPAREL.\textsuperscript{43}
4 Economic Value and Modeling Report

Managing pain in postsurgical patients is challenging, and current approaches have limitations which contribute to the overall increases in cost of care. According to the practice Guidelines for Acute Pain Management in the Perioperative Setting, adverse outcomes that may result from the under treatment of perioperative pain include, but are not limited to: thromboembolic and pulmonary complications, additional time spent in an intensive care unit or hospital, hospital readmission for further pain management, needless suffering, impairment of health-related quality of life, and development of chronic pain. Adverse outcomes associated with the management of perioperative pain include (but are not limited to) respiratory depression, brain or other neurologic injury, sedation, circulatory depression, nausea, vomiting, pruritus, urinary retention, impairment of bowel function, and sleep disruption. Health-related quality of life includes (but is not limited to) physical, emotional, social, and spiritual well-being.

Patient satisfaction scores are becoming an increasingly important tool to measure hospital performance, and pain is a major contributing factor toward those scores. The Hospital Consumer Assessment of Healthcare Providers and Services survey, (HCAHPS) is randomly administered to a sample of patients across medical conditions between 48 hours to 6 weeks following hospital discharge. HCAHPS has become a major influence affecting hospital economics and scores will soon be used to calculate hospital incentive payments. According to the Centers for Medicare and Medicaid Services, beginning in October 2012 HCAHPS will be among the measures used to calculate hospital value-based incentive payments placing further emphasis on the adequate management of postsurgical pain in order to increase patient satisfaction and HCAHPS ratings. This will serve as a major stimulus for hospitals to improve on their ability to provide improved analgesia.

Despite a moderate amount of attention and significant effort at the national, state, hospital, and provider level, only a modest advance has been made in the last 20 years toward addressing the current public health issue of appropriately recognizing and treating acute pain in US hospitals. In fact, in a 2009 Journal of Pain publication, Gupta and colleagues reminded us that the treatment of pain, according to the Joint Commission on Accreditation of Healthcare Organizations (JCAHO), has become even more of a major public health concern today than it was in 1992 when the AHRQ published their first set of Clinical Practice Guidelines entitled Acute Pain Management in Operative or Medical Procedures and Trauma.

Treatment of Postsurgical Pain with Opioids Is Not Without Risk

In order to better assess the burden associated with opioids used to treat postsurgical pain, two retrospective claims-based studies were conducted. The goals of these two studies were to determine the prevalence of postsurgical opioid use in the inpatient surgical setting, to ascertain the incidence and associated risk factors of administratively documented opioid related adverse drug events (ORADE) among opioid users, and to evaluate the impact of ORADEs on hospital length of stay (LOS), total hospitalization costs, readmission rates, and inpatient mortality.
The first study utilized data from 26 participating member hospitals in the Southeast region of the United States. The hospitals combined have over 9,000 inpatient beds with an average bed size of 351 and accounted for over 400,000 unique discharges over the two year study period (January 1, 2009 to December 31, 2010). The hospitals are located predominantly (88%) in urban settings and 23% are teaching hospitals.68

Study design and sample selection
Patients were eligible for inclusion in the study if they were aged 18 years or older with a primary inpatient surgery during the study period. The selection of these procedures was done in order to align with previous research121-125 and to represent common orthopedic and soft tissue surgeries performed in US hospitals. Patients were identified as opioid recipients if they received a charge for an opioid-based pain regimen on the day of surgery or any day afterward up to discharge from the hospital. Opioid analgesics included in the study were morphine, oxycodone, hydrocodone, hydromorphone, fentanyl, meperidine, codeine, methadone, and propoxyphene. Oral opioid and acetaminophen combinations were also included (i.e. Percocet, Lortab, etc.). Over a two year period (1/1/2009 to 12/31/2010), patients ≥18 years of age who underwent a common surgical procedure were identified and evaluated for receipt of an opioid-based pain regimen post surgery. Among opioid users, the rate of ORADEs was assessed along with identification of key risk factors associated with ORADEs. Outcomes were compared between patients experiencing an ORADE using propensity score matching based on age, race, gender, opioid use prior to surgery, Charlson Comorbidity Index (CCI), and presence of degenerative joint disease. Outcomes included length of stay (LOS), hospitalization costs, 30-day readmission rates, outlier status and inpatient mortality. LOS and cost rate ratios were generated using negative binomial regression and generalized linear models, respectively. Odds ratios for 30-day readmission, inpatient mortality and outlier status were generated using logistic regression.

Results
A total of 37,031 surgical patients were eligible to comprise the base study population. Of all the procedures evaluated, laparoscopic cholecystectomy, total hip replacement and total abdominal hysterectomy were the three most common procedures and accounted for approximately half (53%) of the study population. Of the surgical patients eligible, 98.6% received postsurgical opioids. The majority of patients received a combination of parenteral and oral medications (57.3%), while 41.9% received only parenteral and 0.8% received only oral medications.

Figure 10 below depicts the incidence of ORADEs divided by system organ class. The overall incidence of ORADEs was 13.6%, with gastrointestinal adverse events being the most commonly reported. Patients with an ORADE had a higher occurrence of 30-day readmissions (odds ratio 1.36; 95% CI: 1.15, 1.61; p<0.001) vs. patients with no ORADE. For inpatient mortality, the odds ratio was 3.39 (95% CI: 2.42, 4.74; p<0.001) and for LOS and/or cost outlier the odds ratio was 4.08 (95% CI: 3.57, 4.65; p<0.001) for patients...
with an ORADE vs. patients with no ORADE (Figure 11). The Rate/Cost Ratio for LOS of ORADE vs. No ORADE was 1.55 (95% CI: 1.50, 1.60) and for cost was 1.47 (95% CI: 1.42, 1.52); in both endpoints, \( P<0.001 \).

**Figure 10. Incidence of opioid-related adverse drug events for overall surgical population using opioids (N=36,529)**

![Incidence of opioid-related adverse drug events](chart)

- Respiratory: 4.2%
- GI: 6.0%
- CNS: 1.1%
- GU: 2.5%
- Other: 1.9%
In a second retrospective cohort study, information was obtained from a National hospital administrative database, the Premier research database. The database is a large, service-level, all-payer (including Medicaid, Medicare and commercial) comparative database, containing information on approximately five million annual hospital discharges (approximately one-fifth of all acute care hospitalizations in the US) from primarily non-profit, non-governmental community, teaching hospitals and health systems. This database included discharges from more than 450 hospitals for the time period studied (2008 to 2010).

Study design and sample selection
Similar methodologies were used as described in the previously discussed study. Briefly, patients included in the study were adult inpatients within the Premier research database discharged between September 1, 2008 and August 31, 2010 having a billing record for one of the selected procedures. Outcomes were compared between patients who experienced an ORADE versus those who did not. Multivariate regression was used to determine differences in hospital costs, LOS, odds of being an outlier in total cost, LOS, and having a thirty day all-cause readmission.

Unadjusted outcomes of surgical patients with an ORADE vs. patients with no ORADE
In the patient population there were a total of 319,898 surgeries performed during the study time period. The mean age for the study population was 59.0 years, the majority were female (67.5%) and white
(67.6%). Approximately 12% had an ORADE (defined via ICD-9 CM diagnosis codes). Patients with an ORADE were older (67 years vs. 58 years, \( P<0.0001 \)) and less likely to be female (58% vs. 69%, \( P<0.0001 \)). The mean total cost (US dollars; $22,871 vs. $12,835; \( P<0.0001 \)), LOS (9.0 days vs. 4.2 days, \( P<0.0001 \)) and 30-day all cause readmission rate (15.7% vs. 9.4%, \( P<0.0001 \)) were significantly greater if patients experienced an ORADE compared to patients with no ORADE (Table 16). Likewise, the percent of outliers in the total cost (15.7% vs. 9.4%, \( P<0.0001 \)), LOS (15.7% vs. 9.4%, \( P<0.0001 \)), were higher in patients who experienced an ORADE.

**Table 16. Unadjusted outcomes in patients with vs without ORADEs after selected surgeries**

<table>
<thead>
<tr>
<th></th>
<th>ORADE (n=39,116)</th>
<th>no ORADE (n=280,782)</th>
<th>(P)-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Cost (mean, SD), US Dollars</td>
<td>22,871</td>
<td>17,970</td>
<td>(&lt;0.0001^*)</td>
</tr>
<tr>
<td>Median</td>
<td>17,695</td>
<td>11,179</td>
<td></td>
</tr>
<tr>
<td>Length of Stay (mean, SD), days</td>
<td>9.0</td>
<td>7.0</td>
<td>(&lt;0.0001^*)</td>
</tr>
<tr>
<td>Median</td>
<td>7.0</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>Readmission (n, %)</td>
<td>6,164</td>
<td>15.7%</td>
<td>(&lt;0.0001^*)</td>
</tr>
<tr>
<td>Total Cost Outlier (n, %)</td>
<td>4,597</td>
<td>11.7%</td>
<td>(&lt;0.0001^*)</td>
</tr>
<tr>
<td>Length of Stay Outlier (n, %)</td>
<td>6,728</td>
<td>17.1%</td>
<td>(&lt;0.0001^*)</td>
</tr>
</tbody>
</table>

\(^*\text{Hip Replacement, Lap Cholecystectomy, Lap Colectomy, Open Colectomy, Total Abdominal Hysterectomy}\)

\(^{*}\text{Significant at 0.05 level}\)

**Model adjusted results**

The odds of being a total cost outlier were 2.8 times (95% CI 2.7-2.8) higher in patients with an ORADE compared to patients with no ORADE. The odds of being a LOS outlier were 3.2 times higher for the same comparison (95% CI 3.1-3.3) [Table 17]. The cost for an ORADE was $22,077 versus $17,197 (\( P<0.0001 \)). The adjusted mean cost was approximately $5,000 greater for patients with an ORADE compared to patients with no ORADE (Table 18).
Table 17. Model-adjusted* odds of being an outlier: ratios comparing ORADE to non ORADE surgical† patients

<table>
<thead>
<tr>
<th></th>
<th>OR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Cost Outlier</td>
<td>2.75</td>
<td>2.68-2.83</td>
</tr>
<tr>
<td>Length of Stay Outlier</td>
<td>3.17</td>
<td>3.09-3.26</td>
</tr>
<tr>
<td>30-day Readmission</td>
<td>1.06</td>
<td>1.02-1.09</td>
</tr>
</tbody>
</table>

*Adjusted for race/ethnicity, urbanicity, teaching status of hospital, geographic location, use of other analgesics, various different co-morbidities, opioids at some point during the visit
†Hip Replacement, Laparoscopic Cholecystectomy, Laparoscopic Colectomy, Open Colectomy, Total Abdominal Hysterectomy

Table 18. Adjusted* estimated mean values for all surgical procedures

<table>
<thead>
<tr>
<th></th>
<th>No ORADE</th>
<th>ORADE</th>
<th>Difference in Mean Value</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Visit Cost (US Dollars)</td>
<td>$22,077</td>
<td>$17,370</td>
<td>$4,707</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Length of Stay (days)</td>
<td>7.6</td>
<td>4.2</td>
<td>3.3</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

*Adjusted for race, urban versus rural status, teaching status of hospital, geographic location, use of other analgesics, various different comorbidities
†Open Colectomy, Laparoscopic Colectomy, Laparoscopic Cholecystectomy, Total Abdominal Hysterectomy, Hip Replacement

In summary, both recently conducted retrospective cohort studies demonstrate that the use of opioids may lead to side effects which in turn leads to increases in hospital cost (~$5,000) and hospital length of stay (increase LOS of ~ 3 days).68,120

Patient Dissatisfaction: Can we do Better Using Opioid-Sparing Pain Management Strategies?
Since the AHQR Postoperative Pain Clinical Practice Guidelines (CPG) published in 1992, it has been well documented that patients continue to have postsurgical pain and remain dissatisfied with pain management in US hospitals.16-21

A 1995 Warfield and Kahn special article in Anesthesiology called to light that 57% of patients with planned surgery reported the fear of postsurgical pain as their number 1 concern before surgery.17 The legitimacy of this concern was validated by survey responses from 500 individuals who underwent surgical
procedures in U.S. hospitals. Seventy-seven percent of patients reported experiencing postsurgical pain; 72% reported that pain was moderate to severe in intensity.\textsuperscript{17}

Although not specific to pain, a 1999 Institute of Medicine (IOM) report placed the issue of patient safety high on the nation’s health care agenda, with its most salient finding being that preventable medical errors caused 44,000 to 98,000 deaths each year, with an associated cost of $17 to $29 billion.\textsuperscript{127}

- One of the chief concerns for patient safety is the risks associated with the use of opioids. The dangers of postsurgical opioids were the focus of the Anesthesia Patient Safety Foundation symposium in 2006 and the consensus opinion was that opioid-induced respiratory depression remains a significant and preventable threat to patient safety for which institutions must have zero tolerance.\textsuperscript{128}
- It is estimated that 50\% of in-hospital resuscitations involve patients who have received opioid analgesia.\textsuperscript{129}

In addition to the inherent risks of opioid use, there are additional risks and costs associated with the concomitant medications used to treat opioid-related adverse events such as nausea/vomiting, constipation, and ileus.

In today’s rapidly progressing practice of medicine, treatment of acute postsurgical pain is in need of advancement. Despite the fact that better pain management has been the objective of many quality improvement programs over the past two decades, these recent reports suggest that major changes in practice behaviors still need to occur.

As an effective agent for treating postsurgical pain while reducing the need for opioids, EXPAREL has a significant opportunity to improve the treatment of postsurgical pain, patient satisfaction, and hospital economics through reduced opioid pain management protocols, particularly in select patient populations. EXPAREL is designed to be administered as a single postsurgical injection to provide significant local analgesia that is intended to replace the current use of elastomeric pump systems and to reduce the use of PCA systems. Additionally, by reducing the need for opioids, including the burden associated with documentation of use and management of side effects, EXPAREL may contribute to improved outcomes. The cost of EXPAREL is $285 per patient. When considering the cost of 3 days of postsurgical pain control, the average price per day of EXPAREL is roughly $95. The administration of EXPAREL does not require any additional staff time to maintain, document, and monitor its use beyond what is commonly considered when giving local aesthetic via wound infiltration.

**Post hoc analysis of ORADEs**
In a recently published study comparing the efficacy and tolerability of 3 dosages of EXPAREL with bupivacaine HCl administered intra-operatively via wound infiltration in patients undergoing excisional
hemorrhoidectomy, EXPAREL was associated with a mean 47% relative reduction in cumulative pain score and 66% relative reduction in amount of opioid medication consumed. A blinded post-hoc analysis using a definition of ORADEs similar to one already agreed to by the FDA demonstrated an 89% reduction in ORADEs compared with bupivicaine HCl (P<0.05 for all comparisons).

**Figure 12. Relative reduction in cumulative pain score, postsurgical opioid consumption, and opioid-related adverse events for EXPAREL compared to bupivacaine HCl**

*P=0.002 vs bupivacaine HC; †P=0.007 vs bupivacaine HCl; ‡P=0.007 vs bupivacaine HCl.

**Pooled Data From Five EXPAREL Studies Confirm Effect on ORADEs**

An analysis of pooled efficacy and safety data from 5 double-blind, placebo- or active- (bupivacaine HCl) controlled multimodal analgesia studies of >700 patients was conducted to assess the comparative efficacy of liposome bupivacaine administered at doses up to 266 mg and bupivacaine HCl administered (both administered via infiltration at the end of the procedure) at doses up to 150 mg for postsurgical analgesia. Of the five studies, 3 different surgical procedures were represented including inguinal hernia repair (2), hemorrhoidectomy (2), total knee arthroplasty (1).

Outcome measures included area under the curve (AUC) of pain intensity scores assessed by a numeric rating scale (NRS) through 72 hours postsurgery, time to first use of rescue opioid medications, total amount (mg) of opioid medications used, and occurrence of ORADEs Incidence of overall adverse events was also assessed.

The mean cumulative pain score (AUC of NRS scores through 72 hours) was statistically significantly lower
with liposome bupivacaine (n=315) compared with bupivacaine HCl (n=427, \( P<0.0001 \)). Median time from administration of study drug to first use of opioid rescue medication was significantly longer for liposome bupivacaine (10 hours vs. 3 hours, \( P<0.0001 \)). Liposome bupivacaine was associated with a significant reduction in opioid use (8 mg vs 16 mg; \( P<0.0001 \)), percentage of patients reporting \( \geq 1 \) ORAE (24.6% vs 45.1%; \( P<0.0001 \)) and mean number of ORADEs per patient (0.25 vs 0.46, \( P<0.0001 \)) compared with bupivacaine HCl.

In this analysis, the use of liposome bupivacaine 266mg or less (in a multimodal treatment regimen) was associated with a lower cumulative pain score at 72 hours, delayed use of opioids, less consumption of opioid medications, and fewer ORAEs than bupivacaine HCl. Reductions of approximately 50% in both opioid use and opioid related adverse events were noted.\(^\text{115}\)

**Rationale for EXPAREL**

These analyses support the rationale for the use of a non-opioid, locally administered analgesic agent that provides up to three days of analgesia as a means to achieve the goal of effective pain control with reduced reliance on opioids, which would logically reduce the risk for opioid related side effects.

Furthermore, alternative treatment strategies other than a single injection of EXPAREL require additional staffing and equipment costs to administer them safely and efficiently over an extended period of time. Results from a survey showed that the average cost per patient stay for IV opioids by PCA is $616: $235 for the PCA pump, $179 for tubing and fittings, and $202 to fill the opioid order in the pharmacy (Table 19).\(^\text{130}\) Additionally, opioids incur extra expenses for the hospital in terms of secure storage and tracking in the hospital. The average cost per patient stay for local anesthetic for continuous instillation is $646: $284 for the elastomeric pump, $166 for the tubing and fittings, and $196 to fill the order in the pharmacy. These substantial expenses are direct costs, but there are many indirect costs as well.

**Table 19. Estimated total cost of postsurgical pain control measures over 3 days for different analgesic modalities**\(^\text{130}\)

<table>
<thead>
<tr>
<th></th>
<th>PCA</th>
<th>On-Q</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pump</td>
<td>$235</td>
<td>$284</td>
</tr>
<tr>
<td>Fittings and tubing</td>
<td>$179</td>
<td>$166</td>
</tr>
<tr>
<td>Pharmacy</td>
<td>$202</td>
<td>$196</td>
</tr>
<tr>
<td>Staff time to maintain,</td>
<td>3.9 hrs</td>
<td>3.4 hrs</td>
</tr>
<tr>
<td>document, and monitor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cost</td>
<td>$616</td>
<td>$646</td>
</tr>
</tbody>
</table>

Note: Costs for PCA and On-Q provided from Frost & Sullivan’s survey of medical/surgical nurse managers and directors.\(^\text{130}\)

By extending the duration of postsurgical analgesia up to 72 hours, EXPAREL could eliminate the need for
elastomeric pumps often used following cardiovascular, urologic, gynecologic, obstetric, orthopedic and
general surgical procedures.85,86 These consist of a pressurized ball containing a local analgesic connected
to a catheter, which drips the analgesic directly into the wound for an extended period of time, typically
for 2-3 days following major surgery. This effectively extends the duration of analgesia in the postsurgical
site but also has significant shortcomings, particularly with regard to staff training and technical
management issues (in addition to the patient inconvenience of having to wear a ball, catheter, and
potentially wet bandage).

Some of these shortcomings were highlighted by the Institute for Safe Medication Practices, which cited
the following concerns85,86:

- A lack of staff education on the management of the pumps
- Lack of pharmacy involvement in preparing and dispensing the pumps that led to a lack of
documentation and screening of medications used
- Devices are sometimes filled with medications other than local anesthetics
- Varying infusion rates due to inaccurate filling of the pump (other reports note that temperature
changes may also lead to variations in the infusion rates88)
- Use of non-standard concentrations that can contribute to preparation and dosing errors
- In clinical studies, EXPAREL has been shown to reduce or delay the need for postsurgical
opioids.1,2,4,7,98 The delay in time to opioid rescue was delayed up to 14 hours in the pivotal soft
tissue model. This could potentially lead to additional economic advantages:

**Reduce Reliance on PCA Devices**

The PCA process is complex and requires numerous steps before achieving the desired analgesic relief.23
These steps include obtaining and maintaining pumps, replacing supplies, pump training, preparing pumps
for patient use, patient training, and evaluating IV access.23 In addition, patients require careful
monitoring during PCA use to assess their opioid exposure. Involvement of numerous hospital
departments (such as central supply, biomedical engineering, pharmacy and nursing) complicates use of IV
PCA pumps and introduces high potential for error throughout the prescribing, dispensing and
administration process.14 PCA use is associated with a cost of equipment purchase, training and set-up, as
well as labor during set-up and monitoring. In addition to these costs, the narrow therapeutic index of
opioids and the potential for human error when programming PCA pumps can lead to safety concerns that
increase treatment costs, limit use and compromise quality of care.23 For example, PCA is associated with
a 4-fold greater risk of surgical site infection compared with injected or oral analgesic/narcotic
administration in patients undergoing colorectal surgery.22

Furthermore, errors relating to IV PCA have been estimated to arise in approximately 4% of cases, with an
estimated mean error-related cost of $US733, translating into an estimated $US388 million in additional
healthcare expenditure per annum for patients in the United States.23

Reduce the Incidence of Opioid Related Adverse Drug Events (ORADEs)
In clinical studies, EXPAREL has demonstrated effects on reducing both opioid use1,2,4,7,98 and ORADEs.4,40 In an analysis of costs relating to PCA errors, ORADEs were the most costly harmful device error ($US13,803 per error).23 Other ORADEs do not reflect error but are inherent in the pharmacology of the drugs,74 and guidelines recommend limiting opioid use to minimize the occurrence and severity of PONV.131 Use of injectable opioid analgesics post surgically results in an almost 5-fold increase in the risk of developing PONV or constipation, and the need to treat these AEs significantly increases time in hospital (by 0.26 days) and per-patient cost of care (by $756).76 A pharmacoeconomic analysis of the cost of ORADEs in surgical patients reported that 2.7% of patients had an ORADE, resulting in significant increases in hospital LOS (0.53 days) and hospital costs (average median increase $US840) compared with patients without such AEs.73 Consistent with this finding, another study in surgical subjects found that ORADEs significantly increased the median hospital LOS by 10.3% and increased median total hospital costs by 7.4%.74 Adverse events occurred more frequently in subjects receiving higher doses of opioids.7 Recent data from two retrospective cohort studies suggests that ORADE can increase hospital costs by $5,000 and hospital LOS by 3 days.120

Reduce Hospital Stays
Limiting the use of PCA and opioids can shorten the hospital stay for many patients. For example, patients on PCA who develop postsurgical infections had their stay in hospital increased by an average of 5.8 days,22 and those who develop ORADEs also have extended hospital stays.73,74,76 EXPAREL reduces opioid use without compromising pain relief, which is another important determinant of hospital stay. Unrelieved acute pain delays recovery from surgery and may result in increased LOS, increased hospital readmission rates, impaired health-related QOL and higher healthcare costs.24,65 Reimbursement for surgical procedures is typically capitated, or fixed, by third-party payers based on the specific surgical procedure performed, regardless of the cost or amount of treatment provided. However, many subjects, including those who are elderly, obese, or suffer from sleep apnea, or are opioid tolerant, are likely to have a higher incidence of ORADEs, increasing the LOS and the cost relative to the capitated reimbursement. EXPAREL has demonstrated a reduction in opioid use and ORADEs, which may lower total resource consumption and reduce the LOS in hospital.68,120

Reduce Readmissions
Effective pain management is a key element to reducing unexpected patient readmissions. In a study in which 1.5% of subjects undergoing outpatient ambulatory surgery returned within 30 days because of problems directly related to the original procedure, pain was the most common reason for unanticipated admissions and readmissions. In fact, pain accounted for more than one third of return visits, peaking 2 days after surgery, and incurring mean charges of $1,869 per visit, which represents unnecessary,
avoidable cost and opportunity for improvement.⁶²

Hospitals face not only the problem of cost, but also of how to offer value, which includes costs as well as outcomes. Therefore, they should adopt treatments and technologies that have been proven effective with regard to variables such as patient satisfaction, in addition to LOS and readmission rates.¹³² It is important to consider the subjects’ recovery experience and cost of AEs resulting from postsurgical opioid analgesia in the development of guidelines for optimal, cost-effective patient postsurgical care.⁷³,⁷⁴ It is also important to recognize that total costs extend beyond the cost of the drug, and that an analgesic agent with a relatively high cost but that produces relatively few AEs may be the most cost-effective option.⁷⁴ EXPAREL has the potential to reduce the level of pain and the need for supplemental opioid medication over an extended postsurgical period, thereby reducing pain- and ORADE-related costs, as well as improving patient satisfaction with postsurgical care. Additionally, by providing pain management of adequate post discharge duration, EXPAREL may also have the potential to contribute to economically favorable outcomes in the ambulatory setting.

4.1 Modeling Overview

There is a sound basis for an approach to postsurgical pain control that relies on a single perioperative administration of an agent that provides prolonged (up to 72 hours) non-opioid local analgesia. The scientific literature is replete with information concerning the need to better manage postsurgical pain while minimizing the use of opioids due to their inherent limitations and safety concerns. The clinical information available for EXPAREL provides robust evidence to support a model that will demonstrate that the goals of therapy are better met when EXPAREL is considered as part of a multimodal postsurgical pain management strategy.
5 References


34. Pacira Pharmaceuticals Inc. *Clinical trial no. SKY0402-C-103.* A phase 1, randomized, double-blind, dose-finding study to evaluate the safety, pharmacokinetic and pharmacodynamic profiles of sustained-release encapsulated bupivacaine (SKY0402) administered via a single epidural injection to healthy volunteers. Data on file.


37. Pacira Pharmaceuticals Inc. EXPAREL (Bupivacaine liposome injectable suspension) Prescribing Information; 2011.


51. US Food and Drug Administration. *International Conference on Harmonization (ICH) guidance documents: E14*
clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential non-antiarrhythmic drugs 2005.


71. Stephens J, Laskin B, Pashos C, et al. The burden of acute postoperative pain and the potential role of the COX-2-


97. Pacira Pharmaceuticals Inc. *Clinical trial no. SKY0402-C-211. A phase 2, open-label, parallel group, randomized, dose-finding study to assess the efficacy and safety of intercostal SKY0402 in subjects undergoing posterolateral thoracotomy.* Data on file.


108. Pacira Pharmaceuticals Inc. *Clinical trial no. SKY0402-C-201. A phase 2, multicenter, randomized, double-blind, dose-escalating/de-escalating study to evaluate the safety, efficacy, and pharmacokinetics of sustained-release encapsulated bupivacaine (SKY0402) in the management of postoperative pain in subjects undergoing inguinal...*


112. Pacira Pharmaceuticals Inc. Clinical trial no. SKY0402-C-318. An observational study to assess the long-term follow-up of subjects who had participated in SKY0402 breast augmentation studies Data on file.


